Regulation of System Xc-by the Neuropeptide PACAP: Implications for Glutamate Transmission in Drug Addiction

Linghai Kong

REGULATION OF SYSTEM X$_C$- BY THE NEUROPEPTIDE PACAP:
IMPLICATIONS FOR GLUTAMATE TRANSMISSION
IN DRUG ADDICTION

by

Linghai Kong, B.S.

A Dissertation submitted to the Faculty of the Graduate School,
Marquette University,
in Partial Fulfillment of the Requirements for
the Degree of Doctor of Philosophy

Milwaukee, Wisconsin

May 2017

ABSTRACT
REGULATION OF SYSTEM X_C- BY THE NEUROPEPTIDE PACAP:
IMPLICATIONS FOR GLUTAMATE TRANSMISSION
IN DRUG ADDICTION

Linghai Kong, B.S.

Marquette University, 2017

Drug addiction is a chronic brain disorder characterized by heightened relapse susceptibility. Drug-induced aberrant glutamate signaling in corticostriatal circuitry contributes to behaviors in virtually every preclinical model of drug seeking and correlates with drug craving in human. Here, we propose that glutamate signaling is a product of integrated activity between neurons and astrocytes, such that disruptions within astrocytes can stem from abnormal neuronal signaling (e.g., altered corticostriatal firing) and be the source of additional disruptions in other neuronal circuits. The astrocytic mechanism studied in these experiments is system x_c- (Sxc) since drug-induced changes to this non-vesicular glutamate release mechanism contribute to heightened relapse vulnerability in preclinical models of addiction. My first objective was to determine whether neurons or neuronal factors regulate Sxc activity in astrocytes (Chapter II and III) since this would illustrate the degree to which glutamate signaling involves integrated activity of multiple cell types. We found that neurons release a soluble factor that potently increases Sxc activity. Moreover, we discovered that the neuropeptide PACAP (pituitary adenylate cyclase-activating peptide) likely contributes to this effect since it upregulates Sxc activity in astrocytes (Chapters II and III). Next, we focused on the importance of PACAP regulation of Sxc to synaptic transmission in the nucleus accumbens (NAc), since this structure is highly implicated in drug addiction (Chapter IV). PACAP depressed synaptic transmission in NAc neurons projecting to the substantia nigra, an important efferent that encodes motivated behaviors. Interestingly, PACAP-induced control over synaptic transmission required enhanced Sxc activity. Given this, we then determined the behavioral impact of increasing PACAP signaling in the NAc on drug-seeking behavior (Chapter IV). Specifically, we found that microinfusion of PACAP into the NAc attenuated cocaine-primed reinstatement of drug seeking. Lastly, we determined that PACAP is expressed in corticostriatal projections to the NAc, and that endogenous PACAP is an unrecognized factor influencing relapse vulnerability (Chapter IV). Collectively, this dissertation reveals that a novel form of neuron-astrocyte communication, namely PACAP regulation of Sxc, is a critical link integrating the glutamate network that mediates motivated behavior.

ACKNOWLEDGEMENTS

Linghai Kong, B.S.

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF ABBREVIATIONS

AARE	amino acid response element
AC	adenylate cyclase
AMPA	2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)-propionic acid
ANOVA	analysis of variance
AP	action potential
ARE	antioxidant responsive element
ATP	adenosine triphosphate
BCA	bicinchoninic acid
BSA	bovine serum albumin
cAMP	cyclic adenosine monophosphate
CNQX	6-cyano-7-nitroquinoxaline-2,3-dione
CNS	central nervous system
CPP	conditioned place preference
CREB	cyclic-AMP response element binding protein
CSF	cerebral spinal fluid
CTB	cholera toxin subunit B
DIG	digoxigenin
EAAT	excitatory amino acid transporter
eGFP	enhanced green fluorescent protein
eIF2	eukaryotic initiation factor 2
Epac	exchange factor directly activated by cAMP
EPSC	excitatory postsynaptic current
EPSP	excitatory postsynaptic potential
ER	endoplasmic reticulum
ERK	extracellular signal-regulated kinase
FACS	fluorescence-activated cell sorting
FGF-2	fibroblast growth factor 2
GABA	gamma-aminobutyric acid
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GFAP	glial fibrillary acidic protein
GLAST	glutamate aspartate transporter
GLT-1	glial glutamate transporter -1
HBSS	Hanks ´balanced salt solution
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HPLC	high performance liquid chromatography
IGF	insulin-like growth factor
iGluR	ionotropic glutamate receptor
IL	interleukin

IP3	inositol 1,4,5-trisphosphate
LTD	long-term depression
LTP	long-term potentiation
MAPK	mitogen-activated protein kinase
MEK	mitogen-activated protein kinase kinase
mGluR	metabotropic glutamate receptor
MSK	mitogen and stress activated protein kinase
MSN	medium spiny neuron
NAc	nucleus accumbens
NaOH	sodium hydroxide
NMDA	N-methyl-D-Aspartate
Nrf2	eythroid 2-related factor 2
OCT	optimal cutting temperature
PACAP	pituitary adenylate cyclase-activating polypeptide
PCR	polymerase chain reaction
PFC	prefrontal cortex
PI3	phosphatidylinositol 3
PI3K	phosphatidylinositol 3 kinase
PIP2	phosphatidylinositol 4,5-bisphophate
PIP3	3,4,5-triphosphate
PKA	protein kinase A
PKC	protein kinase C
PLC	phospholipase C
RT-qPCR	real-time quantitative
SCN	suprachiasmatic nucleus
SDS	sodium dodecyl sulfate
Slc7a11	solute carrier family 7, member 11
SN	substantia nigra
SSZ	sulfasalazine
Sxc	System x_c-
TBOA	DL-threo-β-benzyloxyaspartic acid
Trk	tyrosine kinase
VIP	vasoactive intestinal peptide
VP	ventral pallidum
VTA	ventral tegmental area
ZFN	Zing-finger nucleases

CHAPTER I

INTRODUCTION

General Introduction

Drug abuse and addiction have long been considered problems resulting from

moral failures such as poor life decisions or a lack of willpower. Slowly, over the past

several decades, scientific advances have progressively worked to break down this

stigma. Today, addiction is defined by most medical associations as a chronic disease of

the central nervous system (CNS). Similar to other diseases such as cancer and heart

disease that are caused by a malfunction of the underlying physiological substrates, the

disease of drug addiction is a result of drug-induced abnormal and persistent changes of

the underlying organ, the brain.

One of the hallmarks of addiction is characterized by periods of heightened

relapse susceptibility, even following protracted abstinence (Jaffe et al., 1989; Withers et

al., 1995). As such, relapse is arguably the most important problem to address when

developing treatments for addiction. Towards this, a better understanding of the

biological basis of relapse becomes a top priority. Studies suggest that relapse originates

from the persistent neuroadaptations at the molecular and cellular levels in the related

brain circuit (Baker et al., 2003; Kalivas and Volkow, 2005; Nestler, 2005; Hyman et al.,

2006; Koob and Volkow, 2010). Among these neuroadaptations, drug-induced changes in

synaptic transmission due to aberrant glutamate signaling have been linked to behavior in

virtually every preclinical model of drug seeking and have been found to correlate with

the severity of drug craving in human substance abusers (Pierce et al., 1996; Breiter et al.,

1997; Volkow et al., 1999; Park et al., 2002; Baker et al., 2003; McFarland et al., 2003; McFarland et al., 2004; Schmidt et al., 2005; Volkow et al., 2005; Madayag et al., 2007; Kau et al., 2008; Ary et al., 2013).

It is becoming apparent that excitatory signaling is the product of a highly integrated activity of a network of glutamate release mechanisms, receptors, and transporters expressed by multiple cell types, especially neurons and astrocytes (Herrera-Marschitz et al., 1996; Timmerman and Westerink, 1997; Danbolt, 2001; Schoepp, 2001; Baker et al., 2002; Baker et al., 2003; Pirttimaki et al., 2011; Bridges et al., 2012a). As a result of the complexity of this network, identifying approaches that can reverse cocaine-induced changes throughout the glutamate system has been challenging. This, at least in part, is due to the emphasis in most studies of a single cell type (e.g. astrocytes or neurons) while overlooking the fact that glutamate transmission results from the integrated actions of neurons and astrocytes. Therefore, understanding how these cells interact to achieve coordinated glutamate transmission is an essential goal for understanding the biological basis of drug relapse.

The main effort of this thesis is to explore neuronal regulation of a non-canonical glutamate transporter, system x_c- (Sxc) and how this novel form of neuron-astrocyte signaling contributes to synaptic transmission in the nucleus accumbens (NAc) efferents that control drug seeking behaviors. As a cystine-glutamate antiporter that is mainly located on astrocytes, Sxc plays an important role in neuronal glutamate signaling and has been repeatedly demonstrated to be involved in cocaine addiction (Baker et al., 2003; Madayag et al., 2007; Moussawi et al., 2009; Amen et al., 2011; Moussawi et al., 2011; Schmaal et al., 2012). In these studies, I focus on the regulation of Sxc by a neuropeptide,

pituitary adenylate cyclase-activating polypeptide (PACAP), which is exclusively

expressed by neurons in the CNS (Figiel and Engele, 2000; Zhang et al., 2014), yet has

been repeatedly demonstrated to regulate astrocytic functions, including glutamate

transmission (Goursaud et al., 2008; Resch et al., 2014b). Therefore, the intersection of

PACAP and Sxc on the regulation and coordination of neuronal and astrocytic glutamate

systems presents itself as a unique opportunity to better understand this important and

complex excitatory signaling network and how its disruption by drugs of abuse

contributes to relapse.

Preclinical Models of Drug Seeking

The attempts to understand the biological basis of addiction have involved two

primary approaches: brain imaging in humans and preclinical models of addiction that

permit mechanistic-type studies. In this section, I will focus on the latter, although many

key discoveries realized by preclinical studies have often been replicated in human

studies (Grant et al., 1996; Breiter et al., 1997; Childress et al., 1999; Volkow et al.,

2005).

Conditioned place preference

Addiction is a multi-faceted disorder. As such, various animal models have been

developed to study the biological underpinnings of multiple components of addiction.

For example, the conditioned place preference (CPP) can be used to study aspects of

addiction related to drug context (Bardo and Bevins, 2000). This is because the CPP

model is a form of classical conditioning, in which drug experience is associated with

certain contextual cues, demonstrated by a longer time spent in the environment

associated with drug administration (Tzschentke, 2007). While useful in studying aspects

of drug addiction related to the formation of contextual associations, this paradigm lacks

face validity when compared to other models that enable self-administered drugs.

Moreover, given that drug-induced plasticity can be intake-dependent, the CPP paradigm

may lack construct validity since the amount of cocaine administered in this paradigm is

relatively low.

Self-administration model

Drug self-administration model is often used to study factors that govern drug

reinforcement and drug intake. In a typical self-administration paradigm as shown in

Figure 1.1A, rats are trained to press an active lever that is equipped in the self-

administration chamber, which triggers a computer interface controlling mechanical

Figure 1.1. Self-administration and reinstatement models of drug seeking. A. Illustration of a typical self-administration chamber. B. Typical lever responses during drug self-administration (self-ad.), extinction training (ext.) and reinstatement test (rein.).

equipment to deliver an intravenous infusion of the drug through a catheter mounted on

the back of the rats. As such, the animals self-administer drugs similarly to human

subjects. Because drug self-administration is a form of operant conditioning, it permits

the study of factors that govern the reinforcing qualities of drugs of abuse. Further, the

self-administration paradigm can be modified to study other aspects of addiction,

including factors related to relapse, as described below.

Reinstatement model

The self-administration paradigm is often modified in order to study factors

related to increases in non-reinforced drug seeking, which is used to model human

relapse (Shaham et al., 2003; Lynch et al., 2010). Typically, the paradigm is extended

such that subjects that have completed cocaine self-administration training, often to the

point of having consumed enough cocaine to produce persistent drug-induced plasticity,

undergo a series of manipulations designed to elicit non-reinforced operant responding

(Shaham et al., 2003; Bossert et al., 2013). For example, many studies examine the

factors enabling a priming dose of cocaine, which typically involves non-contingent

administration to ensure the lack of reinforced responding, to produce significant levels

of operant behavior. To facilitate the detection of increased behavior, extinction training

can be used between the self-administration and reinstatement phases of the experiment

(Figure 1.1B). Similar designs can also be used to test the capacity of stress, discrete

drug-cues, and drug context to reinstate drug seeking (Lee et al., 2006; Crombag et al.,

2008; Anker and Carroll, 2010; Mantsch et al., 2016). This paradigm has face validity in

that the stimuli that cause relapse in humans can cause reinstatement of drug seeking in

rodents (Gerber and Stretch, 1975; de Wit and Stewart, 1981; Self et al., 1996). In

addition, the reinstatement model (incorporating self-administration) captures key

features of human addiction, such as the reinforcing effect of the drugs, transition from

recreational drug use to compulsive drug abuse, and resumption of drug intake after

prolonged periods of abstinence. Lastly, comparable data obtained from this animal model and human subjects supports the construct validity of this model. For example, studies with the reinstatement model demonstrated that activation of the prefrontal cortex (PFC) is required for the expression of drug-seeking behavior (Baker et al., 2003; Capriles et al., 2003; McFarland et al., 2003; McLaughlin and See, 2003), consistent with the results from clinical imaging studies (Grant et al., 1996; Breiter et al., 1997; Childress et al., 1999; Volkow et al., 2005). This indicates that there are shared biological substrates and mechanisms underlying relapse in both animals and human (Kalivas and McFarland, 2003).

With the aid of many neuroscience tools, including traditional techniques such as microdialysis (Baker et al., 2003; Madayag et al., 2010), microinjection (Blacktop et al., 2011; Graf et al., 2013), and also fast developing modern techniques such as chemogenetics (Scofield et al., 2015; Augur et al., 2016) and optogenetics (Stefanik and Kalivas, 2013; Stefanik et al., 2013), the reinstatement paradigm has proven to be a valuable preclinical model over the last few decades in elucidating the mechanisms underlying relapse. The value of this model is further supported by the discoveries of promising treatments for human drug addiction founded in part through the use of this model. For example, *N*-acetylcysteine was found to reduce cocaine-seeking in rodents and similarly to reduce drug craving in human subjects in clinical trials (Baker et al., 2003; LaRowe et al., 2007; Madayag et al., 2007; Amen et al., 2011; Moussawi et al., 2011; Reichel et al., 2011).

The Motive Circuit

The above paradigms have been widely used over the past 30+ years to

specifically unmask the neuroanatomical and neurochemical systems underlying

addiction. One of the major findings is that the rewarding properties of drugs of abuse

and natural rewards such as food and sex share the same neural substrates that mediate

motivated adaptive behaviors. Much of this work has led to the establishment of the

motive circuit (Figure 1.2) as a key circuit involved in multiple components of drug

addiction. Of particular importance, many findings over the past 25 years have supported

Figure 1.2. The motive circuit. Illustration of the interconnected brain regions and nuclei of the
motive circuit. Adapted from (Kalivas and Volkow, 2005)

a central hypothesis in addiction that relapse and compulsive drug seeking arise from

persistent neuroadaptations at molecular and cellular levels in the motive circuitry

(Nestler, 2001; Kalivas and Volkow, 2005; Nestler, 2005; Kalivas, 2009).

The motive circuit, which is characterized by a collective of interconnected brain

areas, including mainly the PFC, the amygdala, the hippocampus, the NAc, and the

ventral tegmental area (VTA), is a circuit of neural networks that controls goal-directed

behaviors.

The PFC, especially the medial portion (mPFC), is the executive center of the

brain that is critical for decision making (Bechara et al., 2000; Rushworth et al., 2011;

Euston et al., 2012). This function in part attributes to its anatomical position of receiving

extensive projections directly from other cortical, subcortical and limbic regions, and

therefore its capability of associating retrieved memory, sensory and emotional inputs

(Miller and Cohen, 2001). As such, inputs from these cortical structures as an important

component of the motive circuit enable executive function to contribute to the expression

of goal-directed behaviors.

The amygdala is a forebrain limbic structure that is critical for the formation of

emotional memory and thus conditioned learning (Rogan et al., 1997). In brief, it

associates the motivationally relevant experiences, either rewarding or aversive, with the

environmental stimuli, which subsequently predict the relevant events (Belova et al.,

2007). As such, the amygdala, specifically, the basolateral amygdala has been heavily

implicated in cue-induced drug-seeking behavior (See et al., 2001; Alleweireldt et al.,

2002; Crombag et al., 2002). Therefore, inputs from the amygdala should be viewed as

enabling conditioned learning and/or emotional memory to also contribute to the expression of goal-directed behaviors.

The hippocampus, which is also part of the limbic cortex, is located in the temporal lobe of the brain and is a structure critical for the formation of contextual and declarative memories (Eichenbaum, 2000, 2004). Together with amygdala, these structures form and preserve detailed contextual memories of experiences, for example, those associated with drug taking (Kelley, 2004; Robbins et al., 2008). Hence, inputs from these structures enable contextual memories to contribute to the expression of goal-directed behaviors.

Midbrain nuclei, including the VTA, project throughout the motive circuit and are thought to release neurotransmitters, which collectively encode multiple aspects of motivated behavior (Adinoff, 2004; Alcaro et al., 2007). While these projections are primarily studied for their dopaminergic inputs, which have been long recognized to be strong modulators of motivated behavior (Kauer and Malenka, 2007; Gerfen and Surmeier, 2011), additional neurotransmitters include glutamate, gamma-aminobutyric acid (GABA), and co-neurotransmitters such as opioid peptides (Chuhma et al., 2009; Jarjour et al., 2009; Stuber et al., 2010; Tecuapetla et al., 2010; Tritsch et al., 2012). While much work is needed to parse out the components of motivated behavior encoded by each of these key neurotransmitters, it is clear that these inputs to the motive circuit enable goal-directed behavior to be a product of incentive salience, motivation, and reward.

Among all these structures in the motive circuit, this dissertation focuses on the NAc. The NAc is part of the ventral striatum and is located in the basal forebrain. It is a

central structure in the expression of goal-directed behaviors, in part because it connects the limbic subcircuit to the motor subcircuit. Specifically, it integrates inputs from the PFC, amygdala, hippocampus, and midbrain nuclei (Morgane et al., 2005). In turn, it then projects to the motor nuclei, ventral pallidum (VP) and the substantia nigra (SN). As such, the NAc is anatomically positioned as a gateway to integrate limbic information and lead to the expression of behaviors through recruitment of the motor system (Groenewegen et al., 1996; Yin and Knowlton, 2006).

Projections from the PFC to the NAc core have been shown to be involved in multiple forms of drug seeking (Cornish and Kalivas, 2000; Di Ciano and Everitt, 2001; McFarland and Kalivas, 2001; Kalivas and Volkow, 2005). This glutamatergic projection and the NAc efferents to the motor system, simplified as the corticostriatal pathway, have been described to be the final common pathway for generating reinstatement behavior (Kalivas and Volkow, 2005). This is supported by its obligatory involvement in the initiation of drug seeking induced by all the three common triggers, i.e. cues, stress and drug (Cornish and Kalivas, 2000; McFarland and Kalivas, 2001; Park et al., 2002; Capriles et al., 2003; McFarland et al., 2003; McLaughlin and See, 2003; McFarland et al., 2004).

As introduced above, the development of addiction involves both the limbic and motor units of the corticostriatal pathway with the NAc serving as the gateway connecting the two (Kalivas, 2009). While the limbic subcircuit is critical for the development and establishment of addiction, such as the expression of drug seeking behavior, it also retains the power for altering well-established behaviors in order to adapt to constantly changing environment, in other words, generating new adaptive behaviors

(Barnes et al., 2005; Doya, 2008). For example, in the model of cocaine self-administration, when lever pressing reliably yields desired drug delivery, the influence of the limbic unit diminishes while the motor function gradually predominates in performing the task (Barnes et al., 2005; Yin and Knowlton, 2006). The same rules apply to the development of other habitual behaviors. However, when lever pressing fails to yield the expected drug delivery, such as in extinction training, the limbic subcircuit re-engages to re-evaluate environmental stimuli and reassign values, while the established motor pattern re-organizes concordantly. As such, a new adaptive behavior develops (Barnes et al., 2005; Doya, 2008).

These concepts indicate that drug-seeking behavior arises from the neuroadaptions that favor such established behavior, and/or that impair the capability of controlling or changing such behavior (Kalivas, 2009; Belin et al., 2013). In other words, drug reinstatement results from weakened limbic control and/or strengthened motor involvement. Consistently, extended drug intake promotes the progressive reliance on the motor systems, and at the same time the gradual disengagement of the limbic system (Ito et al., 2000; Ito et al., 2002; Porrino et al., 2004; Vanderschuren and Everitt, 2004; Vanderschuren et al., 2005; Pelloux et al., 2007).

As introduced above, the NAc is a gateway where limbic information gains its access for the motor expression. As such, dysfunction of this structure induced by repeated drug exposure might underlie the declining engagement of the limbic subcircuit. In fact, studies from the past two decades indicate that the imbalanced corticostriatal pathway arises at least in part from the malfunction of the glutamatergic signaling in the

NAc. This involves neuroadaptations in glutamate receptors, release and clearance mechanisms, for review see (Kalivas, 2009).

Glutamate Transmission in Addiction

Glutamate is the primary excitatory neurotransmitter in the brain (Curtis and Johnston, 1974; Choi, 1988; Harris and Kater, 1994; Meldrum, 2000; Franks et al., 2002; Javitt et al., 2011). Its transmission underlies virtually all brain functions, as supported by its involvement in numerous CNS disorders (Carlsson and Carlsson, 1990; Olney, 1990; Brown and Bal-Price, 2003; Hynd et al., 2004; Maragakis and Rothstein, 2004; Foster and Kemp, 2006; Niswender and Conn, 2010; Rondard and Pin, 2015).

Figure 1.3. A typical glutamate synapse. Pre: presynaptic terminal; Post: postsynaptic terminal; Glu: glutamate; A: AMPA receptor; N: NMDA receptor; M: metabotropic glutamate receptor; E: excitatory amino acid transporter; CC: cystine; Sxc: system x_c- . Adapted and modified from (Bridges et al., 2012a).

With advances in neuroscience, it is gradually becoming apparent that glutamate neurotransmission is achieved by a complicated network that is formed by multiple cell types, including mainly neurons and astrocytes. Both of these cell types express glutamate receptors, transporters and release mechanisms (Figure 1.3).

Glutamate receptors

There are two types of glutamate receptors, ionotropic (iGluR) and metabotropic glutamate receptors (mGluR). iGluRs are ligand-gated ion channels that are formed by tetramers and mediate fast excitatory synaptic transmission (Dingledine et al., 1999; Platt, 2007; Traynelis et al., 2010). Based on their sequence differences and pharmacological ligand (agonist) selectivity, iGluRs are further divided into three subtypes, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), *N*-Methyl-D-aspartate receptor (NMDAR) and kainate receptor (Dingledine et al., 1999; Platt, 2007; Traynelis et al., 2010). These different receptor subtypes are distinctly distributed in the CNS and exhibit different channel properties determined by their subunit compositions and location (Dingledine et al., 1999; Platt, 2007; Traynelis et al., 2010). In this dissertation, I will focus on AMPARs and NMDARs, as they are the most studied iGluRs in addiction.

AMPA receptors

Most AMPARs are heterotetrameric, consisting of subunits GluA2 and either GluA1, GluA3, or GluA4, with a prototype of dimers of dimers (Nakagawa et al., 2005). Each of the four subunits harbors a binding site for glutamate. AMPARs are activated upon the occupation of as little as two binding sites by glutamate or agonists (Platt, 2007). The channel formed by the four subunits then opens to allow the influx of sodium

and potassium. The binding sites to glutamate are of low-affinity (EC50: 200-500 μM),

and AMPARs deactivate fast due to the transient bound time of the glutamate that is

caused by the rapid diffusion and dilution of the transmitter (Dingledine et al., 1999;

Platt, 2007; Traynelis et al., 2010). Given that AMPARs are not voltage gated, this fast

gating property renders AMPARs obligatory players in most of the fast excitatory

neurotransmission (Zhang and Trussell, 1994; Edmonds et al., 1995; Palmer et al., 2005).

Specifically, activation of AMPARs initiates depolarization that is essential for removing

the magnesium blockers residing within NMDAR ion channels (Nowak et al., 1984;

Dingledine et al., 1999). Thus, it facilitates the participation of NMDARs in generating

the excitatory postsynaptic potential (EPSPs). As such, synaptic expression of AMPARs

is critical in determining synaptic strength (Malinow and Malenka, 2002; Shepherd and

Huganir, 2007).

Functional AMPARs are primarily located on postsynaptic terminals. The

membrane expression of the receptors is a rather dynamic and highly amendable process

(Anggono and Huganir, 2012; Niciu et al., 2012). It involves the expression of the

receptors, the trafficking from the cell soma, and the lateral membrane diffusion from the

extrasynaptic to the synaptic compartment (Groc and Choquet, 2006; Kennedy and

Ehlers, 2006; Shepherd and Huganir, 2007; Newpher and Ehlers, 2008; Kapitein et al.,

2010). The whole process is highly dependent on synaptic events, and in turn plays a key

role in synaptic plasticity (Malinow and Malenka, 2002). For example, it has been well

established that the integration of AMPARs to the synaptic membrane is critical in

mediating long-term potentiation (LTP), a key mechanism that underlies learning and

memory formation (Lynch, 2004). As such, AMPARs are broadly involved in

experience-induced neuroadaptations; disruption of AMPAR functions often negatively impact brain functions and has been demonstrated in various CNS disorders, including addiction.

AMPARs are enriched in the medium spiny neurons (MSNs) in the striatum (Martin et al., 1993; Bernard et al., 1997) where the NAc resides. Drug-induced AMPAR plasticity has been recurrently implicated in addiction studies. For example, repeated cocaine leads to increased surface expression of GluA1-containing AMPARs (GluA1-AMPARs) in the NAc, and consequently postsynaptic potentiation (Conrad et al., 2008; Moussawi et al., 2009). In addition, impairment of GluA1-AMPAR trafficking decreases cocaine induced reinstatement, suggesting that increased membrane expression of GluA1-AMPARs is critical for cocaine relapse (Anderson et al., 2008). Consistently, activating AMPARs with AMPA in the NAc reinstates cocaine-seeking behavior, while blocking AMPARs with receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) eliminates cocaine-induced reinstatement (Cornish and Kalivas, 2000).

Membrane expression of AMPARs is, to a certain degree, dependent on the phosphorylation of the receptor, a labile post-translational modification that is reversible and relatively dynamic (Wang et al., 2006; Mao et al., 2011). Phosphorylation sites exist on the C-terminals of each GluA subunit, which are intracellular domains that undergo protein-protein interaction and phosphorylation. There are four sites identified on the GluA1 intracellular domain, including serine 818 (S818), S831, S845 and threonine 840 (T840). Among these, T840 could be phosphorylated by p70S6 kinase and PKC (Delgado et al., 2007; Lee et al., 2007). Dephosphorylation of GluA1-T840 by NMDAR-mediated signaling has been implicated in long-term depression (LTD) (Delgado et al., 2007).

S845 is a substrate for PKA. Phosphorylation of S845 by PKA in response to cellular activity facilitates synaptic trafficking of the receptor, augments AMPAR-mediated currents, and is critical for LTP (Roche et al., 1996; Derkach et al., 1999; Banke et al., 2000; Esteban et al., 2003). Phosphorylation of S845 in striatal neurons has been extensively studied in addiction. It contributes to the psychostimulant (e.g. cocaine)-induced increase of synaptic AMPAR expression, and consequently the potentiation of synaptic strength (Price et al., 1999; Snyder et al., 2000; Chao et al., 2002; Mangiavacchi and Wolf, 2004; Swayze et al., 2004). Therefore, this mechanism is likely correlated with the neuroadaptations that underlie drug-seeking behavior.

NMDA receptors

Similar to AMPAR, NMDARs are also heterotetrameric. The receptor is composed of subunits from three classes, including GluN1, GluN2, and GluN3. Each NMDAR contains two GluN1 obligatory subunits, and two GluN2 and/or GluN3 subunits (Dingledine et al., 1999; Platt, 2007; Traynelis et al., 2010). Unlike AMPARs that are activated by glutamate or agonists, opening of the NMDAR ion channel requires the binding of both glycine/D-serine (co-agonists) and glutamate, with glycine to GluN1 and glutamate to the other two subunits (Kleckner and Dingledine, 1988; Chen et al., 2005; Wolosker, 2006). Additionally, full occupation of all four binding sites appears to be necessary for maximum activation of the receptor. However, activation of the receptor and the opening of the NMDAR channel does not assure the ion flux, as the channel is constitutively blocked by magnesium, which could be removed by the rapid depolarization of the membrane potential mediated by AMPARs (Nowak et al., 1984; Dingledine et al., 1999). Unblocked NMDAR channels allow the influx of sodium, and

calcium, and the outflow of potassium (Dingledine et al., 1999; Liu and Zhang, 2000; Cull-Candy et al., 2001; Paoletti and Neyton, 2007). The intracellular surge of calcium from NMDARs leads to activation of different calcium-dependent signaling pathways that are differentially involved in the induction of LTP and LTD (Shouval et al., 2002; Citri and Malenka, 2008; Luscher and Malenka, 2012).

In contrast to AMPARs, NMDARs demonstrate much higher affinity for glutamate. The affinity varies depending on the subunit composition and splicing variance of each receptor, yet the EC50 of NMDARs typically falls at micromolar or sub-micromolar level (McBain and Mayer, 1994; Meldrum, 2000). Unlike AMPARs, NMDARs activate and deactivate much slower (Edmonds et al., 1995; Wyllie et al., 1998), and thus mediate the slow component of the EPSP (Meldrum, 2000; Vargas-Caballero and Robinson, 2004). The slow kinetics of NMDARs allows a temporal summation of depolarization which generates a persistent excitation and thus is critical for neuronal firing (Herron et al., 1986; Daw et al., 1993; Larkum and Nevian, 2008; Polsky et al., 2009). Given that ion flux through NMDARs requires both the binding of glutamate that is released from the presynaptic terminal and the removal of channel blockers by postsynaptic depolarization, the slow kinetics of the receptor render NMDARs the capability to simultaneously detect both the pre- and post-synaptic activities that are necessary for the induction of LTP and LTD (Malenka and Nicoll, 1993; Luscher and Malenka, 2012). As such, NMDAR-mediated synaptic plasticity has been extensively studied in learning and memory formation (Tsien et al., 1996; Nakazawa et al., 2004).

NMDARs are enriched in the striatum and are predominantly GluN2A- and GluN2B-containing in this region; they are widely expressed by MSNs projecting to both the SN and the VP, and cholinergic interneurons (Landwehrmeyer et al., 1995; Chen et al., 1996; Dunah and Standaert, 2003). The concentrated expression of NMDARs in the striatum and their critical role in synaptic transmission and plasticity implicate that NMDARs are likely involved in addiction. In support, blocking NMDARs in the NAc induces reinstatement of drug seeking (Cornish and Kalivas, 2000; Famous et al., 2007). While not studied as extensively as AMPARs, NMDARs also demonstrate drug-induced plasticity. For example, cocaine self-administration alters the phosphorylation of striatal NMDARs in rats (Edwards et al., 2007). Such plasticity may in turn contribute to drug craving and relapse.

<u>Metabotropic glutamate receptors</u>

In comparison to iGluRs, which are ion channels that mediate fast synaptic transmission, mGluRs are G-protein coupled receptors that mediate their modulatory effects through activation of G-proteins and downstream second messenger systems (Pin et al., 2003). There are eight subtypes of mGluRs which are divided into three groups based on their amino acid compositions and signaling cascades (Niswender and Conn, 2010). Group I mGluRs (mGluR1 and 5) are coupled to Gαq, stimulation of which results in the calcium release from the endoplasmic reticulum (ER), as well as the activation of PKC, and thus related transduction cascades. Both group II (mGluR2 and 3) and group III mGluRs (mGluR4, 6, 7 and 8) are coupled to Gαi that negatively impact the activity of adenylate cyclase (AC). Therefore, activation of group II or group III mGluRs decreases

the production of cyclic adenosine monophosphate (cAMP), and consequently inhibits downstream signaling pathways including PKA-mediated cascades.

Both neurons and astrocytes express mGluRs. Neuronal mGluRs are located on presynaptic and extrasynaptic membranes. Activation of postsynaptic mGluRs has been shown to modulate ion channel activity (Haak et al., 1997; Benquet et al., 2002; Niswender and Conn, 2010), while presynaptic mGluR activation leads to reductions in presynaptic neurotransmitter release including glutamate and GABA (Schrader and Tasker, 1997; Mitchell and Silver, 2000; Pinheiro and Mulle, 2008). Such a mechanism is potentially involved in addiction. Specifically, repeated cocaine exposure leads to a persistent functional disruption of mGluR2/3 in the NAc (Xi et al., 2002). As presynaptic mGluR2/3 reduces the release probability of glutamate (Moran et al., 2005), this results in an augment of synaptic glutamate transmission and contributes to the reinstatement of cocaine seeking (McFarland et al., 2003; McFarland et al., 2004; Madayag et al., 2007; Miguens et al., 2008). Given that mGluR2/3 binds to glutamate with nanomolar high affinity (Muguruza et al., 2016) and is potentially activated by extrasynaptic glutamate released from Sxc (Xi et al., 2002; Losonczy et al., 2003; Moran et al., 2003; Grueter and Winder, 2005; Moran et al., 2005), cocaine-induced attenuation of Sxc in the NAc may exaggerate such consequences resulting from blunted mGluR2/3.

Glutamate clearance through EAATs

Extracellular glutamate needs to be maintained at a relatively low level, for at least two reasons. First, excessive stimulation of glutamate receptors by high concentrations of glutamate is toxic. For example, pathological surges of extracellular glutamate over-stimulate extrasynaptic glutamate receptors, which leads to cell death

(Hardingham et al., 2002; Ivanov et al., 2006; Leveille et al., 2008). Second, a relatively low level of extracellular glutamate is critical in limiting tonic activation of glutamate receptors (Danbolt, 2001). It has significant physiological meaning, because in such a manner, activation of glutamate receptors by activity/excitation-dependent glutamate becomes distinguishable from that induced by basal glutamate. As such, it provides appropriate signal-to-noise ratio (Danbolt, 2001). However, unlike many other neurotransmitters that can be enzymatically degraded, there is a lack of evidence for the existence of such an extracellular mechanism to metabolize glutamate. Therefore, a cellular uptake machinery is the only clearance mechanism that could rapidly eliminate the build-up of extracellular glutamate from constant synaptic release and other release mechanisms (Logan and Snyder, 1971; Balcar and Johnston, 1972; Danbolt, 2001). In fact, this function is mainly carried out by a family of cell-surface expressed proteins, excitatory amino acid transporters (EAATs).

EAATs are a family of Na+-dependent high-affinity glutamate transporters. They are symporters; 2-3 Na^+ and one proton are co-transported intracellularly with each molecule of glutamate, while a K+ is counter-transported to complete the circle and restore conformation of the transporter for the next circle (Rose et al., 2009). Five subtypes of EAATs (EAAT1-5) have been identified (O'Shea, 2002). EAAT1&2 are primarily expressed by astrocytes and EAAT 3-5 predominantly by neurons (Lehre et al., 1995; Anderson and Swanson, 2000; Pow and Barnett, 2000; Hu et al., 2003; Holmseth et al., 2012). Glial EAATs, EAAT1 and EAAT2 are believed to play the major role in extracellular glutamate clearance (Danbolt, 2001). EAAT1 is predominantly distributed in the neocortex and cerebellum and is the main transporter in the CNS during

development. EAAT2 is abundantly expressed in the forebrain; it occurs almost exclusively in astrocytes (Lehre et al., 1995), with particularly high densities in the astrocytic compartments that surround the synaptic cleft (Minelli et al., 2001). EAAT2 is the primary player in glutamate clearance, given that it accounts for as much as 90% of glutamate uptake in adult brain tissues (Haugeto et al., 1996; Tanaka et al., 1997; Danbolt, 2001). As such, disruption of glial glutamate transporter-1 (GLT1; rodent homologue of EAAT2) functions leads to toxic accumulation of extracellular glutamate (Rothstein et al., 1996; Tanaka et al., 1997).

Disruption of GLT1 has been repeatedly demonstrated in addiction studies. (Knackstedt et al., 2010; Fischer-Smith et al., 2012; Fischer et al., 2013; Reissner et al., 2014; Reissner et al., 2015). For example, cocaine self-administration reduces expression of GLT1 in the NAc (Knackstedt et al., 2010; Fischer-Smith et al., 2012; Trantham-Davidson et al., 2012). This down-regulation of GLT1 is likely involved in the drug relapse. In support, a number of studies demonstrated that restoration of GLT1 in animals with cocaine history prevented the reinstatement of drug-seeking behavior that is induced by cues or the drug, for review see (Roberts-Wolfe and Kalivas, 2015).

To date, studies of the regulation of EAAT2/GLT1 are still scarce. EAAT2/GLT1 undergoes post-translational alterations that are induced by several factors, including the substrate glutamate and arachidonic acid, resulting in a rapid activity change (Gegelashvili and Schousboe, 1998). Neurochemical signals, such as epidermal growth factor, influence EAAT2/GLT1 expression (Zelenaia et al., 2000; Su et al., 2003). Interestingly, several studies using *in vitro* cell cultures reveal that the expression of GLT1 in astrocytes is regulated by neurons or secretory neuronal factors including

PACAP, most likely through activating PKA (Gegelashvili et al., 1997; Swanson et al., 1997; Schlag et al., 1998; Figiel and Engele, 2000). Neuronal regulation of GLT1 is further demonstrated *in vivo,* as the expression of this transporter is regulated by inputs from presynaptic neurons (Yang et al., 2009).

Glutamate release through Sxc

System x_c- (Sxc) is a sodium-independent, chloride-dependent cystine-glutamate antiporter (Bannai and Kitamura, 1980, 1981; Sato et al., 1999). It belongs to the heteromeric amino acid transporter family that are glycoprotein associated amino acid exchangers (Broer and Wagner, 2002; Verrey et al., 2004; Palacin et al., 2005). Functional Sxc, expressed on plasma membrane, is a heterodimer that consists of a heavy chain 4F2 (corresponding gene SLC3A2) and a light chain xCT (corresponding gene SLC7A11) (Sato et al., 1999). The two subunits are covalently linked through a disulfide bond (Bridges et al., 2012b). While the 4F2 heavy chain is shared by multiple amino acid transport systems and contributes to membrane expression of Sxc, the light chain xCT is unique to Sxc and determines its substrate specificities to cystine and glutamate (Sato et al., 1999; Sato et al., 2000; Bridges et al., 2001). By driving the release of glutamate into the extracellular space, Sxc transports cystine molecules into the cytoplasm (Figure 1.3) at a 1:1 ratio (Sato et al., 1999). As such, Sxc serves as a non-vesicular glutamate releasing mechanism.

Functions of Sxc

Both cystine and glutamate play important roles in maintaining normal functions of the CNS. Intracellular transport of cystine through Sxc is a rate limiting step for the

synthesis of glutathione (Deneke and Fanburg, 1989; Kato et al., 1992; O'Connor et al., 1995), a major antioxidant in the CNS. It is synthesized mostly in astrocytes (Raps et al., 1989; Trenga et al., 1991), yet yields its protection against oxidative stress for not only astrocytes, but also neurons (O'Connor et al., 1995; Shih et al., 2003; He et al., 2015). Glutamate release from Sxc, on the other hand, is critical for maintaining extracellular glutamate level/glutamate homeostasis. As introduced above, glutamate and glutamate receptors exist both within and outside of a synapse. Glutamate that is released from presynaptic terminals into the synaptic cleft contributes to the synaptic pool of glutamate. In contrast, extrasynaptic glutamate originates from mainly astrocytes through multiple mechanisms, including calcium-dependent vesicular release (Araque et al., 2000; Bezzi et al., 2004; Montana et al., 2004; Malarkey and Parpura, 2008), hemi-channels (Ye et al., 2003), and Sxc (Murphy et al., 1990; Warr et al., 1999; Baker et al., 2002). Among these, non-vesicular release from Sxc has been implicated to be the major source of basal glutamate in brain regions including the NAc (Baker et al., 2002; De Bundel et al., 2011; Massie et al., 2011).

Extrasynaptic glutamate is important in shaping synaptic transmission and plasticity by activating extrasynaptic receptors. For example, activation of presynaptic autoreceptor mGluR2/3 negatively regulates synaptic glutamate release. Such an inhibitory effect is facilitated by Sxc function, which provides extracellular glutamate for the activation of mGluR2/3 (Manzoni et al., 1997; Moran et al., 2005; Moussawi and Kalivas, 2010). Extrasynaptic NMDARs facilitate the induction of LTD (Liu et al., 2013), while excessive activation of extrasynaptic NMDARs is involved in the inhibition of LTP (Katagiri et al., 2001; Izumi et al., 2008; Li et al., 2011). Interestingly, extrasynaptic

NMDARs cluster at the perisynaptic domain and dendritic shaft (Petralia et al., 2010),

where they are in close proximity to processes from neighboring cells including

astrocytes (Tao-Cheng et al., 2007), and thus are likely to be activated by astrocyte-

released glutamate (Angulo et al., 2004; Fellin et al., 2004; Le Meur et al., 2007;

Shigetomi et al., 2008; Nie et al., 2010). In support, it has been shown that activation of

extrasynaptic NMDARs requires glutamate release from glia (Bezzi et al., 2004; Fellin et

al., 2004; Bergersen and Gundersen, 2009; Hamilton and Attwell, 2010; Bergersen et al.,

2012). However, the direct link between Sxc and extrasynaptic NMDAR activation

remains unclear. Sxc originated glutamate has been shown to attenuate postsynaptic

clustering of glutamate receptors (Augustin et al., 2007). It also facilitates postsynaptic

removal of AMPAR, resulting in the attenuation of synaptic strength (Williams and

Featherstone, 2014). Consistently, loss of functional Sxc in mice leads to decreased levels

of basal glutamate, and disruption of LTP, working memory and long-term memory (De

Bundel et al., 2011; Li et al., 2012).

Therefore, dysregulation/dysfunction of Sxc has been shown to cause disrupted

glutamate homeostasis and inability in coping with oxidative stress, and is implicated in

various neuropsychiatric and neurodegenerative diseases, including addiction,

schizophrenia, amyotrophic lateral sclerosis and Parkinson's disease, for review see

(Bridges et al., 2012a; Lewerenz et al., 2013). With the rodent model of drug seeking, it

has been demonstrated that repeated cocaine exposure leads to a significant reduction in

basal glutamate and disrupted glutamate transmission in the NAc, resulting from

decreased function of Sxc, which consequently lead to the reinstatement of drug seeking

(Baker et al., 2003; Madayag et al., 2007; Kau et al., 2008; Knackstedt et al., 2010). In

support, restoration of NAc Sxc activity by ceftriaxone or prodrug *N*-acetylcysteine

normalizes the basal level of glutamate, and significantly decreases the reinstatement of

cocaine-seeking behavior (Madayag et al., 2007; Kau et al., 2008; Knackstedt et al., 2010;

Trantham-Davidson et al., 2012).

Regulation of Sxc

Regulation of Sxc has been shown at the expression and phosphorylation levels.

Consistent with its role in antioxidant defense, Sxc activity is upregulated in response to

oxidative stress (Kim et al., 2001; Dun et al., 2006; Mysona et al., 2009). This

upregulation is likely mediated by the nuclear factor erythroid 2-related factor 2 (Nrf2),

which could be induced by oxidative insults and increases xCT transcription through

interacting with the Nrf2-antioxidant responsive element (ARE) sequences on the

SLC7A11 promoter (Itoh et al., 1997; Sasaki et al., 2002; Itoh et al., 2004; Shih et al.,

2006). Such a pathway also underlies ceftriaxone-induced upregulation of xCT in

astrocytes (Lewerenz and Maher, 2009). Another transcription factor identified is the

eukaryotic initiation factor-2-activating transcription factor 4 (ATF4). By binding to the

ATF4-amino acid response elements (AAREs) on the SLC7A11 promoter, it increases

the transcription of xCT (Sato et al., 2004; Lewerenz and Maher, 2009; Lewerenz et al.,

2012b). In addition to its involvement in coping with oxidative stress, this pathway

mediates the upregulation of Sxc by insulin-like growth factor-1 (IGF-1), and may be

induced in response to neuronal activity (Lewerenz et al., 2014; Yang and Yee, 2014).

Fibroblast growth factor-2 (FGF-2) has also been implicated in increasing Sxc activity

and xCT expression by recruiting both PI3K/Akt and MEK/ERK cascades (Liu et al.,

2012; Liu et al., 2014a).

Studies suggest that Sxc activity is also influenced by post-translational modification, such as phosphorylation. For example, xCT harbors multiple phosphorylation sites, including those for PKA (Baker et al., 2002; McClatchy et al., 2016). Besides, the phosphorylation states are subjected to regulation and have been shown to influence the activity of Sxc (McClatchy et al., 2016). It has also been demonstrated that inhibiting cAMP and hence PKA activity rapidly decreases Sxc activity in rat striatal tissue slices (Baker et al., 2002). Interestingly, cAMP mediated signaling also appears to increase the expression of Sxc (Gochenauer and Robinson, 2001). In spite of the important roles of Sxc in brain functions such as its involvement in motivated behavior, the endogenous mechanism that mediates the regulation of Sxc is still not clear.

Neuron-Astrocyte Interactions

As introduced above, both neurons and astrocytes possess glutamate receptors, release and uptake mechanisms, which form a glutamate network that mediates the primary excitatory neurotransmission. A large body of studies suggests that these two cell types must coordinate to reach organized glutamate signaling.

Astrocytes

It has been frequently stated in the literature, especially in glia studies, that glia far outnumber neurons (commonly used ratio, 10:1) in the human or non-human primate brains. However, there is no direct evidence that supports such a remark. In fact, the most compelling study quantifying glia and neurons suggests a 1:1 ratio in the human brain

(Herculano-Houzel, 2009) and this ratio varies depending on brain regions. Regardless, glia compose no less than half of the human brain, and the ratio is probably one of the lesser questions, since prevalence does not equal significance. What is important, is that there is accumulating evidence suggesting that glial participation is critical for every major aspect of brain functions, for review see (Barres, 2008; Oliveira et al., 2015).

There are two major classes of glia in the CNS, macroglia (astrocytes and oligodendrocytes) and microglia. Microglia function as macrophages in the CNS, while the major role of oligodendrocytes is to provide axonal myelination. In this dissertation, I will focus on astrocytes.

Astrocytes are the major type of macroglia in the CNS. Anatomically, astrocytes are grouped into two main groups, protoplasmic astrocytes that are mainly distributed in the grey matter, and fibrillary astrocytes mainly in the white matter (Molofsky et al., 2012). These two groups of astrocytes demonstrate different morphologies, antigenic phenotypes/biochemical markers and likely different functions. Astrocytes are often times identified with the expression of glial fibrillary acidic protein (GFAP), the reason for this protein to be routinely used as an astrocyte-specific marker. However, it is necessary to mention that not every astrocyte expresses GFAP, and GFAP-expressing cells may be precursors for neurons (Alvarez-Buylla et al., 2001; Bushong et al., 2002).

Neuron-astrocyte interactions

Metabolism and homeostasis

Astrocytes typically harbor numerous membranous processes that give its star-like shape, as implicated in the name. Through these end-feet, astrocytes are in close

contact with both vasculature and synapses (Grosche et al., 1999; Ventura and Harris, 1999; Abbott et al., 2006). Such anatomical positions contribute to the central role of astrocytes in regulating brain microcirculation (Anderson and Nedergaard, 2003; Zonta et al., 2003; Takano et al., 2006). Specifically, astrocytes mediate vasodilation to boost local blood supply in response to increased synaptic/neural activity of a specific brain area. The metabolic supporting roles of astrocytes also includes serving as a glycogen reservoir (Brown et al., 2004; Brown and Ransom, 2007; Vilchez et al., 2007). Glycogen is converted to lactose and glucose, which are exported to neurons and used as fuel (Dringen et al., 1993; Ghosh et al., 2005). Interestingly, a recent study shows that instead of providing glucose to neurons in response to neuronal activity, astrocytes actively influence neuronal activity by gating the energy source to neurons (Garcia-Caceres et al., 2016). Astrocytes are also critical in maintaining extracellular ion levels and neurotransmitter (e.g. glutamate) homeostasis.

Gliotransmission and synaptic transmission

One of the principle differences between neurons and astrocytes is that neurons possess dendrites and axons and are capable of generating action potentials and long distance signal transductions (Raps et al., 1989). In contrast, astrocytes are incapable of AP-mediated signal transmission due to the low density of sodium channels (Vijayaraghavan, 2009). This somewhat contributes to the long-standing stigma that astrocytes do not participate in neurotransmission. However, this point of view has been challenged by a growing body of evidence, which implicates the direct involvement and critical role of astrocytes in synaptic transmission.

Similar to neurons, astrocytes express various receptors for neurotransmitters, including AMPARs (Seifert et al., 1997b; Seifert et al., 1997a), NMDARs (Lalo et al., 2006; Verkhratsky and Kirchhoff, 2007), mGluRs (Shelton and McCarthy, 1999), and GABA receptors (Fraser et al., 1994; Fraser et al., 1995). Electron microscopy studies have indicated that a number of astrocyte receptors are in proximity of neurotransmitter releasing sites on synapse, suggesting that astrocytes respond to neuronal neurotransmitters (Aoki, 1992; Douyard et al., 2007). In support, NMDAR-mediated currents have been demonstrated in astrocytes in response to synaptic neurotransmitter release (Lalo et al., 2006).

Even though astrocytes are not capable of generating action potentials, they demonstrate a special form of excitability and signal transduction. It is mediated by sophisticated calcium transmission that appears in the form of calcium waves and propagates through the cell volume (Yagodin et al., 1994; Fiacco et al., 2007). The calcium transients could be induced via activation of G-protein coupled receptors by various transmitters (e.g. glutamate) that are potentially released by neurons (Agulhon et al., 2008). For example, activation of mGluRs induces the Gαq mediated cascades and the production of inositol trisphosphates (IP3). IP3 binds to the IP3 receptors (IP3R) on the ER, which leads to calcium release from ER stores, and consequently, the intracellular calcium propagation along clusters of IP3R (Porter and McCarthy, 1996; Pasti et al., 1997; Perea and Araque, 2005; Fiacco et al., 2007; Weerth et al., 2007).

Astrocytes are capable of releasing several gliotransmitters, including glutamate, D-serine, adenosine triphosphate (ATP) and its metabolic byproduct adenosine, for review see (Haydon, 2001; Agulhon et al., 2008; Araque et al., 2014). All of these

molecules have corresponding receptors on the neurons. To date, it is well-established that activation of neuronal receptors by gliotransmitters is actively involved in synaptic transmission, plasticity and neuronal functions. For example, ATP released by astrocytes modulates synaptic release of neurotransmitters (e.g. glutamate, GABA and dopamine), as well as postsynaptic responses. D-serine acts as a co-agonist for NMDARs by interacting with the glycine-binding site of GluN1. Also, astrocyte glutamate, including that released from Sxc, is involved in various synaptic functions by activating a spectrum of presynaptic and extrasynaptic glutamate receptors, for review see (Agulhon et al., 2008; Araque et al., 2014).

To date, the releasing mechanism of these neuroactive substances is still not fully understood. A large body of evidence obtained from *in vitro* and *in situ* studies implicates that gliotransmitter release is dependent on the calcium transient-mediated exocytosis that is potentially induced by neuronal activity, for review see (Araque et al., 2014). Among these, vesicular exocytosis of glutamate has received considerable attention (Bezzi et al., 2004; Montana et al., 2004; Zhang et al., 2004; Crippa et al., 2006). However, the existence of this mechanism has been challenged by a study demonstrating the lack of known machinery that is required for vesicular glutamate release in mature mouse astrocytes (Barres, 2008; Cahoy et al., 2008). Therefore, whether or not vesicular glutamate release occurs *in vivo* remains a topic of debate (Volterra and Meldolesi, 2005; Barres, 2008; Hamilton and Attwell, 2010; Parpura and Zorec, 2010). Notably, among the glutamate releasing mechanisms expressed by astrocytes, Sxc is not frequently considered (Haydon, 2001; Araque et al., 2014).

Synaptogenesis and synaptic elimination

The impact of neuron-astrocyte interaction is not limited to its influence on metabolism and synaptic functions. It also appears to be critical for brain development and functions. For example, synaptogenesis is not simply controlled by pre and postsynaptic neurons (Christopherson et al., 2005), but is dependent on the facilitation from astrocytes. In fact, astrocytes are involved in the formation, elimination, maturation and maintenance of synapses (Slezak and Pfrieger, 2003; Christopherson et al., 2005; Kucukdereli et al., 2011; Chung et al., 2013; Clarke and Barres, 2013; Chung et al., 2015). In support, it has been recently postulated that astrocytes are involved in neurodevelopmental diseases such as autism and schizophrenia, both of which demonstrate abnormal synaptogenesis or synaptic elimination (Clarke and Barres, 2013; Sloan and Barres, 2014; Petrelli et al., 2016).

Neuronal regulation of astrocytes

Conversely, neurons appear to be critically involved in the differentiation and maturation of astrocytes, for review see (Stipursky et al., 2011). For example, cortical neurons regulate the onset of cortical gliogenesis during early brain development (Barnabe-Heider et al., 2005). In addition, neurons promote the expression of astrocyte GFAP *in vitro* via soluble factors (Gomes et al., 1999; de Sampaio e Spohr et al., 2002). Interestingly, such a function is influenced by the origin of the astrocytes and also the developmental stage of the neurons. Similarly, as mentioned earlier, expression of GLT1 in astrocytes is significantly influenced by the presence of neurons or secretory neuronal factors including PACAP (Gegelashvili et al., 1997; Swanson et al., 1997; Schlag et al.,

1998; Figiel and Engele, 2000). In addition, neurons influence molecular and functional phenotypes of local astrocytes *in vivo* (Farmer et al., 2016). Clearly, neuron-to-astrocyte communication plays a critical role in astrocyte functions. However, the underlying mechanisms are not clear and the related studies, especially those investigating the neuronal regulation of astrocytic machinery that is involved in astrocyte-to-neuron communication (e.g. Sxc), are still scarce.

PACAP

PACAP (pituitary adenylate cyclase-activating polypeptide) was first discovered in ovine hypothalamus and named by virtue of its high potency in activating adenylyl cyclase (AC) in pituitary cells (Miyata et al., 1989; Arimura, 2007). It was subsequently found that PACAP is widely expressed by both the CNS and peripheral tissues (Vaudry et al., 2009). PACAP expression has been found in many species, including human, mouse, rat, fish, sheep, chicken (Vaudry et al., 2009). Moreover, the biologically active portion of PACAP amino acid sequence is almost completely preserved during evolution, as its structure is almost identical in species from fish to mammals, suggesting that the biological functions of PACAP may be essential (Vaudry et al., 2009). There are two forms of PACAP, the originally discovered PACAP1-38 that contains 38 amino acids, and PACAP1-27 which is a C-terminally truncated version of PACAP1-38 (Miyata et al., 1990). PACAP1-27 demonstrates a similarly high potency in stimulating AC compared to PACAP1-38 (EC50 for both: 0.3nM) (Miyata et al., 1990). In the CNS, the predominant form is PACAP1-38 (Arimura et al., 1991; Dickson and Finlayson, 2009). It is enriched in the hypothalamus, yet is expressed in a number of brain regions, including the cerebral

cortex and the amygdala (Arimura et al., 1991; Ghatei et al., 1993; Masuo et al., 1993; Fukuhara et al., 1997).

Studies using *in vitro* neural cell cultures demonstrate that PACAP is expressed exclusively by neurons (Figiel and Engele, 2000; Jaworski, 2000). Such cell-type specific expression patterns are likely applicable *in vivo*, as PACAP mRNA is only detected in cortical neurons compared to other cell types (Zhang et al., 2014). Interestingly, in the cortex, PACAP appears to be preferably expressed by glutamatergic and primarily pyramidal neurons in layer V (Koves et al., 1994; Hannibal et al., 2000; Hannibal, 2002a, b; Stumm et al., 2007; Engelund et al., 2010; Hu et al., 2011). Co-stores of PACAP and glutamate in nerve terminals also suggest that PACAP is co-transmitted through glutamatergic synapses (Hannibal et al., 2000; Hannibal, 2002a; Engelund et al., 2010). In support, it appears that the localization of PACAP does not parallel with the distribution of PACAP receptors, implicating that PACAP may function as a neurotransmitter (Masuo et al., 1992; Masuo et al., 1993; Golombek and Rosenstein, 2010; Purrier et al., 2014).

PACAP receptors

Three receptors, PAC1R, VPAC1R and VPAC2R have been identified to mediate PACAP signaling. These receptors belong to group B G-protein coupled receptor family (Harmar et al., 1998; Harmar, 2001). As is a major characteristic of this family, all three receptor subtypes are positively coupled to Gαs (Harmar et al., 1998; Harmar, 2001). Therefore, activation of these receptors by PACAP leads to stimulation of AC and consequently, intracellular accumulation of cAMP (Harmar, 2001). While VPAC receptors are mainly coupled to Gαs, PAC1R is reportedly paired with more diverse

transduction systems such as the activation of Gαq and the downstream cascades including the induction of PKC and the elevation of intracellular calcium (Arimura, 1998; Vaudry et al., 2000; Zhou et al., 2001; Dickson and Finlayson, 2009; Vaudry et al., 2009). PAC1R mRNA undergoes extensive splicing, resulting in variances in the transmembrane domain, N-terminal and intracellular loops, and hence corresponding splicing variants that possess differential signaling properties, including selectivity in coupling to downstream pathways, agonist potencies and maximal effects in response to agonist binding, for review see (Dickson and Finlayson, 2009; Vaudry et al., 2009; Blechman and Levkowitz, 2013).

PACAP receptors are also targets of vasoactive intestinal peptide (VIP) (Vaudry et al., 2009). Interestingly, PACAP and VIP have high resemblance in their amino acid sequences and both belong to the secretin superfamily, a collection of revolutionarily related peptides that exert a variety of functions through activating G-protein coupled receptors (Dickson and Finlayson, 2009; Vaudry et al., 2009). Out of the three receptors, PAC1R exhibits selectivity for its ligand, with a much higher affinity for PACAP (Kd: 0.5 nM) compared to VIP (Kd: 500 nM) (Cauvin et al., 1990; Gottschall et al., 1990; Lam et al., 1990; Gottschall et al., 1991; Suda et al., 1992). In contrast, VPAC receptors demonstrate similar affinities (Kd: 1 nM) for both PACAP and VIP (Gottschall et al., 1990; Lam et al., 1990).

Expression of the three PACAP receptors in the CNS is regionally different and cell-type specific. For example, PAC1R, as the major binding site for PACAP (Dejda et al., 2011), is the dominant form of all three subtypes in the cortex, while both VPAC receptors demonstrate lower levels of mRNA expression (Zhang et al., 2014).

Interestingly, PAC1R mRNA is primarily expressed by cortical astrocytes compared to all the other cell types (Zhang et al., 2014), while VPAC2R mRNA is also more abundant in cortical astrocytes compared to neurons.

PACAP functions

PACAP is a pleiotropic peptide, namely it has many different physiological functions (Vaudry et al., 2009). In the CNS, PACAP acts as a neurohormone, neurotropic factor, and also a neurotransmitter, for review see (Vaudry et al., 2009). In this dissertation, I will focus on the impact of PACAP on astrocyte functions, synaptic transmission, and the possibility of PACAP as a neuronal factor regulating Sxc.

Regulation of astrocytes

Consistent with the abundant occurrence of PACAP receptors in astrocytes (Zhang et al., 2014), PACAP exerts a number of actions on these cells, including the regulation of astrocyte proliferation, differentiation, plasticity and release of neuroactive substances. For example, PACAP at pico-molar concentrations promotes the proliferation of cultured astrocytes by recruiting MEK/ERK pathway (Hashimoto et al., 2003). Similarly, PACAP signaling induces astrocytic differentiation of cortical neural precursors (Vallejo and Vallejo, 2002; Seo and Lee, 2016), and appears critical in neocortical astrocytogenesis (Zupan et al., 1998). PACAP incubation increases the number and length of astrocyte processes *in vitro*, namely provoking the stellation (Ikeda et al., 2003; Perez et al., 2005). PACAP promotes the expression and release of neurotropic factors from astrocytes, including ciliary neurotrophic factor (CNF), activity-dependent neurotrophic factor (ADNF), activity-dependent neuroprotective protein

(ADNP), glial cell derived neurotrophic factor (GDNF), interleukin (IL) 1

and 6, macrophage inflammatory protein (MIP) and neurotrophin-3 (Masmoudi-Kouki et

al., 2007; Vaudry et al., 2009). These factors, in turn, induce neuronal proliferation and/or

differentiation, and promote neuroprotection.

PACAP also regulates gliotransmission. For example, PACAP induces

endozepine release from cultured astrocytes, which, in turn, regulates neuronal activity

through multiple mechanisms, including interaction with $GABA_A$ receptors (Bormann,

1991; Masmoudi et al., 2003; Compere et al., 2004, 2005; Masmoudi-Kouki et al., 2006;

Papadopoulos et al., 2006). Interestingly, the precursor for endozepine appears to be

exclusively expressed by astrocytes (Guidotti et al., 1983; Tong et al., 1991; Alho et al.,

1995; Burgi et al., 1999). As such, neurons appear to exert self- or neuron-to-neuron

regulation through the releasable factor, PACAP, which mediates neuron-to-astrocyte

communication for recruiting astrocyte machinery. PACAP also regulates astrocyte

glutamate transporters, which is important in maintaining glutamate homeostasis. For

example, PACAP mediates neuronal regulation of the expression and activity of astrocyte

GLT1 and glutamate aspartate transporter (GLAST) (Figiel and Engele, 2000).

Consistently, activation of VPAC2R rapidly increases GLAST mediated glutamate

uptake (Goursaud et al., 2008).

Regulation of synaptic transmission and plasticity

PACAP also regulates synaptic transmission and plasticity mediated by glutamate

receptors, including NMDARs, AMPARs and mGluRs. Potentiation of NMDAR-

mediated synaptic activity by PACAP has been repeatedly demonstrated (Liu and

Madsen, 1997; Wu and Dun, 1997; Harrington et al., 1999). This function likely involves

the post-translational modification of NMDARs. For example, PACAP promotes phosphorylation of GluN2B and enhances NMDAR-mediated currents in hippocampal neurons (Yaka et al., 2003; Macdonald et al., 2005). Similarly, PACAP-induced regulation of GluN2B phosphorylation is also demonstrated in the hypothalamic ventromedial nuclei, and is involved in feeding behavior (Resch et al., 2014a).

PACAP differentially regulates AMPAR-mediated synaptic transmission in a dose-dependent manner; the amplitude of AMPAR-mediated excitatory postsynaptic currents (EPSCs) in hippocampal slices increase with a lower concentration of PACAP (i.e., 0.5 nM), while decreases with a higher concentration (i.e., 10 nM) (Costa et al., 2009). In contrast, another group showed that a high concentration of PACAP (100 nM) induces and amplifies AMPAR-mediated intracellular calcium concentrations in rat suprachiasmatic nucleus (SCN) neurons, while a low concentration (100 pM) fails to do so (Kopp et al., 2001). Moreover, it has been shown that PACAP alters hippocampal synaptic strength (Kondo et al., 1997; Roberto and Brunelli, 2000; Roberto et al., 2001; Ciranna and Cavallaro, 2003) and reduces synaptic expression of GluA1 (Gardoni et al., 2012). This function is likely mediated by post-translational events. For example, phosphorylation of T840 on the GluA1 subunits of AMPARs enhances channel conductance of AMPARs (Jenkins et al., 2014), while PACAP decreases GluA1-T840 phosphorylation (Toda and Huganir, 2015). Interestingly, the dephosphorylation of GluA1-T840 subunit induced by PACAP appears to be mediated by NMDARs (Toda and Huganir, 2015). In support, NMDARs have been demonstrated to regulate the phosphorylation of this site (Delgado et al., 2007; Lee et al., 2007; Gray et al., 2014), and as introduced above, PACAP regulates the function of NMDARs.

Though still preliminary, studies indicate that PACAP modulates group I mGluR-mediated calcium currents in rat SCN neurons. For example, 100nM PACAP inhibits intracellular calcium increases mediated by activation of mGluR1/5 (Kopp et al., 2001). In another study, however, PACAP (200nM) appears to promote mGluR1/5-coupled calcium currents in SCN and hippocampal neurons (Kammermeier, 2008).

Integrating neuron-astrocyte glutamate transmission through Sxc: a possibility

The broad impact of PACAP on glutamate machinery raises a question of whether or not PACAP also regulates astrocyte Sxc. In fact, a recent study by (Resch et al., 2014b) shows that PACAP increases Sxc activity in glial cultures from mouse cortices. Given the converging actions (or potential actions) of PACAP and Sxc on NMDAR functions and AMPAR-mediated synaptic transmission, and the potential link between NMDARs and AMPARs, as discussed above (Figure 1.4), we speculate that PACAP may be a neuronal factor that regulates Sxc in rat astrocytes, through which to integrate glutamate transmission across neurons and astrocytes, and therefore to achieve the proper expression of behaviors.

Summary

Drug addiction is a chronic CNS disorder characterized by persistent relapse susceptibility, even after years of abstinence. This results at least in part from drug-induced aberrant glutamate signaling within the corticostriatal projections of the motive circuit, the substrate in the brain that mediates motivated behaviors. A challenge in revealing the glutamatergic basis of CNS pathology is that excitatory neurotransmission

likely relies on integrated activities between neurons and astrocytes, yet how these cells interact to form a coordinated glutamate network is largely unknown. Therefore, in these studies, we aim to investigate whether the neuronal PACAP and the astrocyte Sxc form a critical link that orchestrates neuron-astrocyte communication to achieve integrated glutamate transmission that underlies motivated behavior. Specifically, we hypothesize that PACAP mediates neuronal regulation of Sxc in astrocytes, which, in turn, releases glutamate to activate extrasynaptic NMDARs, through which to modulate AMPAR functions (Figure 1.4). Findings from these studies should further our understanding of the complex excitatory signaling network and how its disruption by drugs of abuse may contribute to relapse. Beyond this, our findings may have implications for understanding other CNS conditions, given the fundamental role of glutamate in mediating the excitatory signaling that contributes numerous brain functions.

Figure 1.4. The hypothetical model. Schematic illustrates the hypothesized mechanistic model in this dissertation. Pre: presynaptic terminal; Post: postsynaptic terminal; Glu: glutamate; A: AMPA receptor; N: NMDA receptor; PRs: PACAP receptors; Sxc: system x_c-.

CHAPTER II

PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE
ORCHESTRATES NEURONAL REGULATION OF THE ASTROCYTIC
GLUTAMATE RELEASING MECHANISM SYSTEM X$_C$-

Introduction

Glutamate is often described as the primary excitatory neurotransmitter in the
brain, in part because it may be present in up to 80% of all synapses (Curtis and Johnston,
1974; Choi, 1988; Harris and Kater, 1994; Meldrum, 2000; Franks et al., 2002; Javitt et
al., 2011). As such, altered excitatory neurotransmission likely contributes to most CNS
diseases (Carlsson and Carlsson, 1990; Olney, 1990; Brown and Bal-Price, 2003; Hynd et
al., 2004; Maragakis and Rothstein, 2004; Foster and Kemp, 2006; Niswender and Conn,
2010; Rondard and Pin, 2015). While traditional models of glutamate signaling depict
release solely from presynaptic terminals and diffusion throughout the synaptic cleft to
activate pre- and postsynaptic receptors, it is becoming increasingly evident that
excitatory neurotransmission is achieved by an elaborate network expressed across
multiple types of cells that regulate signaling within and outside of the synaptic cleft
(Herrera-Marschitz et al., 1996; Timmerman and Westerink, 1997; Jabaudon et al., 1999;
Danbolt, 2001; Schoepp, 2001; Baker et al., 2002; Baker et al., 2003; Pirttimaki et al.,
2011; Bridges et al., 2012a). In support, astrocytes and neurons express glutamate
receptors, transporters, and release mechanisms, and astrocyte to neuron signaling has
been shown to be a key determinant of synaptic transmission (Porter and McCarthy,
1996; Pasti et al., 1997; Araque et al., 1999; Fellin et al., 2004; Perea and Araque, 2005;
Fellin et al., 2006a; Haydon and Carmignoto, 2006; Panatier et al., 2011; Santello et al.,

2012; Perez-Alvarez et al., 2014; Gomez-Gonzalo et al., 2015). Therefore, decoding the complex molecular and cellular regulation of glutamate could lead to novel opportunities to better understand and treat pathological excitatory signaling.

A critical gap in modeling excitatory signaling is how distinct components of the glutamate system expressed by neurons and astrocytes are coordinated. In these experiments, we tested the hypothesis that neurons regulate the activity of glutamate-related mechanisms expressed by astrocytes. To do this, we examined the neuronal regulation of system x_c- (Sxc), a non-canonical glutamate-release mechanism primarily expressed by astrocytes (Bannai and Kitamura, 1980, 1981; Sato et al., 1999; Pow, 2001; Zhang et al., 2014).

Sxc is a key component of glutamate signaling that is implicated in the pathology or treatment of multiple CNS diseases. It contributes to glutamate signaling by coupling the release of non-vesicular glutamate to the intracellular transport of cystine (Bannai and Kitamura, 1980, 1981; Sato et al., 1999). Manipulations that increase Sxc activity have been shown to a) influence multiple aspects of synaptic transmission and plasticity (Baker et al., 2002; Xi et al., 2002; Moran et al., 2005; Moussawi et al., 2009; Moussawi et al., 2011; Kupchik et al., 2012), b) normalize behavior in preclinical disease models (Baker et al., 2003; Madayag et al., 2007; Baker et al., 2008; Knackstedt et al., 2010; Alajaji et al., 2013; Lutgen et al., 2013), and c) exert therapeutic effects against multiple CNS diseases including drug addiction and schizophrenia (Berk et al., 2008; Amen et al., 2011; Lewerenz et al., 2013; Canavan et al., 2014; Verrico et al., 2014). Unfortunately, the regulation of Sxc is poorly understood.

In these studies, our primary objective was to evaluate the possibility that neurons regulate astrocyte Sxc. In addition, we tested the hypothesis that the pituitary adenylate cyclase-activating peptide (PACAP) is a neuronal factor capable of regulating astrocyte Sxc activity. To do this, we verified that PACAP is expressed by rat cortical neurons and not astrocytes, and that rat cortical astrocytes express PACAP receptors. We then found that application of PACAP to cortical astrocytes increased Sxc activity. Moreover, inhibition of PACAP signaling blocked neuron-induced upregulation of Sxc. Collectively, these data are consistent with the possibility that altered neuronal activity could give rise to pathological changes in astrocyte functions, including altered Sxc activity which may be present in numerous CNS disorders ranging from drug addiction to schizophrenia.

Material and Methods

Animals and materials: These experiments utilized cortical tissues obtained from Sprague Dawley rats (age was gestational day 15-16 or post-natal day 3-4; sex was undetermined; Envigo, Indianapolis, IN). Experimental procedures were approved by the Marquette University Institutional Animal Care and Use Committee. The primary materials included fetal bovine serum and horse serum (Atlanta Biologicals; Lawrenceville, GA), ^{14}C-cystine (PerkinElmer, Waltham, MA), rabbit anti-PACAP1-38 antiserum (final dilution 1:600; Peninsula Laboratories, San Carlos, CA), PACAP1-38 (California Peptide Research, Napa, CA), and PACAP6-38 (Anaspec, Fremont, CA). PACAP1-38 (PACAP) is the endogenous full-length peptide whereas PACAP6-38 (P6-38) is a truncated version of PACAP and inhibits PACAP receptors (Miyata et al., 1989; Robberecht et al., 1992; Arimura, 2007; Vaudry et al., 2009).

Cell culture procedures: <u>Purified cortical astrocyte cultures</u> were prepared from post-natal days 3-4 rat pups. In brief, cortical cells were disassociated and then suspended in Neurobasal A media (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum, and 1% Glutamax (Thermo Fisher Scientific, Waltham, MA). Cells were initially grown in $25cm^2$ or $75cm^2$ cell culture flasks. Once confluent, cells were then subjected to prolonged, orbital shaking (250 rpm for 18 hours at 37^oC) which has been used to yield purified astrocyte cultures (McCarthy and de Vellis, 1980; Schildge et al., 2013). Purified astrocytes were then plated on 24-well plates, and refreshed with 70% new culture media every 2-3 days.

<u>Purified cortical neuronal cultures</u> were prepared from embryonic rat cortical tissue (gestational day 15 to 16) as previously described (Lobner, 2000). In brief, dissociated cells were suspended in Eagles' Minimal Essential Medium (MEM, Earle's salts, glutamine-free) supplemented with glutamine (2mM), glucose (21mM), horse serum (5%), and fetal bovine serum (5%). Cells were seeded on 24-well plates. Forty eight hours later, cytosine arabinoside (at a final concentration of 10 μM) was added to the culture media to inhibit glial reproduction (Dugan et al., 1995). Neurons were then grown for an additional 11-13 days.

<u>Mixed Neuronal and Glial Cultures</u> Procedure for preparing mixed cultures was identical to that of obtaining neuronal cultures (see above) except that cytosine arabinoside was not added to the culture media.

<u>Physically Separated Astrocyte and Neuronal Cultures.</u> Because the above mixed cultures also contained a limited number of non-astrocyte glial cells, and to determine whether neuron-astrocyte communication involves the release of a neuronal factor, we

utilized a "non-contact" co-culture system in which purified astrocytes were physically

separated from purified neurons. Note, these cells are referenced in the manuscript as

Astrocytes + NCM (neuronal conditioned media). In these experiments, purified

astrocytes were obtained as described above. When astrocytes reached confluency after

13-16 days *in vitro* (DIV), neuronal cultures were seeded on removable inserts (Corning,

Corning, NY) that had been placed into the wells containing astrocytes, such that both

cell types were immersed in the media but were not in physical contact. Fourteen days

later, downstream experiments to examine the effects of neurons on astrocytes were

performed upon removal of the neuronal inserts. As a result, the DIV for these cells was

27-30.

All cell-growing surfaces in culture flasks and 24-well plates were pre-coated

with poly-D-lysine (10mg/L) and laminin (0.4mg/L). All cell cultures were maintained in

humidified 5% CO_2 incubators at $37^{\circ}C$.

[14]C-cystine uptake assay: The assessment of system x_c- (Sxc) activity is often

achieved by measuring intracellular uptake of radiolabeled cystine since this is primarily

dependent on Sxc (Liu et al., 2009; Liu et al., 2014a; Resch et al., 2014b; Albano et al.,

2015). Note, we demonstrated that over 85% of ^{14}C-cystine uptake in our cells was

blocked by the Sxc inhibitor sulfasalazine (SSZ; see Figure 2.3B). In contrast,

extracellular glutamate is an insensitive indicator of Sxc since this is a product of

numerous mechanisms (Swanson et al., 1997; Duan et al., 1999; Perego et al., 2000;

Montana et al., 2004; Hires et al., 2008). Radiolabeled cystine uptake assays were

performed as described previously with minor modifications (Liu et al., 2009). In brief,

experiments were conducted in a bead bath at $37^{\circ}C$. Cells were washed 3 times with

warm HEPES buffered saline solution, after which ^{14}C-cystine was added to the media for 20 min at a final concentration of 0.3µM. This concentration was used since it is similar to extracellular cystine concentrations in the brain (Baker et al., 2003). DL-threo-β-Hydroxyaspartic acid (TBOA; 10 µM) was added to the culture media to prevent ^{14}C-cystine uptake by sodium-dependent glutamate transporters. As described below, some of the experiments also involved the addition of the Sxc inhibitor SSZ (300 µM), PACAP, or P6-38. After incubating cells with ^{14}C-cystine, cells were washed 3 times with ice-cold HEPES buffered saline solution, and then solubilized with 1M NaOH solution. One aliquot of cell lysate was used for protein determination using a BCA protein assay, and another aliquot was used for scintillation counting to measure the level of ^{14}C-cystine uptake. ^{14}C-cystine content was normalized to protein concentration. Data are presented as CPM/µg of protein.

RNA extraction and cDNA construction: Total RNA was isolated from cell cultures with Trizol Reagent (Invitrogen; Carlsbad, CA) following the manufacture's protocol. DNase treatment was applied to all RNA samples to remove potential genomic DNA contamination with a DNA-free kit (Life Technologies, Carlsbad, CA). Assessment of RNA purity and quantity was performed on a NanoVue Plus Spectrophotometer (GE life sciences; Pittsburg, PA). cDNA was constructed from total RNA using the Reverse Transcription System (Promega, Madison, WI) with oligo(dT) primers following the manufacture's protocol.

Real-time quantitative PCR: Quantitative PCR was performed using a StepOne Real-Time PCR System (Applied Biosystems; Carlsbad, CA) and PerfeCTa SYBR Green FastMix with ROX (Quanta Biosciences; Gaithersberg, MD). Relative quantification of

target gene expression was normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the $\Delta\Delta C_t$ method (Schmittgen and Livak, 2008). Primer sequences were as follows. xCT (catalytic subunit of Sxc) forward- 5' AGG GCA TAC TCC AGA ACA CG 3'; xCT reverse- 5' ATG CTC GTA CCC AAT TCA GC 3'; PACAP forward-5' AAC CCG CTG CAA GAC TTC TA 3'; PACAP reverse- 5' CTT TGC GGT AGG CTT CGT TA 3'; PAC1R forward- 5' TGC CTG TGG CTA TTG CTA TG 3'; PAC1R reverse- 5' TTT AGT CCC ATC AGG TCG TTG 3'; GAPDH forward- 5' CTC CCA TTC TTC CAC CTT TGA 3'; GAPDH reverse- 5' ATG TAG GCC ATG AGG TCC AC 3'. Primers were designed to be intron-spanning using the online primer design tool Primer3 (http://biotools.umassmed.edu/bioapps/primer3_www.cgi). A single product from amplification was confirmed by melt curve analysis. Amplification efficiency of all genes was determined to be approximately 95%.

Statistics: Statistical analyses were performed using SPSS Statistics (Version 19, IBM; Armonk, New York). Analysis of variance (ANOVA) was used when comparing data sets that included more than two groups. Bonferroni tests were used for subsequent *post hoc* analyses of significant effects involving more than two groups. Student's t tests were used when comparing results from only two groups. In all instances, statistical significance was designated as $p < 0.05$.

Experiment 1: Neuronal regulation of Sxc. The goal of this experiment was to test the hypothesis that a releasable neuronal factor regulates Sxc activity in astrocytes. To do this, we used two distinct approaches to co-express rat cortical neurons and astrocytes in culture. First, we measured ^{14}C-cystine uptake in rat mixed cortical cultures

(DIV 13-16). The advantage of this approach is that astrocytes are continuously grown in the presence of neurons. A disadvantage of this approach is that these cultures contain a limited number of microglia and oligodendrocytes. In addition, neurons physically contact astrocytes in these cultures. To address these two points, we also measured ^{14}C-cystine uptake by astrocytes that had been exposed to neuron-conditioned media.   To do this, we first generated purified astrocyte cultures as described above. When astrocytes reached confluency (typically 13-16 DIV), neuronal cultures were seeded on removable inserts which were placed into the wells containing astrocytes, such that both cell types were co-cultured yet with no physical contact. Fourteen days later, the neuronal inserts were removed, and ^{14}C-cystine uptake was measured as described above. Note the 14-day period represents the time needed for the neurons to mature. The control cells in this experiment were purified astrocyte cultures in which the inserts lacked neurons. Tests using these cells occurred on DIV 27-30.

   Experiment 2: Neuronal upregulation of Sxc requires PACAP receptor signaling. In an effort to begin to unmask the molecular basis of neuron-astrocyte signaling that regulates Sxc, we examined the impact of disrupting PACAP signaling on cystine uptake in rat cortical cultures. Our interest in PACAP stems from previous studies showing that stimulation of PACAP receptors increases the activity of Sxc and GLT1 (Figiel and Engele, 2000; Resch et al., 2014b), both of which are primarily expressed by astrocytes (Rothstein et al., 1994; Lehre et al., 1995; Rothstein et al., 1996; Torp et al., 1997; Pow, 2001; Zhang et al., 2014). To examine the involvement of PACAP, we modified the neuronal insertion design that was introduced in Experiment 1. In brief, media from cultured astrocytes only or astrocytes that were cocultured with

neurons (i.e., neuronal insertion) were applied to astrocytes (13-16 DIV) for 24 hours.

PACAP antiserum was added to the media of some cultures during 24-hour incubation to

neutralize the potential PACAP content (Figiel and Engele, 2000). Alternatively, we

examined the impact of blocking PACAP receptors on cystine uptake. To do this, vehicle

or 10 µM P6-38 (see Figiel and Engele, 2000 for concentration justification) was applied

to rat cortical cultures (DIV 13-16) for 60 min, at which point ^{14}C-cystine uptake was

measured as described above.

Experiment 3: PACAP upregulates Sxc on astrocytes. In this experiment, we

tested the hypothesis that exogenous application of PACAP would significantly

upregulate Sxc activity in purified astrocyte cultures. To test this, PACAP (0-100 nM)

was applied to purified astrocyte cultures (DIV 13-16) for 24 hours. Afterwards, ^{14}C-

cystine uptake was measured as described above. This experiment was also conducted in

purified neuronal and mixed cortical cultures although the predicted outcome was less

certain given the likely expression of endogenous PACAP in these cultures.

Experiment 4: Cellular distribution of PACAP and PAC1R in rat cortical

cultures. To further examine the possibility that PACAP is a neuronal factor capable of

regulating astrocytes, we examined the cellular expression patterns of PACAP and its

primary receptor, PAC1R. We were specifically interested in determining whether

PACAP was solely expressed in neurons and PAC1R in purified astrocytes. To do this,

we used RT-qPCR to measure mRNA expression for PACAP and PAC1R in mixed

cultures, purified astrocyte cultures, and purified neuronal cultures (DIV 13-16).

Experiment 5: Regulation of xCT mRNA by neurons and the neuronal factor

PACAP. To better understand the observed upregulation of astrocyte Sxc by neurons or

PACAP, we measured xCT mRNA in purified astrocytes and mixed cultures, purified

astrocytes ± neuronal-conditioned media, and purified astrocytes ± PACAP.

Results

Experiment 1: Neuronal regulation of Sxc. To determine whether neurons are

capable of regulating astrocyte Sxc activity, we used two approaches to permit neuron-

astrocyte signaling. First, astrocyte and neurons were co-cultured upon plating (mixed

Figure 2.1. Neurons upregulate Sxc activity in astrocytes. Data depict the mean ± SEM levels of ^{14}C-cystine measured in rat cortical cells (N=8-12/condition) that had been cultured for 13-16 or 27-30 days *in vitro* (DIV). Astro, astrocytes; NCM, neuronal conditioned media. * represents a significant difference from corresponding purified astrocytes, $p < 0.001$.

cultures). This approach is designated in Figure 2.1 as DIV 13-16, which refers to the

number of days the cells had been cultured. In addition, confluent, purified astrocyte

cultures were exposed to neuronal conditioned media (NCM) by placing neurons grown

onto an insert into the wells containing the astrocytes for 14 days (as described in the

methods for experiment 1). This approach is designated in Figure 2.1 as DIV 27-30. A univariate ANOVA with DIV and culture cellular composition (i.e., astrocytes only or mixed or astrocyte + NCM) as between subjects factors produced a main effect of cell composition [Figure 2.1; $F_{(1,36)}=77.979$, $p < 0.001$] but not a main effect of DIV or an interaction between these variables. These findings illustrate that a releasable neuronal factor significantly upregulates Sxc activity on astrocytes (see Figure 2.1).

Experiment 2: Neuronal upregulation of Sxc requires PACAP receptor signaling. Previous studies have shown that PACAP increases the activity of Sxc and GLT1 (Figiel and Engele, 2000; Resch et al., 2014b), both of which are primarily expressed by astrocytes (Rothstein et al., 1994; Lehre et al., 1995; Rothstein et al., 1996; Torp et al., 1997; Pow, 2001; Zhang et al., 2014). In an effort to reveal the molecular basis of neuron-astrocyte signaling that regulates Sxc, we examined the impact of inhibiting PACAP signaling via neutralizing PACAP on the ^{14}C-cystine uptake in rat cortical cultures. Twenty-four hours later, Sxc activity was assessed with cystine uptake assay (Figure 2.2A). A univariate ANOVA with media origin (ACM vs NACM) and PACAP antiserum treatment (vehicle or 1:600 antiserum) as between-subjects variables yielded a significant interaction [Figure 2.2A; $F_{(1,30)}=10.577$, $p < 0.01$].

Figure 2.2. PACAP mediates neuronal regulation of Sxc activity. (A) Data depict mean ± SEM levels of ^{14}C-cystine in rat purified astrocyte cultures after 24 hours treatment with the media transferred from astrocytes (astrocyte-conditioned media, ACM) or astrocytes cocultured with neurons (neuron-astrocyte-conditioned media, NACM), with or without the presence of PACAP antiserum (Ab; N=6-12/condition). * indicates a significant difference relative to ACM treated cells that were not exposed to PACAP antiserum, T-test $p < 0.01$. # indicates a significant difference relative to NACM treated cells that were not exposed to PACAP antiserum, T-test $p < 0.01$. (B) Data depict the uptake of ^{14}C-cystine in rat cortical cultures in the presence or absence of the PACAP receptor inhibitor P6-38 (vehicle or 10 μM; N=6-12/condition). * indicates a significant difference relative to vehicle treated mixed cortical cultures, Bonferroni, $p < 0.001$.

As predicted, media from the astrocyte-neuron cocultures (NACM) increased Sxc activity (T-test, $p <0.01$), while removing free-PACAP from the NACM with PACAP-neutralizing antiserum significantly decreased Sxc activity (T-test, $p <0.01$). In addition, we examined the impact of inhibiting PACAP receptors with PACAP6-38 (P6-38) on ^{14}C-cystine uptake in rat mixed, purified astrocyte, and purified neuronal cortical cultures. A univariate ANOVA with cell composition and P6-38 treatment (0 or 10 μM) as between-subjects variables yielded a significant interaction [Figure 2.2B; $F_{(2,62)}=73.849$, $p < 0.001$]. To deconstruct the interaction, we compared ^{14}C-cystine levels in vehicle-treated mixed cultures to every other condition. We found that vehicle-treated cultures containing neurons and astrocytes (i.e., mixed) displayed significantly higher levels of ^{14}C-cystine, and that this effect was blocked by inhibiting PACAP receptors with PACAP6-38 (P6-38) (Bonferroni, $p < 0.001$). Interestingly, P6-38 did not alter ^{14}C-cystine levels in purified astrocyte or in purified neuronal cultures. Together, these data suggest that PACAP mediates neuronal regulation of Sxc activity on astrocytes through activating PACAP receptors, and that the endogenous PACAP-induced upregulation of Sxc activity is only present in mixed cortical cultures (see Figure 2.2).

Experiment 3: PACAP up-regulates Sxc on astrocytes. To confirm that PACAP promotes Sxc activity in rat cortical astrocytes, we compared ^{14}C-cystine uptake in mixed cultures, purified astrocyte cultures, and purified neuronal cultures following PACAP application (24 hours) in the presence or absence of the Sxc inhibitor sulfasalazine (SSZ). A univariate ANOVA with culture cell composition and PACAP treatment as between subjects factors produced a significant interaction [Figure 2.3A; $F_{(4,62)}=31.958$, $p < 0.001$]. To further analyze the data, we examined the impact of

PACAP on ^{14}C-cystine uptake in each type of culture. A significant simple main effect

of PACAP treatment was obtained only in purified astrocyte cultures [F(2,21)=75.904, *p*

< 0.001]. Subsequent *post hoc* analyses revealed that PACAP increased uptake at 10 and

100 nM (Bonferroni, *p* < 0.001).

Figure 2.3. PACAP upregulates Sxc activity in cortical astrocytes only. (A) Data depict mean ±SEM levels of ^{14}C-cystine in rat cortical cell cultures after 24 hours PACAP treatment (0-100 nM; N=8/condition). * indicates a significant difference relative to vehicle-treated purified astrocyte cultures, Bonferroni, *p* < 0.001. (B) Data depict mean ±SEM levels of ^{14}C-cystine in rat purified astrocyte cultures after 24 hours PACAP (0 or 100 nM) assessed in the presence of an Sxc inhibitor sulfasalazine (SSZ, 0 or 300 μM; N=4/condition). * indicates a significant difference relative to PACAP vehicle treated cells that were not exposed to SSZ (-SSZ), Bonferroni *p* < 0.001.

Although Sxc is primarily associated with astrocytes, we verified that PACAP-induced increases in ^{14}C-cystine uptake reflect Sxc activity. To do this, we assessed the impact of PACAP on ^{14}C-cystine uptake by astrocytes in the presence and absence of the Sxc inhibitor SSZ. A univariate ANOVA with PACAP and SSZ treatments as between-subjects factors resulted in a significant interaction [Figure 2.3B; $F(1,12)=19.130$, $p < 0.01$]. *Post hoc* analyses indicated that PACAP increased ^{14}C-cystine uptake in astrocytes when tested in the absence (Bonferroni, $p < 0.001$), but not in the presence of SSZ.

Experiment 4: Cellular distribution of PACAP and PAC1R in rat cortical cultures. To further examine the possibility that PACAP is a neuronal factor capable of regulating astrocytes, we assessed the cellular expression patterns of PACAP and its primary receptor, PAC1R (Gottschall et al., 1990; Lam et al., 1990). A one-way ANOVA with culture cell composition as a between-subjects factor yielded a main effect on PACAP mRNA levels [Figure 2.4A; $F(2,17)=294.774$, $p < 0.001$]. *Post hoc* analyses revealed that mixed and purified neuronal cultures expressed the highest levels of PACAP mRNA (Bonferroni, $p < 0.001$). In fact, PACAP mRNA was not detectable in purified astrocyte cultures (Figure 2.4A). A one-way ANOVA comparing the cellular distribution of PAC1R mRNA yielded a main effect of cell type [Figure 2.4B; $F(2,17)=93.863$, $p < 0.001$]. *Post hoc* analyses revealed expression of PAC1R in every cell type, but with the highest levels evident in mixed cortical cultures (Bonferroni, $p < 0.001$). Collectively, these results demonstrate that in rat cortical cultures, PACAP is solely expressed in neurons and its primary receptor, PAC1R, is expressed by astrocytes.

A

B

Figure 2.4. The cellular expression patterns of PACAP and its primary receptor, PAC1R, support the possibility that PACAP is a neuropeptide capable of regulating astrocyte Sxc activity. (A) Data depict mean $\pm$ SEM levels of PACAP mRNA in rat cortical cells cultures (N= 5-8/cell type). * indicates a significant difference relative to mixed cultures, Bonferroni, $p <$ 0.001. # indicates a significant difference relative to purified astrocyte cultures, Bonferroni, $p <$ 0.001. (B) Data depict mean $\pm$ SEM levels of PAC1R mRNA in rat purified astrocyte and neuronal cultures relative to that in cortical mixed cell cultures (N= 5-8/cell type). * indicates a significant difference relative to mixed cultures, Bonferroni, $p < 0.001$.

Experiment 5: Neurons and PACAP increase xCT mRNA. To better

understand the observed upregulation of astrocyte Sxc activity by neurons or PACAP, we

measured mRNA levels of xCT, the functional subunit of Sxc (Sato et al., 1999; Sato et

al., 2000; Bridges et al., 2001). Mixed cultures of astrocytes and neurons [t(6)=17.734, *p*

< 0.001], as well as purified astrocyte cultures exposed to NCM [t(13)=13.431, $p < 0.001$]

expressed significantly higher levels of xCT mRNA relative to respective controls

(Figure 2.5). Similarly, PACAP application in purified astrocytes also robustly increased

xCT mRNA [Figure 2.5; t(10)=16.554, $p < 0.001$]. Together, these results suggest that

the upregulation of astrocyte Sxc by neurons or PACAP may involve increased Sxc

expression.

Figure 2.5. Exposure to neurons and PACAP increase xCT mRNA in cultured cortical astrocytes. Data depict mean ±SEM levels of xCT mRNA (normalized to respective controls) in rat cortical cells cultures (N=4-12/condition). Astro refers to purified astrocyte cultures; mixed cells refer to cultures comprised of neurons and astrocytes; NCM refers to neuronal conditioned media achieved by placing neurons grown on inserts into the culture wells containing astrocytes for 14 days; PACAP treatment was for 24 hours at 10 nM. * indicates a significant difference relative to the respective control, t-test, $p < 0.001$.

Discussion

Glutamate signaling is achieved by an elaborate network likely requiring coordinated activity between neurons and astrocytes. In support, both cells express glutamate receptors, transporters, and release mechanisms (Choi, 1988; Greenamyre et al., 1988; Coyle and Puttfarcken, 1993; Moghaddam and Adams, 1998; Araque et al., 1999; Tapia et al., 1999; Marino et al., 2001; Franks et al., 2003; Haydon and Carmignoto, 2006; Javitt et al., 2011; Santello et al., 2012; Araque et al., 2014; Perez-Alvarez et al., 2014). The purpose of these experiments was to determine whether, and how, neurons regulate components of the glutamate system expressed by astrocytes. To do this, we focused on system x_c- (Sxc) since this non-canonical release mechanism has been shown to be expressed primarily by astrocytes (Bannai and Kitamura, 1980, 1981; Sato et al., 1999; Pow, 2001; Zhang et al., 2014), significantly contributes to glutamate homeostasis (Baker et al., 2002; Xi et al., 2002; Melendez et al., 2005), regulates neuronal activity (Xi et al., 2002; Moran et al., 2005; Moussawi et al., 2009; Moussawi and Kalivas, 2010; Moussawi et al., 2011; Kupchik et al., 2012), and has been linked to multiple CNS diseases (Bridges et al., 2012a; Lewerenz et al., 2013; Deepmala et al., 2015). Our major finding is that Sxc activity is significantly increased when astrocytes are exposed to neurons or to neuronal factors, including pituitary adenylate cyclase-activating peptide (PACAP). These findings are significant, in part, because they illustrate a novel form of neuron to astrocyte communication. Hence, pathological changes involving components of the glutamate system expressed by astrocytes, such as Sxc, may stem from aberrant activity of neuronal circuits.

Neuronal Regulation of Sxc

In these studies, we found that the uptake of ^{14}C-cystine was higher in rat cortical cultures comprised of neurons and astrocytes relative to purified astrocyte cultures. One interpretation of these data is that neurons up-regulate Sxc activity in astrocytes. This conclusion, along with findings that neurons are critical in regulating the expression and activity of sodium-dependent glutamate transporters (Swanson et al., 1997; Figiel and Engele, 2000), highlights the need for neurons and astrocytes to display coordinated activity in order to achieve normal glutamate signaling. Alternative interpretations of our data include the possibility that neurons indirectly regulate Sxc activity. For example, neurons may influence the development of astrocytes, which may in turn influence Sxc.

In order to more directly test the hypothesis that a releasable neuronal factor coordinates Sxc activity on astrocytes, we evaluated the impact of neuronal conditioned media on ^{14}C-cystine uptake in cortical astrocytes. In this experiment, purified astrocyte cultures were conditioned to neurons through a non-contact co-culture system, in which neurons seeded on removable inserts were placed in astrocyte cultures for 14 days. Afterwards, the neuronal inserts were removed in order to measure ^{14}C-cystine uptake into astrocytes. Similar to our earlier finding, we found that cortical astrocytes that were exposed to neuronal conditioned media displayed significantly higher ^{14}C-cystine uptake. We did not observe any other difference in the astrocyte cultures exposed to neuronal conditioned media from those lacking neurons. For example, the protein counts (mean $\pm$ SEM: astrocytes, 267.1 ± 6.8 μg/ml; astrocytes exposed to NCM, 254.4 ± 6.0 μg/ml) or cell confluency did not differ. As a result, these findings support the conclusion that

neurons are capable of regulating components of the glutamate system expressed on astrocytes.

Regulation of Sxc by the neuropeptide PACAP

In an attempt to identify potential neuronal factors capable of regulating Sxc on astrocytes, we examined the possible involvement of PACAP since this peptide has been shown to be expressed by cortical neurons (Koves et al., 1991; Waschek et al., 1998; Figiel and Engele, 2000) and capable of regulating components of the glutamate system expressed by astrocytes including GLT1 and GLAST in rat cortical glial cultures and Sxc in mouse glial cultures (Figiel and Engele, 2000; Resch et al., 2014b). We sought to extend these studies by examining whether neuron-induced upregulation of ^{14}C-cystine uptake requires PACAP signaling. To do this, we took two separate approaches to disrupt signaling of PACAP in astrocytes. First, we sought to use neutralizing antiserum to remove PACAP from neuronal conditioned media (Figiel and Engele, 2000). In order to do this, however, we needed to modify the assay such that the compensatory changes involving PACAP release would not overwhelm PACAP antiserum. Therefore, instead of co-incubating astrocytes with neurons for 14 days, we applied neuronal conditioned media for 24 hours. As we predicted, media from neuron-astrocyte cocultures were capable of significantly increasing Sxc activity in astrocytes in a much shorter time period (e.g., 24 hours versus 14 days). This is important because it allowed us to examine the involvement of PACAP by neutralizing the potential PACAP content in the media with PACAP antiserum. Alternatively, blocking PACAP receptors with antagonists could also inhibit PACAP signaling. Application of PACAP6-38 (P6-38), a truncated version of PACAP that inhibits PACAP receptors including PAC1R and VPAC2R, and also CART

receptor (Robberecht et al., 1992; Gourlet et al., 1995; Laburthe et al., 2007; Hawke et al., 2009; Mounien et al., 2009; Lin et al., 2011), decreased ^{14}C-cystine uptake in mixed cortical cultures to the level observed in purified astrocyte cultures. Interestingly, P6-38 did not alter ^{14}C-cystine uptake in purified astrocytes or neurons. The results obtained in purified neuronal cultures likely reflect the relative lack of Sxc activity in these cells, although it should be noted that low amounts of ^{14}C-cystine are detected in these cells. The lack of a P6-38 effect in purified astrocytes indicates the lack of endogenous PACAP signaling in these cells.

In order to further evaluate the conclusion that PACAP is a neuropeptide capable of directly regulating astrocytes, we examined the cellular distribution of mRNA for PACAP and its primary receptor, PAC1R. PACAP mRNA expression in cortical cultures was restricted to neurons, thereby establishing PACAP as a neuropeptide in these cultures. In contrast, both cortical neurons and astrocytes express mRNA for PAC1R, which has been shown to be the most abundant PACAP receptor that is expressed in cortical astrocytes (Zhang et al., 2014). However, PACAP also stimulates VPAC1 and VPAC2 receptors, which are also expressed by astrocytes (Grimaldi and Cavallaro, 1999). Hence, there is a need to identify the receptor(s) that contributes to the regulation of Sxc by PACAP. Interestingly, we found significantly higher levels of PACAP and PAC1R in mixed cultures comprised of neurons and astrocytes, compared to either cell type cultured alone, which may suggest that astrocytes influence the neuronal PACAP expression. Yet, whether the upregulation of PAC1R reflects an increase in astrocytes or neurons is not clear. Notably, changes in mRNA do not always result in changes in protein expression and function. While future experiments are needed to further explore the potential for

astrocyte-neuron communication to be an important determinant of PACAP signaling, our extant results are consistent with the possibility that PACAP is a neuropeptide capable of regulating components of the glutamate system expressed by astrocytes.

Next, we directly tested the hypothesis that PACAP application increases Sxc activity in astrocytes. We found that PACAP application significantly increased ^{14}C-cystine uptake in rat cortical astrocytes, but not in mixed or purified neuronal cultures. While we anticipated PACAP-induced increases in ^{14}C-cystine uptake in rat cortical astrocytes and a lack of an increase in purified neuronal cultures since these cells generally display little to no Sxc activity, we expected a modest increase in the mixed cortical cultures, an outcome we previously observed in mouse cultures (Resch et al., 2014b). Aside from species, the difference between these studies is not clear, but likely reflects the existence of endogenous PACAP signaling. Collectively, these results are consistent with PACAP functioning as a neuronal factor controlling glutamate signaling involving astrocytes.

The nature of PACAP-induced regulation of Sxc in astrocytes is likely complex. For example, we found evidence that application of PACAP for 24 hours increased mRNA of xCT, the active subunit for Sxc. While increases in mRNA do not always result in augmented protein, it is important to note that PACAP also upregulated Sxc activity. Further, elevated xCT mRNA and increased Sxc activity were also evident in astrocytes cultured with neurons. Collectively, these data suggest that neurons influence the expression of Sxc in astrocytes. In addition, however, we found that relatively brief inhibition of PACAP signaling (i.e., 60 min) produced a significant reduction in Sxc

activity, which suggests the possibility of post-translational modification. Additional studies are needed to better understand neuron or PACAP-induced regulation of Sxc.

Altered glutamate signaling likely underlies, at least in part, many disorders of the brain. Hence, it is critical to better understand how coordinated activity across distinct cell types involved in the transmission of this amino acid, is achieved. For example, Sxc has been implicated in several CNS diseases (Baker et al., 2003; Chung et al., 2005; Madayag et al., 2007; Baker et al., 2008; Knackstedt et al., 2010; Bridges et al., 2012a; Lewerenz et al., 2013; Lutgen et al., 2013; Albano et al., 2015; Ching et al., 2015; Deepmala et al., 2015). Similarly, altered activity of GLT1 and other glutamate transporters expressed by astrocytes has also been implicated in pathological glutamate transmission (Soni et al., 2014; Jensen et al., 2015; Roberts-Wolfe and Kalivas, 2015). In each case, however, it is unclear how glutamate signaling involving astrocytes may be altered. Collectively, these studies indicate that aberrant neural activity may be a novel factor underlying pathological changes in glutamate stemming from altered regulation of astrocytes. Moreover, PACAP itself is especially interesting in this regard as it has been shown to regulate glutamate uptake and release by astrocytes.

CHAPTER III

PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE-INDUCED
REGULATION OF SYSTEM X_C- IN STRIATAL ASTROCYTE

Introduction

The previous chapter revealed that neurons regulate system x_c- (Sxc), a cystine-glutamate antiporter expressed primarily by astrocytes, through releasable factors. Moreover, this regulation appears to be mediated by the pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide expressed exclusively by neurons. This novel form of neuron-astrocyte interaction likely contributes to coordinated glutamate transmission in the brain, to which malfunctions have been indicated in numerous CNS disorders.

The regulation involved 24-hr PACAP application. Thus, it is unclear whether rapid, phasic changes in PACAP would regulate Sxc. This is important because phasic regulation is likely necessary for rapid control of synaptic transmission and behavior. At this point, the impact of PACAP is only observed in cortical astrocytes. Given our interest in understanding the regulation of NAc astrocytes, there is a need to determine whether these properties are restricted to the cortex. As such, in this chapter, we seek to expand our understanding of PACAP-induced regulation of Sxc in the cortex and striatum.

Three receptors, PAC1R, VPAC1R and VPAC2R, have been identified to mediate PACAP signaling (Vaudry et al., 2009). They are G-protein coupled receptors and are positively linked to Gαs (Harmar et al., 1998; Harmar, 2001). Therefore, activation of these receptors leads to stimulation of adenylyl cyclase (AC) and

intracellular accumulation of cAMP (Harmar, 2001). In addition, PAC1R is reportedly paired with more diverse transduction systems, including the activation of a Gαq-PLC cascade and the elevation of intracellular calcium (Arimura, 1998; Vaudry et al., 2000; Zhou et al., 2001; Dickson and Finlayson, 2009; Vaudry et al., 2009).

PKA and PKC are the two canonical kinases induced by Gαs and Gαq activations. Interestingly, sequence analyses of human xCT demonstrate two consensus PKA sites (Baker et al., 2002), and both PKA and PKC have been shown to influence Sxc activity (Gochenauer and Robinson, 2001; Baker et al., 2002; Tang and Kalivas, 2003). Taken together, PKA and PKC are potentially involved in PACAP-induced regulation of Sxc. Other cascades induced by PACAP include AC-cAMP-Epac, PI3K-AKT, MEK-ERK and CaMK pathways, some of which have been implicated in the regulation of Sxc and/or PACAP-induced regulation of astrocyte functions (Moroo et al., 1998; Vallejo and Vallejo, 2002; Hashimoto et al., 2003; Perez et al., 2005; Liu et al., 2012; Seo and Lee, 2016). Therefore, these pathways also potentially contribute to the actions of PACAP on Sxc.

In this chapter, we used purified astrocyte cultures derived from striatal tissues to expand our understanding of PACAP-induced regulation of Sxc. We found that PACAP upregulates Sxc in a dose- and time- dependent manner in both striatal and cortical astrocytes. Importantly, phasic PACAP significantly increases Sxc activity. In addition, we show the expression of all three PACAP receptor subtypes in both cortical and striatal astrocytes, with PAC1R and VPAC2R more abundantly expressed in astrocytes than in neurons. Lastly, our data suggest that the actions of PACAP on astrocyte Sxc are mediated by PKA, Epac and MEK/ERK.

Material and Methods

     Animals and Materials: These experiments utilized cortical tissues obtained from Sprague Dawley rats (age was gestational day 15-16 or post-natal day 3-4; sex was undetermined; Envigo, Indianapolis, IN). Experimental procedures were approved by the Marquette University Institutional Animal Care and Use Committee. The primary materials included fetal bovine serum and horse serum (Atlanta Biologicals; Lawrenceville, GA), ^{14}C-cystine (PerkinElmer, Waltham, MA) and PACAP1-38 (PACAP; California Peptide Research, Napa, CA). All kinase activators and inhibitors were obtained from Sigma-Aldrich (Milwaukee, WI), including H89 (PKA inhibitor), Go6983 (PKC inhibitor), ESI09 (Epac inhibitor), KN93 (CaMKII inhibitor), LY294002 (PI3K inhibitor), U0126 (MEK inhibitor) and PD98059 (MEK inhibitor). All peptides were dissolved in saline, while all kinase inhibitors were reconstituted in DMSO.

     Cell Culture Procedures: <u>Purified astrocyte cultures</u> were prepared from rat pups on post-natal day 3-4. In brief, cortical or striatal cells were disassociated and then suspended in Neurobasal A media (Thermo Fisher Scientific, Waltham, MA), supplemented with 10% fetal bovine serum, and 1% Glutamax (Thermo Fisher Scientific, Waltham, MA). Cells were initially grown in 25cm^2 or 75cm^2 cell culture flasks. Once confluent, cells were then subjected to prolonged, orbital shaking (250 rpm for 18 hours at 37°C), which has been used to yield purified astrocyte cultures (McCarthy and de Vellis, 1980; Schildge et al., 2013). Purified astrocytes were then plated on 24-well plates, and refreshed with 70% new culture media every 2-3 days. Typically, it required 13-16 days *in vitro* (DIV13-16) for these cells to reach confluency, after which experiments were conducted.

Purified neuronal cultures were prepared from embryonic rat cortical (gestational day 15 to 16) tissues as previously described (Lobner, 2000), or striatal tissues (gestational day 17 to 18). In brief, dissociated cells were suspended in Eagles' Minimal Essential Medium (MEM, Earle's salts, glutamine-free), supplemented with glutamine (2mM), glucose (21mM), horse serum (5%), and fetal bovine serum (5%). Cells were seeded on 24-well plates. Forty eight hours later, cytosine arabinoside (at a final concentration of 10 μM) was added to the culture media to inhibit glial reproduction (Dugan et al., 1995). Neurons were then grown for an additional 11-13 days.

All cell-growing surfaces in culture flasks and 24-well plates were pre-coated with poly-D-lysine (10mg/L) and laminin (0.4mg/L). All cell cultures were maintained in humidified 5% CO_2 incubators at 37°C.

^{14}C-cystine Uptake Assay: The assessment of system x_c- (Sxc) activity is often achieved by measuring intracellular uptake of radiolabeled cystine, since this is primarily dependent on Sxc (Liu et al., 2009; Liu et al., 2014a; Resch et al., 2014b; Albano et al., 2015). As demonstrated previously, over 85% of ^{14}C-cystine uptake in our cells was blocked by the Sxc inhibitor sulfasalazine (SSZ; Chapter II, Figure 2.3B). Radiolabeled cystine uptake assays were performed as described previously with minor modifications (Liu et al., 2009). In brief, experiments were conducted in a bead bath at 37°C. Cells were washed 3 times with warm HEPES buffered saline solution, after which ^{14}C-cystine was added to the media for 20 min at a final concentration of 0.3μM. This concentration was used since it is similar to extracellular cystine concentrations in the brain (Baker et al., 2003). DL-threo-β-hydroxyaspartic acid (TBOA; 10 μM) was added to the culture media to prevent ^{14}C-cystine uptake by sodium-dependent glutamate transporters. After

incubating cells with ^{14}C-cystine, cells were washed 3 times with ice-cold HEPES buffered saline solution, and then solubilized with 1M NaOH solution. One aliquot of cell lysate was used for protein determination using the bicinchoninic acid (BCA) assay, and another aliquot was used for scintillation counting to measure the level of ^{14}C-cystine uptake. ^{14}C-cystine content was normalized to protein concentration. Data are presented as CPM/µg of protein or normalized to respective controls.

RNA extraction and cDNA construction: Total RNA was isolated from cell cultures with Trizol Reagent (Invitrogen; Carlsbad, CA) following the manufacture's protocol. DNase treatment was applied to all RNA samples to remove potential genomic DNA contamination with a DNA-free kit (Life Technologies, Carlsbad, CA). Assessment of RNA purity and quantity was performed on a NanoVue Plus Spectrophotometer (GE life sciences; Pittsburg, PA). cDNA was constructed from total RNA using the Reverse Transcription System (Promega, Madison, WI) with oligo(dT) primers following the manufacturer's protocol.

Polymerase Chain Reaction (PCR) and Gel Electrophoresis: PCR were performed with GoTaq Green Master Mix (Promega, Madison, WI) on a thermocycler with the following parameters: initial denaturation (3min at 95 ℃), amplification (35 cycles of the following: 95 ℃ for 30s, 60 ℃ for 45s, 72 ℃ for 45s), and extension (72 ℃ for 10min). PCR products were then examined with electrophoresis on an agarose gel (1.8%) along with a 100bp DNA Ladder (Promega, Madison, WI) to locate target PCR products.

Real-time quantitative PCR: Quantitative PCR was performed using a StepOne Real-Time PCR System (Applied Biosystems; Carlsbad, CA) and PerfeCTa SYBR Green

FastMix with ROX (Quanta Biosciences; Gaithersberg, MD). Relative quantification of target gene expression was normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the $\Delta\Delta C_t$ method (Schmittgen and Livak, 2008). Primer sequences were as follows. xCT (catalytic subunit of Sxc) forward- 5' AGG GCA TAC TCC AGA ACA CG 3'; xCT reverse- 5' ATG CTC GTA CCC AAT TCA GC 3'; PAC1R forward- 5' TGC CTG TGG CTA TTG CTA TG 3'; PAC1R reverse- 5' TTT AGT CCC ATC AGG TCG TTG 3'; VPAC1R forward-5' TGA GAT ACA GCG TCA GCA GTG 3'; VPAC1R reverse- 5' GCA AAC AGC TGA AAG ATG AGG 3'; VPAC2R forward-5' TGG CAA TGA CCA GTC ACA GT 3'; VPAC2R reverse- 5' CCT GGA AGG AAC CAA CAC AT 3'; GAPDH forward- 5' CTC CCA TTC TTC CAC CTT TGA 3'; GAPDH reverse- 5' ATG TAG GCC ATG AGG TCC AC 3'. Primers were designed to be intron-spanning using the online primer design tool Primer3 (http://biotools.umassmed.edu/bioapps/primer3_www.cgi). A single amplified product was confirmed by melt curve analysis. Amplification efficiency of all genes was determined to be approximately 95%.

Statistics: Statistical analyses were performed using SPSS Statistics (Version 24, IBM; Armonk, New York). Analysis of variance (ANOVA) was used when comparing data sets that included more than two groups. Tukey HSD tests were used for subsequent *post hoc* analyses of significant effects involving more than two groups. Student's t-tests were used when comparing results from only two groups. In all instances, statistical significance was designated as $p < 0.05$.

Results

  Experiment 1: PAC1R and VPAC2R are enriched in cultured astrocytes obtained from striatal tissues. Since Sxc in the nucleus accumbens (NAc, ventral striatum) is critical for motivated behavior (Baker et al., 2003; Kau et al., 2008; Berglind et al., 2009; Kalivas, 2009; Knackstedt et al., 2009; Kupchik et al., 2012), we were interested in examining whether PACAP would regulate Sxc in striatal astrocytes. To do this, we first sought to determine which PACAP receptors these cells express. To date, three PACAP receptors, including PAC1R, VPAC1, and VPAC2R, have been identified. Therefore, we investigated the expression of these receptors in cortical and striatal astrocytes; cortical astrocytes were used as positive controls as they have been shown to express all these receptors (Zhang et al., 2014). Using PCR, we detected mRNAs of all three receptors in both cortical and striatal astrocytes. With a more stringent quantitative method, RT-qPCR, we investigated the relative levels of PAC1R and VPAC2R in striatal cell cultures (Figure 3.1B, C). These two PACAP receptors are selected because they have been shown to be significantly more abundant than VPAC1R in astrocytes, with FPKM (fragments per kilobase of transcript per million mapped reads) values to be > 150 (PAC1R), < 0.2 (VPAC1R) and ≈ 2 (VPAC2R) (Zhang et al., 2014). Moreover, both PAC1R and VPAC2R appear to be more enriched in astrocytes than in neurons, with ratios at 10:1 (PAC1R) and 5:1 (VPAC2R), while VPAC1R is more enriched in neurons, with a 5:1 ratio compared to astrocytes (Zhang et al., 2014). Consistently, we found that striatal astrocytes express significantly higher levels of mRNA for both PAC1R [Figure 3.1B; $t(6)=5.618$, $p < 0.01$] and VPAC2R [Figure 3.1C; $t(6)=11.082$, $p < 0.001$], compared to neurons of the same origin.

Figure 3.1. PAC1R and VPAC2R are enriched in cultured astrocytes obtained from striatal tissues. (A) Pictures illustrate the PCR products on agarose gels (1.8%) after electrophoresis. cDNA was synthesized through reverse transcription with mRNA extracted from cortical or striatal astrocyte cultures: CTA, cortical astrocytes; STA, striatal astrocytes. PCR was conducted with cDNA templates and primers specific to rat PAC1R, VPAC1R and VPAC2R. Presence of bands at expected sizes indicates the expression of the target genes. (B, C) Data depict mean ± SEM levels of PAC1R (B) or VPAC2R (C) mRNA in rat striatal cell cultures (N= 4/cell type). STN, striatal neurons. * indicates a significant difference relative to STA cultures, T-test, $p <$ 0.01.

Experiment 2: Twenty-four hour PACAP incubation increases Sxc activity in

striatal astrocytes. Having observed the expression of PACAP receptors in striatal

astrocytes, we next examined the impact of PACAP on Sxc. In Chapter II, we

demonstrated that 24-hr PACAP treatment significantly increased Sxc activity in cortical

astrocytes. Therefore, we investigated whether the same treatment would also impact

striatal astrocytes (Figure 3.2). One-way ANOVAs revealed a main effect of PACAP

concentration on the uptake levels in either cortical [Figure 3.2A; $F_{(4,43)}=82.563$, $p <$

0.001] or striatal [Figure 3.2B; $F_{(4,47)}=18.04$, $p < 0.001$] astrocytes, suggesting that

PACAP dose-dependently increases astrocyte Sxc activity, independent of cell origins.

Figure 3.2. Twenty-four hour PACAP incubation increases Sxc activity in striatal astrocytes.
Data depict mean $\pm$SEM levels of ^{14}C-cystine in purified rat cortical (A) or striatal (B) astrocyte
cultures (14-15 days *in vitro*) after incubation with PACAP for 24 hours (0-100 nM; N=8-
16/condition). * indicates a significant difference relative to vehicle-treated group, Tukey HSD, *p*
< 0.01.

Experiment 3: Inhibition of PKA or Epac attenuates the upregulation of Sxc

activity by 24-hr PACAP treatment in striatal astrocytes. Each of the PACAP

receptors is coupled to Gαs and/or Gαq. As such, PKA and PKC have been primarily

implicated in the intracellular actions of PACAP (Miyata et al., 1989; Lazarovici et al.,

1998; Figiel and Engele, 2000; Zhou et al., 2001). However, PACAP has also been

shown to signal through AC-cAMP-Epac, PI3K-AKT, MEK-ERK or CaMK pathways

(Moroo et al., 1998; Vallejo and Vallejo, 2002; Hashimoto et al., 2003; Perez et al., 2005;

Blechman and Levkowitz, 2013). To determine the involvement of these potential

signaling cascades in PACAP-induced regulation of Sxc, we examined the impact of

inhibiting respective kinases. Specifically, we pre-incubated striatal astrocytes for one

hour with the following kinase inhibitors: H89 (PKA inhibitor), Go6983 (PKC inhibitor),

ESI09 (Epac inhibitor), KN93 (CaMKII inhibitor), LY294002 (PI3K inhibitor) or U0126

(MEK inhibitor). Vehicle or PACAP (10nM) was then added to the cultures for an

additional 24 hours (Figure 3.3). A one-way ANOVA comparing the ^{14}C-cystine uptake

Figure 3.3. Inhibition of PKA or Epac attenuates the upregulation of astrocyte Sxc by 24-hr PACAP treatment. Data depict mean ± SEM levels of ^{14}C-cystine in purified rat striatal astrocyte cultures after 24-hr treatment with vehicle or PACAP 10nM (designated as P1-38), with or without the presence of H89 (10 μM, PKA inhibitor), ESI09 (5 μM, Epac inhibitor), Go6983 (1 μM, PKC inhibitor), KN93 (5 μM, CaMKII inhibitor), LY294002 (designated as LY, 45 μM, PI3K inhibitor), U0126 (25 μM, MEK inhibitor) (N=4-14/condition). Note that the kinase inhibitors were added one hour prior to PACAP application (A). * indicates a significant difference relative to vehicle-treated purified astrocyte cultures, Tukey HSD, $p < 0.001$; # indicates a significant difference relative to PACAP treated purified astrocyte cultures, Tukey HSD, $p < 0.001$.

levels yielded a main effect of treatment [Figure 3.3A; $F_{(7,36)}=61.130$, $p < 0.001$]. *Post hoc* analyses indicate that presence of H89 and ESI09 significantly reduced PACAP-induced Sxc activity (Tukey HSD, $p < 0.001$), suggesting that the effect of 24-hr PACAP is mediated by Gαs-AC-cAMP-PKA/Epac. Note, we observed that applying the kinase inhibitors alone to astrocyte cultures did not alter cystine uptake compared to the vehicle group (Figure 3.3B).

Experiment 4: Phasic PACAP upregulates Sxc activity in a time- and dose-dependent manner in striatal astrocytes. In these studies, we were interested in investigating whether short-term application of PACAP would regulate Sxc, given that phasic regulation is likely involved in the rapid control of synaptic transmission and behavior. To examine this, we applied 10 nM PACAP to cortical or striatal astrocytes cultures (DIV 14-15) for 6 or 20 min, prior to ^{14}C-cystine uptake assays (Figure 3.4A).

Figure 3.4. Time- and dose-dependent regulation of Sxc activity by short-term application of PACAP in striatal astrocytes. (A) Data depict mean ±SEM levels of ^{14}C-cystine in rat cortical or striatal astrocyte cultures after 6 or 20 min treatment with vehicle (designated as 0 min group) or PACAP (10 nM; N=4-38/condition). , * indicates a significant difference relative to the vehicle group of striatal cultures, Tukey HSD, $p < 0.05$; # indicates a significant difference relative to the vehicle-treated cortical cultures, Tukey HSD, $p < 0.01$; + indicates a significant difference relative to 20 min PACAP-treated cortical cultures, T-test, $p < 0.01$. (B) Data depict mean ±SEM levels of ^{14}C-cystine in striatal astrocyte cultures after incubation with PACAP for 20 min (0-100 nM; N=8/condition). * indicates a significant difference relative to vehicle-treated group, Tukey HSD, $p < 0.05$.

This concentration was selected because of its effectiveness in inducing an Sxc increase (see Figure 3.2). A univariate ANOVA with cell origin and incubation time as between-subjects factors produced a significant interaction between these variables. Further analyses revealed that PACAP time-dependently increased Sxc activity in both cortical [One-way ANOVA; $F(2,55)=8.862$, $p < 0.01$] and striatal astrocytes [One-way ANOVA; $F(2,33)=18.405$, $p < 0.001$]. Notably, twenty minute incubation yielded a higher level of Sxc activity in striatal astrocytes compared to cortical cultures [$t(10)=4.397$, $p < 0.01$].

Next, we investigated the dose-dependent effect of phasic PACAP. We chose 20 min as incubation time as it yields a more robust Sxc activity increase than 6 min, as well as a higher level than the cortical group, and also fits the behavior time frame (two hours) that we often use to measure drug seeking behaviors. One-way ANOVAs revealed an effect of PACAP concentration on cystine uptake [Figure 3.4B; $F(4,35)=8.015$, $p < 0.001$], indicating that 20-min PACAP incubation dose-dependently increases Sxc activity in striatal astrocytes. These results indicate that phasic PACAP augments Sxc activity in a time- and dose-dependent manner in striatal astrocytes, suggesting the occurrence of this regulation in the NAc.

Experiment 5: The impact of PACAP on Sxc is reversed by inhibiting PKA, Epac and MEK pathways. Next, we sought to explore the involvement of potential signaling cascades, as introduced above, in the rapid regulation of Sxc. To do this, we first applied PACAP to striatal astrocytes for 72 hr followed by the addition of the kinase inhibitors during the last hour of the PACAP treatment period. A one-way ANOVA comparing the ^{14}C-cystine uptake levels yielded a main effect of treatment [Figure 3.5; $F(7,36)=74.607$, $p < 0.001$]. *Post hoc* analyses revealed that H89 and ESI09 significantly

reduced the upregulation of Sxc activity induced by PACAP (Tukey HSD, $p < 0.001$).

Interestingly, blocking the MEK/ERK pathway with PD98059 also attenuated PACAP-

induced upregulation of Sxc activity, suggesting a differential role of this pathway in

acute PACAP-induced regulation of Sxc.

Figure 3.5. PKA, Epac and MEK pathways are involved in the rapid regulation of Sxc activity by PACAP. Data depict mean ± SEM levels of ^{14}C-cystine in purified rat striatal astrocyte cultures. Prior to ^{14}C-cystine uptake assay, cells were incubated with vehicle or 10nM PACAP (designated as P1-38) for 72 hours. Kinase inhibitors, H89 (10 μM), ESI09 (5 μM), Go6983 (1 μM), KN93 (5 μM), LY294002 (designated as LY, 45 μM), or PD98059 (50 μM, MEK inhibitor) was applied and present only for the last hour during PACAP incubation (N=4-12/condition). * indicates a significant difference relative to vehicle-treated purified astrocyte cultures, Tukey HSD, $p < 0.05$. # indicates a significant difference relative to PACAP treated purified astrocyte cultures, Tukey HSD, $p < 0.001$.

Discussion

The primary goal for these studies was to determine whether Sxc is modulated by

PACAP in regions other than the cortex and to better understand the nature of this novel

form of neuron-astrocyte communication. The major findings in these data are that both

prolonged and phasic PACAP upregulate Sxc in astrocytes obtained from either rat cortex or striatum. We also found that two major subtypes of PACAP receptors, PAC1R and VPAC2R, are enriched in astrocytes compared to neurons. Consistent with the evidence that these receptors are commonly coupled to Gαs (Harmar, 2001; Vaudry et al., 2009), our data suggest that two major Gαs-induced kinases, PKA and Epac, mediate the actions of PACAP.

To date, PACAP-induced regulation of Sxc has only been detected in cortical cells (Resch et al., 2014b; Kong et al., 2016). However, we are interested in understanding the molecular regulation of Sxc in astrocytes obtained from the striatum. This brain region is of particular interest because Sxc function in the nucleus accumbens (NAc, ventral striatum) is critical for the proper expression of motivated behaviors, whereas malfunction of this transporter contributes significantly to the development or maintenance of substance abuse (Baker et al., 2003; Kau et al., 2008; Berglind et al., 2009; Kalivas, 2009; Knackstedt et al., 2009; Kupchik et al., 2012). To examine this, we first compared the impact of 24-hour PACAP treatment on cystine uptake, in part so that we could compare our results with prior observations from cortical astrocytes. We found that PACAP yielded similar effects on striatal astrocytes to those from the cortex, suggesting that PACAP-induced regulation of Sxc is also present in the striatum. This raises the prospect that PACAP-induced regulation of astrocyte Sxc may be a common feature in the brain. This is important, since Sxc is an important component of glutamate signaling, and has been found to regulate synaptic transmission (Manzoni et al., 1997; Baker et al., 2002; Moran et al., 2005; Augustin et al., 2007; Moussawi and Kalivas, 2010; De Bundel et al., 2011; Massie et al., 2011; Williams and Featherstone, 2014). Moreover,

Sxc is expressed in various regions of the CNS, including the amygdala, hippocampus and spinal cord (Roberto and Brunelli, 2000; De Bundel et al., 2011; Albano et al., 2013; Aal-Aaboda et al., 2015), where PACAP signaling has been implicated (Moller et al., 1993; Zhang et al., 1995; Roberto and Brunelli, 2000; Cho et al., 2012). As such, this evidence creates a need to better understand the contribution of this novel form of neuron-astrocyte communication to the excitatory signaling in these brain regions and related CNS functions, including memory, emotion and motor generation.

Next, we determined whether PACAP could produce rapid regulation of Sxc in a manner that would be consistent with the regulation by phasic changes in PACAP. This is important because phasic regulation is likely necessary for rapid control of synaptic transmission and behavior. We found that PACAP application for as short as 6 min induced a significant upregulation of Sxc activity in striatal astrocytes. Given that neuropeptides (e.g. PACAP) are often released in a phasic manner (Nusbaum et al., 2001; van den Pol, 2012), this finding implicates that activity-dependent phasic release of PACAP in the striatum is capable of increasing Sxc, through which to regulate synaptic transmission and motivated behavior.

In these studies, we found that cortical and striatal astrocytes express all three receptor subtypes that mediate PACAP signaling, PAC1R, VPAC1R and VPAC2R (Harmar, 2001; Vaudry et al., 2009), consistent with earlier reports (Ashur-Fabian et al., 1997; Magistretti et al., 1998; Grimaldi and Cavallaro, 1999; Joo et al., 2004; Masmoudi-Kouki et al., 2007; Nishimoto et al., 2007; Nishimoto et al., 2011; Zhang et al., 2014). These receptors bind to PACAP with similarly high affinities and are reportedly expressed at differently levels in the CNS. For example, PAC1R, the major binding site

for PACAP (Dejda et al., 2011), appears to be the most abundant subtype in the cortex, while the VPAC1R appears to be the least expressed subtype (Zhang et al., 2014). For example, the FPKM (fragments per kilobase of transcript per million mapped reads) values of these three receptors in astrocytes are > 150 (PAC1R), < 0.2 (VPAC1R) and ≈ 2 (VPAC2R) (Zhang et al., 2014). Moreover, both PAC1R and VPAC2R appear to be more enriched in astrocytes than in neurons, with ratios at 10:1 (PAC1R) and 5:1 (VPAC2R), while VPAC1R is more enriched in neurons, with a 5:1 ratio compared to astrocytes (Zhang et al., 2014). Interestingly, we also show that both PAC1R and VPAC2R, the more abundant subtypes, are more enriched in striatal astrocytes compared to neurons. Together with our previous observation that PACAP6-38 (antagonist for both PAC1R and VPAC2R) in mixed rat cortical cultures significantly decreased Sxc activity (Chapter II, Figure 2.2), this evidence suggests that PAC1R and VPAC2R may be major receptors mediating the PACAP effects on astrocyte Sxc.

Activation of PAC1R and VPAC2R induces Gαs and Gαq, and subsequently a number of interconnected signaling cascades (Dickson and Finlayson, 2009; Vaudry et al., 2009; Blechman and Levkowitz, 2013). To tease out those that were most likely involved in the current studies, we chose the major pathways that were reported to mediate PACAP-induced regulation of astrocytes, including those that are involved in regulating Sxc (Moroo et al., 1998; Vallejo and Vallejo, 2002; Hashimoto et al., 2003; Perez et al., 2005; Seo and Lee, 2016). With this strategy, we first examined the involvement of PKA, PKC, Epac, CaMKII, PI3K/Akt and MEK/ERK in the action of 24-hr PACAP, as this time point yields the most robust effect on Sxc activity. Our data show that inhibiting cAMP-responding kinases, either PKA or Epac, significantly attenuated the effect of

PACAP in striatal astrocytes. In contrast, inhibition of two major kinases induced by $G\alpha q$, PKC and CaMKII, had no impact on PACAP effect (Figure 3.3). Thus, our results suggest that the $G\alpha s$- but not the $G\alpha q$- induced cascades mediate the actions of PACAP on astrocyte Sxc. This is consistent with a number of studies showing that $G\alpha s$-AC-cAMP-PKA/Epac pathway mediates PACAP-induced regulation of astrocyte functions (Figiel and Engele, 2000; Masmoudi et al., 2003; Seo and Lee, 2016).

In these studies, we also examined the impact of acutely inhibiting the potentially involved kinases (Figure 3.5). To our surprise, we found that inhibiting either PKA or Epac for one hour significantly attenuated the effect of PACAP (by approximately 75% and 100% respectively). In this experiment, striatal astrocytes were incubated with PACAP for 72 hours, for the purpose of maximizing the activity of Sxc. This treatment likely induces increased xCT and subsequently Sxc expression. In support, we showed that 24-hr PACAP incubation robustly upregulates xCT transcripts (Kong et al., 2016). However, the increased Sxc activity induced by 72-hr PACAP is probably not a mere reflection of increased Sxc expression. This is because that inhibiting the involved kinase Epac for only one hour, which unlikely induces a complete turnover of the increased Sxc expression, completely abolished the effect of PACAP. A feasible explanation is that, for the newly synthesized Sxc to gain function, they must undergo certain rapid molecular processes (e.g. post-translational modifications), which are also regulated by PACAP, and that the prolonged PACAP (i.e. 72 hr)-induced upregulation of Sxc activity results from both increased Sxc expression and augmented molecular processes that render Sxc function. Based on this presumption, our data suggest that cAMP-induced cascades (i.e. PKA and Epac) are also important for mediating the rapid effect of PACAP on Sxc.

Interestingly, PI3K/Akt and MEK/ERK, which were shown to mediate Sxc expression (Liu et al., 2012), did not demonstrate their involvement in the actions of 24-hr PACAP (Figure 3.3); yet inhibiting MEK/ERK for one hour after 72-hr PACAP incubation significantly decreased Sxc activity. These results suggest that the MEK/ERK pathway is only involved in mediating the rapid impact of PACAP on Sxc.

Although H89 is commonly used as a PKA inhibitor, it has been shown to inhibit other kinases, including MSK (Lochner and Moolman, 2006). It is intriguing to note that MSK is a downstream kinase of both PKA and Epac (Delghandi et al., 2005; Shi et al., 2012), and sequence analyses reveal that xCT harbors phosphorylation sites for MSK, including amino acid serine 26 (S26). This is important, because it has been recently demonstrated that mutagenesis of S26 on xCT and consequently altering phosphorylation state of the protein lead to changes of Sxc (McClatchy et al., 2016). Such evidence implicates MSK as a potential kinase that could mediate the effect of PKA and Epac on Sxc phosphorylation. Alternatively, PKA itself may also influence Sxc activity through direct phosphorylation of xCT, given that this catalytic subunit also harbors phosphorylation sites for PKA (Baker et al., 2002).

To summarize, we expanded our previous findings by showing that PACAP regulates Sxc in striatal astrocytes, implicating the occurrence of this mechanism in the NAc. Moreover, we observed a rapid upregulation of Sxc activity induced by phasic PACAP. Lastly, we found that two cAMP-regulated signaling pathways, PKA and Epac, may underlie PACAP-induced increases in Sxc activity. These findings indicate that PACAP potentially regulates glutamate transmission in the NAc via its actions on Sxc, and consequently influences motivated behaviors.

CHAPTER IV

PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE PROMOTES
GLUTAMATE RELEASE FROM ASTROCYTE SYSTEM X_C- TO GATE SYNAPTIC
OUTPUT FROM THE NUCLEUS ACCUMBENS

Introduction

Drug addiction is a complex, multi-faceted disorder characterized by compulsive

drug seeking even when such behavior results in profound negative consequences to the

individual. The chronic aspect of the disease involves episodes of heightened relapse

vulnerability even following long periods of abstinence (Jaffe et al., 1989; Withers et al.,

1995). Studies suggest that relapse originates from the persistent neuroadaptations at the

molecular and cellular levels in the related brain circuit (Kalivas and Volkow, 2005;

Nestler, 2005; Hyman et al., 2006; Koob and Volkow, 2010). Among these

neuroadaptations, drug-induced changes in synaptic transmission due to aberrant

glutamate signaling in the nucleus accumbens (NAc) and related circuitry have been

linked to behavior in virtually every preclinical model of drug seeking and have been

found to correlate with the severity of drug craving in human substance abusers (Pierce et

al., 1996; Breiter et al., 1997; Volkow et al., 1999; Park et al., 2002; Baker et al., 2003;

McFarland et al., 2003; McFarland et al., 2004; Schmidt et al., 2005; Madayag et al.,

2007; Kau et al., 2008; Ary et al., 2013). However, a challenge in revealing the molecular

or cellular basis of drug-induced plasticity is that excitatory neurotransmission is

achieved by an elaborate network of glutamate-related proteins expressed across multiple

cell types, including neurons and astrocytes (Herrera-Marschitz et al., 1996; Timmerman

and Westerink, 1997; Danbolt, 2001; Schoepp, 2001; Baker et al., 2002; Baker et al.,

2003; Pirttimaki et al., 2011; Bridges et al., 2012a), and that this signaling occurs in and outside of the synaptic cleft. Hence, it has been difficult to develop a comprehensive model that mechanistically integrates disparate forms of plasticity spanning multiple cell types. Of particular importance, it would be very useful to decode the molecular basis for integrating glutamate-related processes across cell types.

Here, we pursue the idea that the molecular integration of the cellular network underlying glutamate signaling in the NAc is achieved by the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP). Our interest in PACAP stems from emerging results establishing this peptide as a powerful regulator of excitatory signaling capable of regulating neuronal and astrocytic glutamate-related mechanisms. In support, published reports demonstrate that PACAP signaling in hippocampal and SCN (suprachiasmatic nucleus) neurons regulates AMPAR-mediated EPSCs (Kopp et al., 2001; Costa et al., 2009), an effect that may be dependent on the activation of high-affinity extrasynaptic receptors (Toda and Huganir, 2015). Moreover, we and others have discovered that PACAP can upregulate the activity of Sxc (Resch et al., 2014b; Kong et al., 2016), even when briefly applied (Chapter III). Collectively, these studies provide support for the proposed hypothesis that PACAP integrates astrocytes and neurons in a manner that regulates synaptic transmission and behavior.

To test our hypothesis, we first had to determine whether *in vivo* PACAP signaling exists in the adult NAc. It is important to determine whether PACAP and PACAP receptors are expressed in the adult NAc since many glutamate related proteins show drastic development-induced changes (Sun et al., 2013). To do this, we determined whether PACAP mRNA is present in excitatory projections to the NAc and if astrocytes

in this region express mRNA for PACAP receptors. Having found PACAP mRNA in NAc afferents and PACAP receptor mRNA in NAc astrocytes, we then investigated whether PACAP application alters AMPAR-mediated EPSCs in NAc efferents, similar to what has been observed in other brain regions (Kopp et al., 2001; Costa et al., 2009; Gardoni et al., 2012; Toda and Huganir, 2015). Having found that PACAP depresses AMPAR-EPSCs in NAc efferents projecting to the substantia nigra, we determined whether this effect requires Sxc regulation. In support of this idea, PACAP did not alter synaptic transmission in NAc slices obtained from loss of Sxc-function transgenic rats (MSxc rats). Lastly, we examined the relevance of these findings to addiction by assessing the impact of PACAP microinjection into the NAc on cocaine-primed reinstatement. Intra-NAc PACAP blocked cocaine reinstatement in wild-type but not MSxc rats. Collectively, these data are the first to establish that PACAP signaling is a key component of excitatory signaling in the NAc.

Material and Methods

Animals and Materials: These experiments utilized Sprague Dawley rats purchased from Envigo (Indianapolis, IN) and Sprague Dawley wild-type (WT) and transgenic mutants obtained from internal colonies, including Sxc loss of function mutants (MSxc) and eGFP knock-in (GFAP-lck-eGFP) rats. Experimental procedures were approved by the Marquette University Institutional Animal Care and Use Committee. The primary materials included fetal bovine serum and horse serum (Atlanta Biologicals, Lawrenceville, GA), ^{14}C-cystine (PerkinElmer, Waltham, MA), PACAP1-38 (California Peptide Research, Napa, CA), and PACAP6-38 (Anaspec, Fremont, CA).

PACAP1-38 (PACAP) is the endogenous full-length peptide whereas PACAP6-38 is a truncated version of PACAP and inhibits PACAP receptors (Miyata et al., 1989; Robberecht et al., 1992; Arimura, 2007; Vaudry et al., 2009). Picrotoxin and all other common chemicals were obtained from Sigma-Aldrich (St Louis, MO). Tetrodotoxin (TTX) was obtained from Tocris Bioscience (Ellisville, MO).

Creation of GFAP-lck-eGFP Rats: GFAP-lck-eGFP rats were generated using *Sleeping Beauty* (SB) transpositional transgenesis (Katter et al., 2013; Ivics et al., 2014). Briefly, a plasmid harboring a SB transposon transgene consisting of the GFAP promoter (Glial Fibrillary Acidic Protein), Lck-eGFP cDNA, and rabbit beta globin polyadenylation signal, was injected into fertilized embryos with an *in vitro* transcribed source of the SB100X transposase. A transgenic animal was identified harboring a single copy of the transgene inserted on chromosome 13, near 97.97Mb (sequence tag: TAC CTC TGT GAA GAC CCT CAG AGA GCT GTA ATT GTT CAT CCA AAT TTG AAG ACT TTG). A colony was established by back crossing to the parental Crl:SD strain and a fixed transgenic line was established by intercrossing. Genomic PCR primers GFAP04_forward 5' –TTT TCC TGA ATT TAT GTT TGT GCA G -3', GFAP04_reverse 5'- TCA TTC TTA GCT GTT TGA CAT CTG TCC -3', and a transposon specific primer 5'-GAC TTG TGT CAT GCA CAA AGT AGA TGT CC - 3' were used to determine zygosity.

Surgeries: All surgeries were conducted with rats under ketamine HCl (100 mg/kg, i.p.; Henry Schein, Dublin, OH) and xylazine (2 mg/kg, i.p.; Lloyd Laboratories, Shenandoah, IA) induced anesthesia.

Microinjection of Retrograde Tracers: In order to label NAc afferents, red beads (fluorescent latex microspheres that contain rhodamine; Lumafluor Inc., Durham, NC; used for FACS) or Cholera Toxin Subunit B (CTB; Thermo Fisher Scientific, Waltham, MA; used for immunostaining and *in situ* hybridization) were injected into the NAc. In order to label NAc efferents, red beads were injected into either the ventral pallidum (VP) or substantia nigra (SN) to label NAc-VP or NAc-SN medium spiny neurons (MSNs), respectively. In each case, guide cannula (C315G, 26GA, 11mm; Plastic One) were surgically implanted 2mm above the target structure with the coordinates (skull leveled, with Bregma as reference) derived from Paxinos and Watson (2007): Substantia Nigra (SN), AP -5.0, ML +3.0mm, DV -6.1mm, 6° angle from midline; Ventral Pallidum (VP), AP -0.2mm, ML +3.2mm, DV -5.8mm, 6° angle from midline; Nucleus Accumbens (NAc) core, AP +1.7mm, ML +2.4mm, DV -5.3 mm, 6° angle from midline. Microinjectors (C315I-SPC, 33GA, with 2mm projection; Plastic One) were inserted in the cannula. Tracer was then microinjected with 2 μL Hamilton syringes at a rate of 50nL/min, to reach a target volume of 300 nL/hemisphere for SN and VP, and 500 nL/hemisphere for the NAc. For the purpose of a thorough perfusion of the beads, microinjectors remained unremoved after microinjection for 10min and were then slowly pulled out together with cannula. Openings on the skull for guide cannula were then sealed with bone wax before scalp being sutured.

Implantation of jugular catheters: Rats included in self-administration studies were implanted with indwelling catheters. In brief, a custom polyurethane catheter (Access Technologies, Skokie, IL) was implanted such that it entered the superior vena cava and terminated at the right atrium. The catheter was sutured to the vein at the entry

point. The distal aspect of the catheter, which consisted of a 22-gauge guide cannula (Plastics One, Roanoke, VA) attached with dental acrylic to a piece of polypropylene monofilament mesh, exited 2 cm posterior to the scapulae. Throughout the experiment, catheters were filled daily with a heparin solution (83 i.u./ml; Elkins-Sinn, Cherry Hill, NJ) and capped when disconnected from the leash/delivery line assembly.

Implantation of Intracranial Guide Cannula: Some rats received indwelling bilateral guide cannulas (26 gauge, 14 mm; Plastics One) targeting the NAc core using the following coordinates derived from Paxinos and Watson (2007): AP +1.7mm, ML +2.4mm, DV -5.3mm, 6° angle from vertical (skull leveled, with Bregma as reference). Dummy internals were inserted in the cannula to prevent blocking. After surgeries, rats were given at least 7 days to recover before testing. During this time, rats were provided chewable Rimadyl tablets (first three days, Bio-Serv, Flemington, NJ) and injected daily with sterile cefazolin antibiotic solution (15 mg, i.v.; Sagent Pharmaceuticals, Schaumburg, IL).

Cell Dissociation: The NAc or prefrontal cortex (PFC) tissues were freshly dissected from male GFAP-lck-eGFP or WT Sprague Dawley rats and placed immediately into ice-cold Hanks ´Balanced Salt Solution (HBSS) without Ca^{2+} and Mg^{2+} (Sigma-Aldrich, St Louis, MO). Tissues were further minced before enzymatic digestion to obtain single cell suspension with Neural Tissue Dissociation Kit - P (Miltenyi Biotec, San Diego, CA), following manufacturer's protocol. 1% BSA, 1mM EDTA and 12.5 U/ml DNase DNase I (Sigma, Cat. DN25) were added to single cell suspension to reduce cell clustering. Cells were incubated with 3 μM Calcein Violet 450 AM Viability Dye (eBioscience, San Diego, CA) on ice for 10min to stain live cells.

Fluorescence-Activated Cell Sorting (FACS): FACS analyses were performed using FACSDiva software, 6.1.3, (BD Biosciences). Fluorescence Minus One (FMO) control samples derived from store-bought Sprague Dawley rats were first analyzed to set primary gates to exclude double cells, dead cells and debris. An aliquot of cell suspension was extracted as unsorted total population prior to cell sorting. Target cells were collected from a population with high levels of calcein violet staining, indicating live cells. GFP+ and GFP- (see Figure 4.1), or rhodamine + and rhodamine - (see Figure 4.8) cell populations were isolated through FACS based on the intensity of the respective fluorophore (e.g. GFP, rhodamine). Flow rate was carefully adjusted to increase purity.

RNA Extraction and cDNA Construction: Total RNA from sorted cells was isolated with PicoPure RNA Isolation Kit (Thermo Fisher Scientific, Waltham, MA), following the manufacturer's protocol. On column DNase treatment was applied to all samples to remove potential genomic DNA contamination with the RNase-Free DNase Set (Qiagen; Germantown, MD). RNA quantity and quality were assessed on an Agilent 2100 Bioanalyzer using Agilent RNA 6000 Pico Chips. Only those samples with higher quality (e.g RIN > 7.0) were used for downstream procedures.

Total RNA from brain tissues or cell cultures was isolated with Trizol Reagent (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. DNase treatment was applied to all RNA samples to remove potential genomic DNA contamination with a DNA-free kit (Life Technologies, Carlsbad, CA). Assessment of RNA purity and quantity was performed on a NanoVue Plus Spectrophotometer (GE life sciences, Pittsburg, PA).

cDNA was constructed from total RNA using the Reverse Transcription System (Promega, Madison, WI) with oligo(dT) primers following the manufacturer's protocol.

Real-Time Quantitative Polymerase Chain Reaction (qPCR): qPCR was performed using a StepOne Real-Time PCR System (Applied Biosystems; Carlsbad, CA) and PerfeCTa SYBR Green FastMix with ROX (Quanta Biosciences; Gaithersberg, MD). Relative quantification of target gene expression was normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) using the $\Delta\Delta C_t$ method (Schmittgen and Livak, 2008). Primer sequences were as follows: xCT (catalytic subunit of Sxc) forward - 5' AGG GCA TAC TCC AGA ACA CG 3'; xCT reverse - 5' ATG CTC GTA CCC AAT TCA GC 3'; PAC1R forward - 5' TGC CTG TGG CTA TTG CTA TG 3'; PAC1R reverse - 5' TTT AGT CCC ATC AGG TCG TTG 3'; GFAP forward - 5' GCA GGT GAG GAA GAA ATG GA 3'; GFAP reverse - 5' TAC GAT GTC CTG GGA AAA GG 3'; NeuN forward - 5' ATC ATA CCA TCG GCC CCA CA 3'; NeuN reverse - 5' GTG AAG CGG CTG TAC CCT CC 3'. GAPDH forward - 5' CTC CCA TTC TTC CAC CTT TGA 3'; GAPDH reverse - 5' ATG TAG GCC ATG AGG TCC AC 3'. Primers were designed using the online primer design tool Primer3 (http://biotools.umassmed.edu/bioapps/ primer3_www.cgi). Another online software Primer-Blast (https://www.ncbi.nlm.nih. gov/tools/primer-blast/) was used to confirm the target-specificity of the primers. A single product from amplification was confirmed by melt curve analysis. Amplification efficiency of all genes was determined to be approximately 95%.

Creation of Sxc loss of function mutants (MSxc): Zing-finger nucleases (ZFNs) were procured from Sigma Aldrich to target xCT-encoding gene SLC7A11. ZFNs were

introduced to SD rat embryos at the one-cell stage by pronuclear microinjection of *in vitro*-transcribed ZFN mRNAs, to create whole animal disruption of SLC7A11 in a single step. An xCT mutant was identified with a 39-bp deletion in exon 2 of SLC7A11 gene, which predictably leads to the missing of 13 amino acids (see Figure 4.3A) that correspond to the majority of the 3rd transmembrane domain of the xCT protein.

Polymerase Chain Reaction (PCR) and Gel Electrophoresis: PCR was performed with GoTaq Green Master Mix (Promega, Madison, WI) on a thermocycler with parameters as follows. Initial denaturation (3min at 95 ℃), Amplification (35 cycles of the following: 95 ℃ for 30s, 60 ℃ for 45s, 72 ℃ for 45s), and Extension (72 ℃ for 10min). PCR products were then examined with electrophoresis on an agarose gel (1.8%). Sequences of primers used to target the mutation sites in xCT KO rats were as follows, xCT M forward - 5' TTT GGA GCC CTG TCT TAT GC 3'; xCT M reverse - 5' ACC CAG ACT CGA ACA AAA GC 3'. Other primers used for PCR included GFAP forward - 5' GCA GGT GAG GAA GAA ATG GA   3'; GFAP reverse - 5' TAC GAT GTC CTG GGA AAA GG 3'; NeuN forward - 5' ATC ATA CCA TCG GCC CCA CA   3'; NeuN reverse - 5' GTG AAG CGG CTG TAC CCT CC 3'; PACAP forward-5' AAC CCG CTG CAA GAC TTC TA 3'; PACAP reverse- 5' CTT TGC GGT AGG CTT CGT TA. 100bp DNA Ladder (Promega, Madison, WI) was used to locate target PCR products.

Western Blotting: NAc tissues of WT or MSxc rats were mechanically homogenized in buffer containing 320mM sucrose and 10mM Tris-HCl, supplemented with protease and phosphatase inhibitors (Thermo Fisher Scientific, Waltham, MA). 10 μg of total protein was resolved in a 7.5% polyacrylamide SDS-PAGE gel followed by

wet transfer to a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with Odyssey Blocking Buffer (PBS) (LI-COR, Lincoln, NE) for one hour prior to an overnight treatment with a mouse anti-GluA1 antibody (1:1000, Millipore), a rabbit anti-pT840 antibody (1:3333, Abcam), a chicken anti-GAPDH antibody (1:10000, Millipore), or a custom rabbit anti-xCT antibody that was generously donated to us by Dr. Jeffrey Rothstein at John Hopkins School of Medicine. Next, membranes were rinsed and incubated with IRDye 680 goat anti-rabbit (1:15000, LI-COR) or IRDye 800 donkey anti-chicken (1:20000, LI-COR) secondary antibodies for one hour. Membranes were rinsed again prior to imaging on an Odyssey Fc Imaging System (LI-COR).

Ex vivo ^{14}**C-cystine Uptake Assays:** The assessment of system x_c- (Sxc) activity is often achieved by measuring intracellular uptake of radiolabeled cystine, since this is primarily dependent on Sxc (Liu et al., 2009; Liu et al., 2014a; Resch et al., 2014b; Albano et al., 2015). The NAc tissue punches (1mm thick and 1mm in diameter) were freshly dissected and placed immediately into artificial cerebrospinal fluid that was constantly infused with 95% O_2:5% CO_2. Following a 20-minute equilibration period during which the buffer was warmed to 37^oC, ^{14}C-cystine and DL-threo-β-hydroxyaspartic acid (TBOA) were added to the media to reach a final concentration of 1μM and 10 μM, respectively. This concentration of cystine was used since it is similar to extracellular cystine concentrations in the brain (Baker et al., 2003). TBOA was added to the culture media to prevent ^{14}C-cystine uptake by sodium-dependent glutamate transporters. Some conditions also involved the addition of the Sxc inhibitor sulfasalazine (SSZ, 300 μM) to block Sxc-mediated cystine uptake. Immediately following 20-min exposure to ^{14}C-cystine, tissues were washed three times with ice-cold 1xPBS and then

solubilized with 1N NaOH. One aliquot of tissue lysate was used to determine protein concentration with BCA protein assay and another aliquot was used for ^{14}C-cystine uptake determination. ^{14}C-cystine uptake was normalized to protein concentration and data were presented as CPM/µg of protein.

Cell Culture Procedures: Purified striatal astrocyte cultures were prepared from post-natal days 3-4 rat pups. In brief, striatal cells were dissociated and then suspended in Neurobasal A media (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum, and 1% Glutamax (Thermo Fisher Scientific, Waltham, MA). Cells were initially grown in 25cm^2 or 75cm^2 cell culture flasks that were pre-coated with poly-D-lysine (10mg/L) and laminin (0.4mg/L). Once confluent, cells were then subjected to prolonged, orbital shaking (250 rpm for 16-18 hours at 37°C), which has been used to yield purified astrocyte cultures (McCarthy and de Vellis, 1980; Schildge et al., 2013). Purified astrocytes were then plated on 24-well plates, and refreshed with 70% new culture media every 2-3 days prior to experiments. All cell cultures were maintained in humidified 5% CO_2 incubators at 37°C.

Glutamate Release Assay and Glutamate HPLC: Purified striatal astrocytes (DIV14) were incubated with PACAP at designated concentrations for 30 minutes at 37°C in a Na^+ free buffer containing 116mM Choline Chloride, 13.4 mM $MgSO_4$, 1.68 mM KH_2PO_4, 2.34 mM $CaCl_2$, 5.49 mM Dextrose, 11.9 mM HEPES, 10 µM cystine and 0.2% Choline bicarbonate. Buffer pH was titrated to 7.4 with NaOH. After incubation, 100 µL media was extracted for HPLC analysis. Cells were solubilized in 0.5% sodium dodecyl sulfate (SDS). One aliquot of cell lysate was used for protein quantification using the bicinchoninic acid (BCA) assay.

Media collected in glutamate release assays were analyzed for glutamate content via fluorescence detection on an isocratic Shimadzu HPLC system. A 10μL sample underwent pre-column derivatization with ortho-phthalaldehyde (OPA) in the presence of 2-mercaptoethanol. Samples were resolved with a Kinetex XB C-18 (50x4.6mm, 2.6μm; Phenomenex, Torrence, CA) and 100mM Na_2HPO_4, 0.1mM Ethylenediaminetetraacetic acid (EDTA), 10% Acetonitrile, pH 6.04 mobile phase. Peak areas were quantitated in Shimadzu VP client software compared to known standards. Glutamate content for each sample was normalized to protein concentration.

Brain slice preparation: Rats were anesthetized by isoflurane inhalation and perfused through the aorta with a cold sucrose-based solution (4–6 °C) containing 78 mM NaCl, 68 mM sucrose, 26 mM $NaHCO_3$, 2.5 mM KCl, 1.25 mM NaH_2PO_4, 2 mM $CaCl_2$, 2 mM $MgCl_2$ and 25 mM glucose. The rat brain was trimmed and embedded in low-melting-point agarose, and coronal striatal slices (200-250 μm thick) were cut in the sucrose-based solution (4-6 °C) using a vibrating slicer (Leica VT1200s, Nussloch, Germany). The slices were incubated in the sucrose-based solution at room temperature for 30-40 min. Then, the slices were transferred and allowed to recover for at least 1 hour in the artificial cerebrospinal fluid (ACSF) containing 119 mM NaCl, 2.5 mM KCl, 2.5 mM $CaCl_2$, 1 mM $MgCl_2$, 1.25 mM NaH_2PO_4, 26 mM $NaHCO_3$, and 10 mM glucose. All solutions were saturated with 95% O_2 and 5% CO_2.

Electrophysiology: AMPAR-mediated EPSC Male Sprague Dawley rats (300-350g) received a bilateral microinjection of red beads into SN or VP. After 3-5 days of recovery, rats were anesthetized with isoflurane and decapitated. Striatal slices were prepared as previously described (Liu et al., 2014b). Whole-cell voltage-clamp

recordings were made from medium spiny neurons (MSNs) in the core of the NAc.

MSNs that were retrogradely labeled with red beads were selected for recording.

AMPAR-EPSCs were evoked by a bipolar tungsten stimulation electrode that was placed

~300 μm away from the recording pipette. The MSNs were voltage-clamped at -80 mV,

close to the resting membrane potential of these neurons. PACAP or PACAP6-38 was

administered through bath application.

Cocaine Self-Administration Training: Self-administration occurred in operant

chambers (ENV-008CT; MEDAssociates, St. Albans, VT) housed in sound-attenuating

cubicles (ENV- 016M; MED-Associates) and equipped with two retractable levers, two

stimulus lights, and a water bottle. At least 7 d after surgery, rats were food restricted for

18 h with water available *ad libitum*. Rats were then placed into the operant chambers

overnight and responses on the lever designated as active resulted in the delivery of food

pellets under a fixed ratio 1 schedule of reinforcement. Daily food training continued

until subjects received at least 100 food rewards in a session, which typically occurred

after the first session. During the acquisition phase of the experiment, all rats underwent

drug self-administration training during daily 2 h sessions in which operant responses on

the active lever were reinforced with an infusion of saline or cocaine (0.5 mg/kg/200 μL,

i.v.; National Institute on Drug Abuse, Bethesda, MD) under a fixed ratio 1 schedule of

reinforcement. Each reinforced lever response resulted in the illumination of the stimulus

light located above the active lever and was followed by a 25 s time-out period.

Responding on a second, inactive lever located on the back wall was recorded but had no

programmed consequences. Acquisition of cocaine self-administration was operationally

defined as < 10% variation in daily responding over at least three consecutive sessions.

Once rats met the acquisition criteria, they were advanced to maintenance sessions in which saline or cocaine was self-administered under long-access conditions (1.0 mg/kg/200 μL, i.v.; 6 h/d for 12 d).

Extinction Training: After completing maintenance self-administration sessions, rats remained in their home cages for 7 d before extinction training. A seven-day delay was used to ensure an adequate drug-free period before reinstatement, even in rats that quickly extinguished responding. Extinction training involved placing rats into the operant chambers for 2 h/d as described above in the self-administration section except each active lever press now resulted in an infusion of saline. This continued until the mean number of lever presses was no more than 15 responses across two sessions, at which point rats were tested for cocaine-primed reinstatement.

Microinjection and Reinstatement Testing: Once rats reached extinction criteria, mock microinjections were conducted to familiarize rats with the procedure approximately two days prior to reinstatement test day. The reinstatement test was identical to each extinction session except rats were injected with cocaine (10 mg/kg, IP). Prior to the cocaine injection, microinjectors were inserted into indwelling guide cannula, and rats received infusion of vehicle [0.9% NaCl], PACAP [100μM] or [200μM], or PACAP6-38 [1000μM] at a rate of 0.125 μL/min for four minutes. Six minutes after microinjection, rats were given an injection of cocaine (10 mg/kg, IP), and then immediately placed in the self-administration chamber for reinstatement test, behavior was recorded for 120 min.

Histology: Rats that received implantation of indwelling guide cannula were anesthetized with CO_2, and the brains removed and imbedded in OCT compound.

Coronal sections (30 μm) were cut on a cryostat and stained with cresyl violet to verify probe placements.

CTB Immunostaining and PACAP *In Situ* Hybridization: One week after microinjecting CTB into the NAc, brains were collected via rapid decapitation and flash frozen in OCT with a dry ice/ethanol bath. Brains were kept at -80°C before being cut on a cryostat into coronal sections (12 μm thick) which were thaw-mounted onto electrostatically clean slides. The brain sections were stored at -80 ℃ until *in situ* hybridization. Prior to overnight hybridization, the brain sections were post-fixed in 4% PFA, rinsed in 0.1 M PBS (pH 7.4), equilibrated in 0.1 M triethanolamine (pH 8.0) and acetylated in triethanolamine containing 0.25% acetic anhydride. Sense and antisense digoxigenin conjugated riboprobes specific for PACAP were diluted (1:100) in a hybridization solution (Amersco; Solon, OH) containing $1/4^{\text{th}}$ riboprobe volume of tRNA (4 μl riboprobe/1 μl tRNA). The probe cocktail was incubated for 10 minutes at 65 ℃ and then applied to the sections (100 μl/slide). Once the probe was applied, the slides were coverslipped and hybridized overnight at 60 ℃. Approximately 14-16 hours later, the slides were treated with an RNase A solution, stringently washed in 0.1x SSC at 65 ℃ and then incubated overnight at 4 ℃ with an antibody against DIG conjugated to a horseradish peroxidase (HRP; Roche; Indianapolis, IN). The DIG conjugated PACAP riboprobes were visualized using a TSA-plus fluorophore system with fluorescein (Perkin Elmer; Waltham, MA). Following the *in situ* hybridization procedure, slides were then incubated overnight in an antibody against CTB (Goat anti-CTB; List Biological Laboratories Inc.; Campbell, CA). This primary antibody was then visualized using a donkey anti-goat AlexaFluor 594 conjugated secondary antibody (Life Technologies;

Grand Island, NY). Images were then captured using fluorescent microscopy (Axioskop-2, Zeiss; Thornwood, NY) and Axiovision image analysis software (Zeiss; Thornwood, NY).

Statistics: Data are presented as the mean $\pm$ SEM. The data of mEPSCs were analyzed using Mini-analysis (Synaptosft, Decatur, GA). The frequency and amplitude of mEPSCs were calculated for 3-5 min of recordings. The analysis of mEPSCs was performed with cumulative probability plots (Van der Kloot, 1991). All other statistical analyses were performed using SPSS Statistics (Version 24, IBM; Armonk, New York). Analysis of variance (ANOVA) was used when comparing data sets that included more than two groups. Bonferroni tests were used for subsequent *post hoc* analyses of significant effects involving more than two groups. Student's t tests were used when comparing results from only two groups. In all instances, statistical significance was designated as $p < 0.05$.

Results

Experiment 1: xCT and PAC1R mRNAs are enriched in adult NAc astrocytes. The purpose of this experiment was to determine whether PACAP receptors are expressed in NAc astrocytes isolated from adult tissues. In order to do this, we first characterized astrocyte labelling in GFAP:Lck-eGFP rats. To verify this, eGFP expression produced by the transgene was compared with GFAP-IHC (immunohistochemistry) in the same tissue. Figure 4.1B-D illustrates that eGFP provides a more complete labelling of astrocytic processes in GFAP+ cells. To further verify that the eGFP+ cells were astrocytes, we used FACS (fluorescence-activated cell sorting) to

isolate these cells from NAc tissue punches obtained from adult (i.e., aged 3-4 months)

GFAP:Lck-eGFP transgenic rats (Figure 4.1E-J).

Figure 4.1. Isolation of adult NAc astrocytes from GFAP:Lck-eGFP transgenic rats with fluorescence-activated cell sorting. (A) Schematic diagram of the plasmid harboring a Sleeping Beauty transposon transgene consisting of the glial fibrillary acidic protein (GFAP) promoter, cDNA for a membrane-targeted form of enhanced green fluorescent protein (Lck-eGFP) (Benediktsson et al., 2005), and rabbit beta globin polyadenylation signal (pA). (B-D) Visualizing eGFP in GFAP:Lck-eGFP transgenic rat permits a more complete labelling of astrocytes (B) relative to GFAP immunoreactivity of the same tissue (C), see merged images (D). (E-J) The gating parameters of the flow cytometer were utilized to identify/isolate cellular debris (E; forward scatter area (FCS-A)/side scatter area (SSC-A), cell doublets (F: side scatter height (SSC-H)/side scatter area (SSC-A) and G: forward-scatter height/forward scatter width), viable cells (H; calcein violet/SSC-A), background green fluorescent protein in negative control tissue (I; tissue obtained from WT rats), and transgene-induced fluorescence above background (J: tissue obtained from GFAP:Lck-eGFP transgenic rats).

Next, we used PCR to compare the mRNA expression of astrocyte-enriched genes (i.e., GFAP, xCT) and neuron-enriched genes (NeuN). When including the three sample types (total or unsorted, GFP+, and GFP-), one-way ANOVAs revealed significant main effects of sample type for the expression of NeuN [Figure 4.2A; $F(2,9)=27.798$, $p < 0.001$], GFAP [Figure 4.2B; $F(2,9)=16.829$, $p = 0.001$], and xCT [Figure 4.2C; $F(2,9)=11.209$, $p < 0.01$]. *Post hoc* tests revealed that GPF+ cells contained significantly higher mRNA levels of the positive control genes GFAP and xCT (Tukey HSD, $p < 0.05$) and did not express the negative control gene NeuN (Figure 4.2C), indicating that this astrocyte-enriched sample did not contain neurons.

Figure 4.2. xCT and PAC1R mRNAs are highly expressed in rat NAc astrocytes. Data depict Mean ± standard error of means (SEM) mRNA levels of NeuN (A), GFAP (B), xCT (C), and PAC1R (D) in unsorted (total) cell populations, GPF+, and GFP- isolates (N= 4/gene/population) from NAc tissues. * indicates a significant difference relative to unsorted total population, Tukey HSD, $p < 0.05$.

Next, we examined mRNA expression of the test gene PAC1R in the three tissue samples (total or unsorted, GFP+, and GFP-). A one-way ANOVA yielded a main effect of sample type on the PAC1R mRNA expression [Figure 4.2D, F(2,9)=14.993, $p = 0.001$] with *post hoc* analyses revealing enrichment in the GFP+ cells (Tukey HSD, $p < 0.05$).

Experiment 2: PACAP regulates Sxc mediated glutamate release. Given that NAc astrocytes express the receptor needed to encode PACAP signaling, we then examined whether this neuropeptide can regulate glutamate release by Sxc. Note, in Chapter III, our measure of interest was primarily cystine uptake. Thus, we sought to confirm that PACAP would promote glutamate release from striatal astrocytes. To do this, we used loss of function Sxc mutant (MSxc) rats. Zinc-finger nucleases were used to mutate the gene (Slc7A11) that encodes the protein (xCT) containing the binding sites for the transported substrates (i.e., cystine, glutamate). The mutation was identified as a 39-bp deletion in exon 2 of SLC7A11, which predictably leads to the loss of 13 amino acids (Figure 4.3A) that corresponds to the majority of the 3rd transmembrane domain of the xCT protein. For further validation of MSxc rats, we examined the expression of xCT mRNA and protein, and Sxc function in striatal tissues (Figure 4.3B-D). Using primers that partially corresponded to the mutation region, we confirmed the absence of intact xCT mRNA in the mutants (Figure 4.3B). Consistent with this observation, MSxc rats did not display xCT protein as assessed using western blotting (Figure 4.3C). To evaluate the functional consequence of the mutation, we compared ^{14}C-cystine uptake in NAc tissue punches in the presence or absence of an Sxc inhibitor sulfasalazine (SSZ). A univariate ANOVA with genotype and SSZ concentration as between-subjects factors produced a significant interaction [Figure 4.3D; F(1,15)=13.098, $p < 0.01$]. Further

analyses of the data revealed that SSZ significantly reduced uptake levels in WT (T-test, $p < 0.01$) but not in MSxc tissues, suggesting a lack of Sxc activity in the mutants.

A

WT   (101) GTSIKKSGGHYTYILEVFGPLLAFVRVWVELLVIRPGATAVISLAFGRYI (150)

MSxc (101) GTSIKKSGGHYTYIL--------------VELLVIRPGATAVISLAFGRYI (150)

Figure 4.3. PACAP regulates Sxc mediated glutamate release. (A) Amino acid sequence (101-150) of xCT in MSxc and WT rats. Zinc-finger nucleases (ZFNs) specific for exon 2 of the rat SLC7A11 gene (encoding xCT, the catalytic subunit of Sxc) were used to create Sxc mutants; the sequence eliminated by the mutation is denoted by the dotted lines. (B) Gel electrophoresis results showing the lack of intact xCT mRNA in MSxc striatum. Reverse transcription and PCR were used to validate the elimination of xCT mRNA sequence corresponding to AAs 116-128 as depicted in panel A. (C) Western blot analysis was used to confirm a lack of xCT protein in MSxc NAc tissue punches. (D) Data depict the mean ±SEM levels of total (i.e., in the presence of vehicle) or non-Sxc-mediated (i.e. in the presence of the Sxc inhibitor sulfasalazine, SSZ; 300 μM) ^{14}C-cystine uptake in WT or MSxc striatal tissue punches (N=3-6/condition/genotype). * indicates a significant difference relative to WT tissues treated with vehicle, T-test, $p < 0.01$. (E) Data depict the mean ±SEM levels of extracellular glutamate levels in purified striatal astrocytes obtained from WT or MSxc rats after PACAP treatment (30 min at 0-100 nM; N=6/condition). * indicates a significant difference relative to WT with the corresponding PACAP treatment, T-test, $p < 0.001$; # indicates a significant difference relative to WT astrocytes treated with vehicle, Tukey HSD, $p < 0.05$.

Next we examined the impact of PACAP on Sxc-mediated glutamate release in WT or MSxc striatal astrocytes following PACAP application (30 min). A univariate ANOVA with genotype and PACAP concentration as between subjects factors produced a significant interaction [Figure 4.3E; $F(3,40)=4.058$, $p <0.05$]. Further analyses revealed significantly lower levels of glutamate in MSxc astrocytes compared to WT at each of the PACAP concentrations (T-test, $p <0.001$), consistent with the lack of Sxc activity in the mutants. A one-way ANOVA with PACAP concentration as a between-subjects factor revealed a PACAP dose-dependent increase of glutamate in WT [$F(3,20)=4.564$, $p <0.05$] but not in MSxc astrocytes, suggesting that PACAP potentially increases astrocyte Sxc-mediated glutamate release in rat striatum.

Experiment 3: PACAP attenuates AMPAR-mediated EPSCs in SN-projecting MSNs in the NAc. Having established that PACAP regulates astrocyte glutamate release mediated by Sxc, we then determined whether this neuropeptide regulates synaptic transmission in a manner that could contribute to behavior linked to this structure. To do this, we examined the impact of PACAP application on the activity of the two primary NAc efferents, NAc-SN and NAc-VP MSNs, each of which are linked to goal-directed behaviors (Kravitz and Kreitzer, 2012). We found that bath application of PACAP at 100 nM induced significant depression of AMPAR-EPSCs [$t(12) = 2.10$, $p < 0.05$] but failed to do so at 1 nM (Figure 4.4A) in SN-projecting NAc MSNs. In contrast, PACAP at 100 nM or 0.1 nM did not alter AMPAR-EPSCs (Figure 4.4B) in VP-projecting NAc MSNs.

Figure 4.4. PACAP attenuates AMPAR-mediated EPSCs in SN-projecting NAc MSNs. (A) Data depict AMPAR-mediated EPSCs in retrogradely labeled NAc MSNs that project to the SN when incubated with PACAP at 1 nM (n = 7) or 100 nM (n = 8). 100 nM PACAP depressed AMPAR-mediated EPSCs. (B) Data depict AMPAR- mediated EPSCs in VP-projecting MSNs in the NAc when incubated with PACAP at 0.1 nM (n = 15) or 100 nM (n = 8).

Experiment 4: Characterization of PACAP-induced regulation of AMPAR-mediated EPSCs. To investigate the mechanisms mediating the actions of PACAP (100 nM), we first examined the involvement of PACAP receptors in PACAP-induced regulation of synaptic transmission in NAc tissue slices. When co-applied with the PACAP receptor inhibitor PACAP6-38, PACAP-induced depression of AMPAR-EPSCs in NAc-SN MSNs was abolished [Figure 4.5A; t(13) = 3.19, $p < 0.01$].

Next, we sought to test the hypothesis that PACAP regulates synaptic transmission via an Sxc-dependent mechanism. Support for this key hypothesis would provide a clear demonstration that PACAP functions as a molecular bridge linking astrocytes and neurons in the regulation of excitatory signaling-induced synaptic transmission in the NAc. We found that PACAP altered AMPAR-EPSCs in NAc tissue slices obtained from WT but failed to do so in MSxc rats [Figure 4.5B; t(12) = 3.09, $p <$

0.01]. This finding is consistent with the hypothesis that the neuropeptide PACAP

integrates glutamate release from astrocytes to regulate synaptic transmission in the NAc.

Figure 4.5. PACAP-induced regulation of AMPAR-mediated EPSCs in SN-projecting MSNs involves PACAP receptors, Sxc, NMDARs and possibly phosphorylation of GluA1-T840. (A-C) Data depict the effects of PACAP (100 nM) on AMPAR-mediated EPSCs in SN-projecting MSNs in the NAc, with or without the presence of PACAP receptor antagonist PACAP 6-38 (A; N= 7-8/treatment), in WT or MSxc rats (B; N=7/genotype), or with or without the presence of GluN2B-selective NMDAR antagonist Ro 25-6981 (C; 1µM, N= 6-7/treatment), (D) Data depicts the effect of PACAP microinjection (100 pmol; N=7-8/group) into the NAc on the phosphorylation of GluA1-T840. Upper panel: representative western blotting results; lower panel: data depicts the phosphorylation levels (mean+ SEM) of GluA1-T840 in vehicle and PACAP groups (normalized to vehicle group; N=7-8/group). V, vehicle; P, PACAP; pT840, phosphorylated T840. * indicates a significant difference relative to vehicle group, T-test, $p < 0.05$.

Prior work has implicated GluN2B-containing NMDARs, which are high-affinity glutamate receptors that can be tonically activated by astrocytes and expressed extra-synaptically (Barria and Malinow, 2002; Yoshii et al., 2003; van Zundert et al., 2004; Herman and Jahr, 2007; Le Meur et al., 2007; Hamilton and Attwell, 2010; Petralia et al., 2010; Gladding and Raymond, 2011; Paoletti, 2011; Povysheva and Johnson, 2012; Paoletti et al., 2013), in PACAP-induced regulation of synaptic transmission in hippocampal neurons (Toda and Huganir, 2015). Hence, we sought to determine if these receptors also contribute to PACAP-induced regulation of synaptic transmission in the NAc. Interestingly, we found that co-application of the GluN2B-selective NMDAR antagonist Ro 25-6981 blocked PACAP-induced depression of AMPAR-EPSCs [Figure 4.5C; $t(11) = 2.97$, $p < 0.05$].

The negative regulation of AMPARs by extrasynaptic NMDARs is thought to involve dephosphorylation of the key subunit GluA1 at T840 (Delgado et al., 2007; Lee et al., 2007; Gray et al., 2014; Toda and Huganir, 2015). To assess if this may contribute to our above observations, we examined whether PACAP dephosphorylates NAc AMPARs at GluA1-T840. We found that one hour after PACAP microinjection (100 pmol/side) in the NAc, the phosphorylation of GluA1-T840 was significantly decreased [Figure 4.5D; $t(13) = 2.178$, $p < 0.01$].

Experiment 5: Increasing PACAP signaling in the NAc attenuates cocaine-induced reinstatement via the regulation of Sxc. Since either decreased activity of Sxc or activation of SN-projecting MSNs in the NAc are linked to the expression of drug-seeking behaviors (Baker et al., 2003; Madayag et al., 2007; Rogers et al., 2008; Moussawi et al., 2009; Amen et al., 2011; Moussawi et al., 2011; Kravitz et al., 2012;

Schmaal et al., 2012; Bossert et al., 2013; Macpherson et al., 2014), we predicted that

increasing PACAP signaling in the NAc, which potentially restores Sxc function and

suppresses the SN-projecting neurons, would reduce cocaine seeking. To test this, we

first examined the impact of microinjecting PACAP in the NAc on cocaine-induced

reinstatement in rats (Figure 4.6A). A one-way ANOVA with PACAP concentration as a

between-subjects factor yielded a main effect on reinstatement responses [Figure 4.6A;

$F_{(2,26)}=8.814$, $p = 0.001$]. We then examined the impact of PACAP in WT and MSxc

rats. Repeated measures with genotype as a between-subjects factor and microinjection

treatment as a within-subjects factor revealed a main interaction [Figure 4.6B;

$F_{(1,7)}=6.945$, $p < 0.05$]. PACAP microinjection in the NAc decreased reinstatement

levels in WT rats [$t(8) = 5.999$, $p < 0.001$) but failed to do so in MSxc subjects. Therefore,

these data suggest that increasing PACAP signaling in the NAc decreased compulsive

cocaine seeking by upregulating Sxc activity.

Figure 4.6. Increasing PACAP signaling in the NAc attenuates cocaine-induced reinstatement via the regulation of Sxc. Data depict lever responding during a two-hour session following intra-NAc PACAP microinjections (0-100 pmol) and a systemic injection of cocaine (10 mg/kg, i.p.) in commercially purchased WT rats (A; Envigo, Indianapolis, IN; N=6-13/condition) and in internally-generated WT and MSxc rats (B; N=4-5/condition). * indicates a significant difference relative to the vehicle group of WT rats, T-test, $p < 0.001$.

Experiment 6: PACAP is expressed in corticostriatal afferents to the NAc.

Having observed the importance of PACAP signaling in the NAc to synaptic

transmission and motivated behavior, we were interested in investigating the sources of

endogenous PACAP in this brain region. A number of studies implicate that PACAP is

primarily, if not exclusively, expressed by glutamatergic neurons, and is co-transmitted

with glutamate as a neurotransmitter (Masuo et al., 1992; Masuo et al., 1993; Koves et al.,

1994; Hannibal et al., 2000; Hannibal, 2002a, b; Stumm et al., 2007; Engelund et al.,

2010; Golombek and Rosenstein, 2010; Hu et al., 2011; Purrier et al., 2014). Given the

importance of glutamatergic corticostriatal projections to the NAc to cocaine seeking, we

hypothesized that these NAc afferents would express PACAP. To test this, we used two

complementary approaches to determine if these cells express PACAP mRNA. In the

first approach, we combined retrograde circuit tracing with *in situ* hybridization.

Specifically, we microinjected retrograde tracer cholera toxin subunit B (CTB) in rat

NAc (Figure 4.7A). *In situ* hybridization (ISH) shows expression of PACAP mRNA in

the prelimbic PFC, particularly cortical layer V (Figure 4.7B), which has been suggested

to possess a major neuronal population projecting to the NAc (Ding et al., 2001). Co-

localization of the CTB and PACAP mRNA indicates that the majority of PFC neurons

projecting to the NAc express PACAP (Figure 4.7C-E).

Figure 4.7. PACAP is expressed in NAc-projecting PFC neurons. (A) The retrograde tracer cholera toxin subunit B (CTB) was delivered to the NAc core. This was confirmed by visualizing cannula tracts (top right insert) and comparing the spread of CTB (bottom right insert) with the defined boundaries of the NAc core (left); LV, lateral ventricle. Aca, anterior part of anterior commissure. (B) A 10X photomicrograph illustrating PACAP mRNA in the prefrontal cortex as detected using *in situ* hybridization (ISH). The boxed area is further magnified to 20X in panel C-E. The vertical dotted lines define areas approximating layer V of the prelimbic cortex. (C-E) 20X photomicrographs illustrating PFC cells that express PACAP mRNA (C, ISH) and project to the NAc (D, CTB IHC). White arrows represent PFC-NAc projections that express PACAP.

The expression of PACAP in the PFC-to-NAc projecting neurons was confirmed using a second approach, in which we labelled corticostriatal projections by microinjecting a fluorescent retrograde tracer (rhodamine-containing micro-beads) into the NAc. The labeled cells were then isolated from the PFC using FACS (Figure 4.8A, B). Due to the limited efficiency of the experimental procedures and our aim for high circuit specificity, each sample/subject yielded a limited target population (several hundreds to several thousand positive events), yet, we were able to obtain high-quality RNA from such small samples, demonstrated by high RNA integrity numbers (RINs: 7-8.5 on a 1-10

scale; Figure 4.8C). Using PCR combined with gel electrophoresis, we observed the

presence of PACAP mRNA in isolated PFC neurons projecting to the NAc (Figure 4.8D).

Using this approach, we also detected PACAP mRNA in the basolateral amygdala (BLA)

neurons projecting to the NAc. Collectively, these data provide the first demonstration

that PACAP is expressed in the corticostriatal glutamatergic projections to the NAc.

Figure 4.8. PACAP is expressed in PFC- and BLA-NAc projections. (A, B) Representative gating parameters of the FACS for identifying and isolating viable projecting neurons to the NAc in rats that received retro-tracer microinjections (A) or in controls (B). Pacific Blue-A represents the intensity of cell-viability dye, calcein violet; PE-A (phycoerythrin-area) represent the intensity of rhodamine dye contained in the retro-tracer. As such, Hi (high) population represent highly viable projection neurons, while Int (intermediate) are sub-viable or dying cells. (C) Representative RNA electrophoresis diagram showing high quality of RNA with a RNA integrity number (RIN) 8.4 (1-10 scale) extracted from a sorted PFC sample that contained 1376 events. 18s, 28s represent 18s, 28s ribosome RNAs. (D) Picture illustrates the PCR products on agarose gels (1.8%) after electrophoresis. cDNA were synthesized through RNA/cDNA amplification with mRNA extracted from sorted PFC or BLA neurons projecting to the NAc.

Experiment 7: Inhibiting endogenous PACAP signaling in the NAc increases cocaine-induced reinstatement. The above data raise the intriguing prospect that PACAP is a novel contributor to excitatory signaling in the NAc. To determine whether PACAP is an endogenous protective factor capable of limiting drug-seeking behavior, we examined whether a PACAP receptor inhibitor microinjected into the NAc would promote cocaine-seeking behavior. To do this, we modified the reinstatement paradigm to avoid potential ceiling effects of cocaine IP on reinstatement. Particularly, after the initial extinction training, rats received three cocaine reinstatement tests on separate days (Tests 1-3) so that behavior would approach extinction levels, thereby permitting sensitivity within the assay to detect increases in behavior. Next, PACAP6-38 was microinjected into the NAc and behavior was measured. PACAP6-38 microinjection in the NAc during Test 4 significantly increased cocaine-induced reinstatement compared to subjects receiving saline [Figure 4.9; $t(5) = 3.109$, $p < 0.05$), suggesting that endogenous PACAP in the NAc is an unrecognized factor influencing relapse vulnerability.

Figure 4.9. Inhibiting endogenous PACAP signaling in the NAc increases cocaine-induced reinstatement. Data depict lever responding during a two-hour session following intra-NAc microinjections of vehicle (saline) or PACAP6-38 (500 pmol) and a systemic injection of cocaine (10 mg/kg, i.p.) in rats (N=3-4/condition). * indicates a significant difference relative to vehicle group, T-test, $p < 0.05$.

Discussion

In this chapter, we found that PACAP depresses AMPAR-mediated EPSCs in the nucleus accumbens (NAc) medium spiny neurons (MSNs) projecting to the substantia nigra (SN). Moreover, this effect involves PACAP-induced upregulation of Sxc. This is the first finding that PACAP signaling regulates synaptic transmission in the NAc. The significance of this was evident by our finding that increasing PACAP signaling in the NAc significantly decreased cocaine-induced reinstatement of drug seeking. This effect of PACAP is abolished in Sxc loss-of-function mutants, suggesting the involvement of Sxc. In contrast, inhibiting PACAP receptors in the NAc exaggerated cocaine-seeking behavior, suggesting that endogenous PACAP in the NAc is a novel factor influencing relapse vulnerability. Next, we found that PACAP is expressed in NAc-projecting neurons in the prefrontal cortex (PFC) and basolateral amygdala (BLA). These are the first data demonstrating the existence of this peptide in corticostriatal projections to the NAc. Together, our data support the hypothesis that in the NAc, PACAP influences AMPAR-mediated synaptic transmission and plasticity through regulating Sxc. Such a function likely contributes to the coordinated glutamate network in the NAc and the proper expression of motivated behaviors.

The current study demonstrates that xCT and the primary PACAP receptor, PAC1R, are enriched in NAc astrocytes. These findings are consistent with a recent study conducted with mice cortical tissues (Zhang et al., 2014), suggesting that the enrichment of PAC1R and Sxc in *in vivo* astrocytes may be a general pattern in the CNS. The expression of PACAP signaling machinery in the NAc is consistent with the abundant immunoreactivity of this peptide in this brain region (Ghatei et al., 1993). To

investigate the cell-type specific expression of target genes, we used FACS with a newly developed transgenic rat model, which expresses membrane-targeted eGFP under GFAP control in order to better label astrocytes. The successful labeling of astrocytes is demonstrated by the lack of NeuN and abundant expression of GFAP mRNA in the GFP+ populations (Figure 4.1). Note that, even though the GFP- population is enriched in NeuN (e.g., relative to the total sample), it likely contains other cell populations, including astrocytes, microglia and oligodendrocytes. As these glia subtypes also express small amounts of Sxc (Zhang et al., 2014), this may explain the low level of xCT mRNA in GFP- samples.

Using two different approaches including FACS and combined immunohistochemistry and *in situ* hybridization, we found PACAP mRNA in the NAc afferents from the PFC and BLA. These findings support prior observations that PACAP is expressed primarily in glutamatergic neurons. In support, PACAP is co-expressed with vGluT2, and may be co-released with glutamate (Hannibal et al., 2000; Hannibal, 2002a; Engelund et al., 2010). This represents an important finding since neither this nor any other peptide has been implicated in the activity of NAc excitatory afferents. While it is unclear whether PACAP expression is exclusive to or ubiquitously expressed by all NAc excitatory afferents, our finding may have important implications for the cellular basis of cocaine-induced changes in the NAc. For example, cocaine-induced disruptions in glutamate homeostasis may be linked to cocaine-induced reductions in the activity of corticostriatal inputs to the NAc. This outcome may explain an interesting finding whereby manipulations in the cortex appear to be capable of normalizing astrocytic activity in the NAc (Berglind et al., 2009).

PACAP signaling in the NAc was found to depress AMPAR-mediated synaptic transmission. Interestingly, this function of PACAP appears to be circuit specific, as PACAP attenuates the AMPAR-EPSCs in SN-projecting MSNs, but not in VP-projecting MSNs. Moreover, this action of PACAP appears to be mediated by Sxc, since it is not observed in NAc tissues obtained from Sxc loss of function rats. This parallels prior observations in which astrocyte subpopulations in the striatum differentially regulate –SN and –VP projecting MSNs (Martin et al., 2015). Therefore, selective coupling to specific astrocyte subpopulations may add a layer of regulation for the MSNs which lead to the pathway-specific effects of PACAP.

Alternatively, efferent-specific gene expression may prime NAc-SN to undergo PACAP-induced regulation of synaptic transmission. In support, the MSNs involved in NAc-SN and NAc-VP pathways express heterogeneous biochemical profiles. For example, these pathways display differential expression of D1- and D2-like receptors (Lu et al., 1998; Gerfen and Surmeier, 2011). Interestingly, dopamine receptor activation may oppose PACAP-induced regulation of GluA1, which may provide a molecular basis for PACAP-induced signaling in one pathway but not the other. In addition, there may be other biochemical differences in neurons that account for this effect. For example, PAC1R is expressed in the SN-projecting neurons, while it is absent in the VP-projecting neurons (see Figure 5.2). In any of the above scenarios, the regulation of synaptic transmission in the NAc efferents likely results from the collective actions of PACAP on both astrocytes and neurons.

Consistent with others' findings that Sxc facilitates postsynaptic removal of AMPAR, resulting in the attenuation of synaptic strength (Williams and Featherstone,

2014), we found that application of PACAP to the NAc, which potentially increases Sxc activity, suppresses AMPAR-mediated synaptic transmission and reduces the phosphorylation of T840-GluA1, which is positively linked to AMPAR trafficking and channel conductance (Delgado et al., 2007; Jenkins et al., 2014). Given that the T840 site is a substrate for NMDAR-mediated signaling (Delgado et al., 2007; Lee et al., 2007; Gray et al., 2014), it is possible that glutamate from Sxc activates the extrasynaptic NMDARs which in turn reduce the phosphorylation of GluA1-T840. In support of these links, we found that PACAP-induced depression of AMPAR-EPSCs is abolished by Ro 25-6981, a selective antagonist for GluN2B-containing NMDARs, which are high-affinity glutamate receptors that can be tonically activated by astrocytes and expressed extrasynaptically (Barria and Malinow, 2002; Yoshii et al., 2003; van Zundert et al., 2004; Herman and Jahr, 2007; Le Meur et al., 2007; Hamilton and Attwell, 2010; Petralia et al., 2010; Gladding and Raymond, 2011; Paoletti, 2011; Povysheva and Johnson, 2012; Paoletti et al., 2013).

Interestingly, Ro 25-6981blocked PACAP-induced depression of AMPAR-EPSCs even though the MSNs were voltage-clamped at -80 mV, which is near their resting membrane potential. We used these parameters because it was found that astrocyte-induced regulation of GluN2B-NMDARs is voltage- and Mg^{2+}-independent (Hahn et al., 2015). Hence these data support the possibility that PACAP promotes astrocyte-neuron signaling (and/or signaling between extrasynaptic-synaptic microdomains) under resting conditions. This supports the possibility that signaling between astrocytes and neurons (or between extrasynaptic and synaptic domains) influences synaptic transmission even in cells or synapses that have not received recent synaptic inputs, which is important since

astrocytes have been implicated in regulating the firing of distal synapses or even entire networks of neurons (Fellin et al., 2004; Pascual et al., 2005; Fellin et al., 2006a). While beyond the scope of this study, this could be due to several possibilities. First, the voltage response in dendrites to the evoked synaptic inputs may have enabled the removal of the Mg^{2+} block of proximal NMDARs (Palmer and Stuart, 2009; Williams and Wozny, 2011; Acker et al., 2016). While this could contribute to our observations, it would not account for the observations of Hahn et al. (2015) since neurons in their study did not received synaptic (i.e., evoked) inputs. Second, astrocytes (and PACAP) may promote the activity of NMDARs that are incompletely blocked by Mg^{2+}. This could be due to fluctuations in local Mg^{2+} concentrations, which seems more likely in extrasynaptic microdomains since astrocytes are thought to regulate extracellular ion concentrations. Unfortunately, the biology of Mg^{2+} transporters is poorly understood (Ferre et al., 2011). It is shown that these transporters are enriched in astrocytes (Zhang et al., 2014), yet it is unclear if they are restricted to mitochondria in these cells. Alternatively, our finding could involve NMDARs that are partially resistant to Mg^{2+} blockade (e.g., triheteromeric GluN1-GluN2B-GluN2D-NMDARs) (Huang and Gibb, 2014). Lastly, this could indicate that the action of neuronal PACAP receptor signaling may include the removal of Mg^{2+} from NMDARs. In support of this compelling possibility, several studies have shown that PKC, which can be driven by PACAP receptors, is capable of removing Mg^{2+} blockade of NMDARs (Chen and Huang, 1992; Tyszkiewicz et al., 2004; Moriguchi et al., 2007). Regardless, these findings illustrate the potential complexity that exists in the striatum, and suggest that PACAP regulates synaptic transmission through upregulating Sxc activity and ensuring glutamate release from astrocytes, which activates extrasynaptic

NMDARs and subsequently inhibits AMPAR function. This multi-cellular mechanism may also underlie a number of findings in different brain regions where PACAP regulates phosphorylation of GluA1 and synaptic strength (Kondo et al., 1997; Roberto and Brunelli, 2000; Roberto et al., 2001; Ciranna and Cavallaro, 2003; Costa et al., 2009; Gardoni et al., 2012; Toda and Huganir, 2015). However, further studies are needed to validate these links.

Consistent with the behavioral outcome that would be predicted when suppressing the activity of NAc-SN MSNs (Rogers et al., 2008; Kravitz et al., 2012; Bossert et al., 2013; Macpherson et al., 2014), we found that PACAP microinjected into the NAc significantly attenuates cocaine-primed reinstatement. Consistent with our above findings, PACAP-induced regulation of behavior is likely mediated by Sxc since it is not evident in MSxc rats. Collectively, these data may establish PACAP signaling in the NAc as a critical protective factor capable of limiting drug-induced relapse. In support, we found that inhibiting endogenous PACAP signaling in the NAc following micro-injection of the PACAP receptor inhibitor PACAP6-38 augmented cocaine-induced reinstatement. Hence, these data indicate that heightened drug seeking may result from impaired PACAP signaling, which needs to be examined in future studies.

In conclusion, our data establish PACAP signaling in the NAc as a novel, key component of excitatory signaling cocaine seeking behavior. Moreover, PACAP is present in corticostriatal neurons, which are NAc afferents that are known to display persistent hypofunction following long-term cocaine administration (Jentsch and Taylor, 1999; Naqvi and Bechara, 2010; Goldstein and Volkow, 2011). These collective results may yield novel opportunities to understand the biological basis of addiction. In support,

human cocaine abusers exposed to craving-inducing stimuli exhibit increased activation of excitatory circuits originating in cortical regions, including orbital and prefrontal cortex, and projecting to the ventral striatum (Breiter et al., 1997; Volkow et al., 2005). Preclinical data also indicate the existence of drug-induced plasticity leading to activation of corticostriatal pathways. Activation of these circuits results in heightened extracellular glutamate in the NAc (Pierce et al., 1996; Reid and Berger, 1996) and stimulation of ionotropic glutamate receptors, both of which are necessary for cocaine primed reinstatement (Cornish and Kalivas, 2000; McFarland et al., 2003). Thus, these data raise the provocative possibility that PACAP signaling may be altered by cocaine. If so, this could have tremendous implications in understanding the pathological basis of cocaine addiction, since PACAP signaling regulates Sxc activity, NMDAR and AMPAR signaling, dendritic spine morphology (Gardoni et al., 2012), and LTP & LTD (Roberto and Brunelli, 2000) – all of which are altered in the NAc by cocaine.

Beyond cocaine addiction, our findings may have implications for understanding other CNS conditions given the role of glutamate as the primary excitatory signal in the brain. Moreover, our findings are consistent with the emerging viewpoint that normal excitatory signaling involves the highly integrated activity of multiple cell types in the brain, including astrocytes and neurons. These findings parallel compelling studies demonstrating that astrocyte-neuron communication may underlie the activity patterns of entire neural networks (Caudle, 2006; Volman et al., 2007; Pereira and Furlan, 2010; Amiri et al., 2013; Dallerac and Rouach, 2016). In fact, a recent report found that astrocytes contribute to gamma oscillations and recognition memory (Lee et al., 2014). It has been suggested that astrocytes may enable a high-degree of coordination over entire

populations of neurons due to several key morphological and structural features including the non-overlapping domains of these cells and the high number of synapses that can be contacted by an individual astrocytes (which may number in the millions in the human cortex) (Bushong et al., 2002; Halassa et al., 2007; Robertson, 2013, 2014). While astrocytes release a number of neuro-active substances that may underlie this important activity (Araque et al., 1999; Haydon, 2001; Perea and Araque, 2005; Fellin et al., 2006a; Haydon and Carmignoto, 2006; Araque et al., 2014; Perez-Alvarez et al., 2014), glutamate is clearly involved in this process. Hence, it is possible that the unique form of neuron-astrocyte signaling identified in these studies may contribute to the activity of entire neural networks, and changes in PACAP signaling may contribute to pathological states in a variety of CNS conditions.

CHAPTER V

DISCUSSION

General Discussion

Drug addiction is a chronic central nervous system (CNS) disorder characterized by persistent relapse susceptibility, even after years of abstinence (Jaffe et al., 1989; Withers et al., 1995). This results at least in part from drug-induced changes in glutamate signaling, especially within the corticostriatal projections to the nucleus accumbens (NAc) (Pierce et al., 1996; Reid and Berger, 1996; Breiter et al., 1997; Volkow et al., 1999; Cornish and Kalivas, 2000; Park et al., 2002; Baker et al., 2003; McFarland et al., 2003; McFarland et al., 2004; Kalivas and Volkow, 2005; Schmidt et al., 2005; Volkow et al., 2005; Madayag et al., 2007; Kau et al., 2008; Kalivas, 2009; Ary et al., 2013). While it is reasonable to predict that these discoveries could be leveraged to develop novel approaches to treat drug addiction, a challenge in revealing the molecular or cellular basis of pathological glutamate transmission in addiction (or any other CNS disorder) is that excitatory neurotransmission is comprised of a complex network of glutamate transporters, receptors, and release mechanisms expressed by multiple cell types, including neurons and astrocytes (Herrera-Marschitz et al., 1996; Timmerman and Westerink, 1997; Danbolt, 2001; Schoepp, 2001; Baker et al., 2002; Baker et al., 2003; Pirttimaki et al., 2011; Bridges et al., 2012a). Moreover, while it is highly likely that glutamatergic signaling across distinct cell types is highly coordinated, little is known about the molecular basis of integrated astrocyte-neuron signaling.

These studies investigated the molecular basis of orchestrated neuron-astrocyte communication within the context of glutamate transmission in the NAc. To do this, I primarily focused on the regulation of an astrocytic glutamate release mechanism, system x_c- (Sxc) by neurons and a neuropeptide, pituitary adenylate cyclase-activating polypeptide (PACAP). Sxc was chosen, since this non-canonical glutamate transporter is strongly linked to glutamate signaling in the NAc, and because cocaine-induced changes in Sxc are implicated in pathological changes in neuronal synaptic transmission (Baker et al., 2003; Madayag et al., 2007; Moussawi et al., 2009; Amen et al., 2011; Moussawi et al., 2011; Schmaal et al., 2012). As such, we were confident that glutamate released by Sxc contributes to astrocytic regulation of neuronal glutamate signaling. In turn, we examined the capacity for PACAP to sub-serve neuronal regulation of astrocytes, since this peptide is exclusively expressed by neurons in the CNS and has been demonstrated to regulate glutamate release and clearance by astrocytes (Figiel and Engele, 2000; Goursaud et al., 2008; Resch et al., 2014b; Zhang et al., 2014). Therefore, the intersection of PACAP and Sxc on the regulation of astrocytic and neuronal glutamate systems presents itself as a unique opportunity to understand the importance of neuron-astrocyte communication to synaptic transmission and behavior.

The studies in this dissertation demonstrate that glutamate release from astrocytes via Sxc is regulated by neuronal soluble factors (Chapter II), which likely involves the neuropeptide PACAP. In support, inhibiting PACAP signaling reversed the neuronal upregulation of Sxc activity in astrocytes, while PACAP application mimicked the actions of neuronal supplementation of astrocyte cultures. Interestingly, PACAP-induced regulation of Sxc was observed in both cortical and striatal astrocytes (Chapters II and

III), which supports the hypothesis that this unique form of neuron-astrocyte communication may be of relevance to excitatory signaling in each of these brain regions. Having found that PACAP is expressed in corticostriatal inputs to the NAc, we then sought to determine whether this neuropeptide is a novel component of excitatory signaling in this structure (Chapter IV). We found that PACAP application to NAc slices depressed synaptic transmission in neurons projecting to the substantia nigra (SN), an important efferent that is thought to encode positive reinforcement or motivated behaviors (Rogers et al., 2008; Kravitz et al., 2012; Bossert et al., 2013; Macpherson et al., 2014). Interestingly, PACAP-induced control over synaptic transmission required upregulation of Sxc activity. To demonstrate the *in vivo* relevance of each of these findings, we then found that microinfusion of PACAP into the NAc attenuated cocaine-primed reinstatement of extinguished drug seeking in rats (Chapter IV). Collectively, this dissertation reveals that a novel form of neuron-astrocyte communication, namely PACAP-induced regulation of Sxc, is a critical link integrating the glutamate network to permit coordinated excitatory transmission that underlies motivated behaviors and likely many other CNS functions.

Making the Human Brain Great Again: Critical Roles for Neurons and Astrocytes

In considering the importance of the above findings, it is interesting to examine our results through the contemporary perspective that the profound capabilities of the human brain stem from its extraordinary computational capacity as opposed to the size or other potentially unique features that have been historically used to explain why the human brain is so special (Roth and Dicke, 2005; Pereira and Furlan, 2010; Robertson,

2013, 2014; Dicke and Roth, 2016). In the study of the computational capacity of the brain (McCulloch and Pitts, 1990; Quian Quiroga and Panzeri, 2009), mathematical models demonstrate that even simplified neuron-neuron signaling that sum *binary* inputs to yield *binary* outputs is capable of performing logical tasks that are needed for information processing. This simplistic depiction does not fully account for synaptic integration, the computational process by which an individual neuron processes its synaptic inputs and converts them into an output signal. The reason for this is that the inputs and outputs of neurons are not necessarily binary. Towards this, the complexity of human neurons (e.g., extensive dendritic fields enabling important increases in the number of synaptic inputs per cell) has been suggested to account for the extraordinary computational capabilities of the human brain (Roth and Dicke, 2005; Dicke and Roth, 2016). In addition, local processing at axonal terminals (i.e., at the level of the presynaptic neuron) can also confer a degree of additional informational processing. Despite these additional forms of neuronal synaptic integration, it is doubtful that the profound capabilities of the human brain solely stem from neuron-neuron signaling.

In more recent efforts, attempts to model the extraordinary capabilities of the human brain have done so by incorporating astrocytes. By some estimates, astrocytes are the most abundant cell type in the brain (Barres, 2008). While classically depicted as metabolic support cells, work over the past few decades has definitively established astrocytes as key components of synaptic transmission and regulators of neural networks in the brain (Araque et al., 1999; Haydon, 2001; Perea and Araque, 2005; Fellin et al., 2006a; Haydon and Carmignoto, 2006; Araque et al., 2014; Perez-Alvarez et al., 2014). Within the context of computational capacity, it is important to note that astrocytes are

receptive to virtually every known neurotransmitter (NT), may contact millions of synapses, and are capable of releasing numerous neuro-active molecules, including glutamate (Bushong et al., 2002; Fellin et al., 2006a; Haydon and Carmignoto, 2006; Halassa et al., 2007; Verkhratsky, 2009; Robertson, 2013; Araque et al., 2014; Perez-Alvarez et al., 2014; Robertson, 2014).

Perhaps due to these attributes, mathematical models that incorporate neuronal-astrocyte communications portray an important role for astrocytes as reservoirs or storage banks of information flowing through neuronal networks (Caudle, 2006; Volman et al., 2007; Amiri et al., 2013; Dallerac and Rouach, 2016). This and other properties may be due to unique astrocyte features such as non-overlapping spatial domains and relatively slow intra-cellular signaling (at least as compared to neurons) (Bushong et al., 2002; Halassa et al., 2007; Robertson, 2013, 2014). Thus, at a minimum, the incorporation of astrocytes enables the expansion of temporal and spatial limitations of signal computation or integration (Caudle, 2006; Volman et al., 2007; Pereira and Furlan, 2010; Amiri et al., 2013; Dallerac and Rouach, 2016). Therefore, the inclusion of these cells is required to maximize the computational capacity of the human (or any other) brain. In other words, the study of these cells within the context of neuron-astrocyte and astrocyte-neuron communications (Figure 5.1A) will be essential for understanding the local information processing that underlies the output of a given brain region or related circuits.

The above concepts are useful in considering behavioral control by the NAc. To the extent that optimized patterns of behavior promote survival through interactions with the environment in a manner that increases biological fitness, then behavioral control by the NAc should require the integration of a great number of factors. Indeed, the NAc

receives diverse input signals originating from many cortical areas, as well as from the

hippocampus, amygdala, midbrain dopamine nuclei and hypothalamus (Salgado and

Kaplitt, 2015). Each of these inputs encodes key behavioral antecedents, such as decision

making (executive function), memory, emotion, environmental salience, internal states

and more. As such, our findings may be framed as demonstrating that presynaptic

neurons recruit astrocytes into the local integration of incoming information through the

release of PACAP (Figure 5.1B). Moreover, astrocytes then can shape the output from

the NAc in part through the release of glutamate from Sxc. Hence, our work may have

identified an important loop of communication between neurons and astrocytes in a

manner that promotes the integrative capacity of local signaling in the NAc for the

purpose of behavioral control. These key points will be discussed within a functional unit

Figure 5.1. A typical neurotransmission unit. (A) Conceptual illustration of an information processing unit that incorporates an astrocyte. N: neuron; A: astrocyte. (B) Illustration of the major findings of this dissertation in a tripartite synapse in the NAc. Pre: presynaptic terminal; Post: postsynaptic terminal; Glu: glutamate; PRs: PACAP receptors; Sxc: system x_c-.

of neurotransmission/information processing, namely, a tripartite synapse in the NAc that

is formed by a presynaptic neuron from the prefrontal cortex (PFC), a postsynaptic

medium spiny neuron (MSN) projecting to the SN, and the adjacent astrocyte process (Figure 5.1B). As such, the remaining discussion is organized by factors related to a) presynaptic neuronal regulation or signaling to astrocytes and b) astrocytic regulation or signaling to postsynaptic neurons.

Presynaptic Neuronal Recruitment of Astrocytes

In these studies, we observed the expression of PACAP mRNA in cortical neurons both *in vitro* (Chapter II) and *in vivo* (Chapter IV), and this represents the first demonstration that corticostriatal projections to the NAc contain PACAP (Chapter IV). In addition, we observed PACAP mRNA in glutamatergic projections to the NAc from the basolateral amygdala. Lastly, we detected extracellular PACAP in the NAc using peptide microdialysis (data not shown). Collectively, these findings are consistent with other reports suggesting that PACAP is often, if not exclusively, expressed in glutamatergic neurons and is released as a neurotransmitter through the same nerve terminals as glutamate (Koves et al., 1994; Hannibal et al., 2000; Hannibal, 2002b, a; Stumm et al., 2007; Engelund et al., 2010; Hu et al., 2011;Masuo et al., 1992; Masuo et al., 1993; Golombek and Rosenstein, 2010; Purrier et al., 2014).

Co-transmission increases computational capabilities of the neural network

The release of PACAP and glutamate from the same neurons represents a phenomenon that is increasingly recognized to occur throughout the CNS, and this diversifies the manner in which inputs can alter activity within target regions or circuits (Seal and Edwards, 2006; Broussard, 2012; Hnasko and Edwards, 2012). On one hand,

this diversification can involve spatial parameters. For example, the cellular targets of

glutamate and PACAP may be at least partially distinct. It is widely thought that the

primary target of synaptically released glutamate is the postsynaptic neuron and that there

are numerous mechanisms in place to limit spillover (Logan and Snyder, 1971; Balcar

and Johnston, 1972; Danbolt, 2001; Bridges et al., 2012a). Hence, glutamate may be

especially important for neuron-neuron signaling. Alternatively, the primary PACAP

receptor, PAC1R is mainly expressed by astrocytes (Chapter IV). While we have

observed its presence in SN-projecting MSNs (Figure 5.2), I found that the total

Figure 5.2. PAC1R is expressed in NAc neurons projecting to the substantia nigra, but not to the ventral pallidum. Picture illustrates PCR products on an agarose gel (1.8%) after electrophoresis. cDNA was synthesized through RNA amplification and reverse transcription with mRNA extracted from circuit-specific neurons in the NAc that were obtained via fluorescence-activated cell sorting (FACS). PCR was conducted with cDNA templates and primers specific to rat GAPDH and PAC1R. Presence of bands at expected sizes indicates the expression of the target genes. SN: substantia nigra; VP: ventral pallidum.

proportion of PAC1R present in astrocytes from NAc tissues exceeds 95% (Chapter IV).

This is a level of cell-specific expression that is rarely observed for a neurotransmitter

receptor, especially in adult, fully-developed cells. Therefore, glutamate and PACAP

released from corticostriatal inputs to the NAc may differentially target postsynaptic and

astrocytic signaling, with glutamate favoring the postsynaptic terminal, while PACAP

favoring the astrocyte process. In support, a loss of Sxc function completely eliminated the capacity of this neuropeptide to regulate glutamate release from striatal astrocytes, synaptic transmission in the NAc and cocaine reinstatement (Chapter IV). In addition, PACAP may also increase the temporal aspects of information encoded by incoming corticostriatal (or other) inputs, given that neuropeptide transmission often permits increased temporal domains (Nusbaum et al., 2001; van den Pol, 2012). As such, the co-transmission of transmitters (e.g. glutamate and PACAP) provides strong support for the idea that this novel form of neuron-astrocyte signaling has the benefit of enhancing the information processing capabilities within local NAc circuits.

Co-transmission in the motive circuit

Interestingly, co-transmission has been demonstrated in other parts of the motive circuit. For example, it is shown that VTA (ventral tegmental area) dopaminergic afferents to the striatum co-release (i.e., transmitted through the same vesicles) GABA (Tritsch et al., 2012). Similarly, it has been demonstrated that VTA neurons projecting to the NAc express both tyrosine hydroxylase and vesicular glutamate transporter 2 (vGluT2), suggesting the co-transmission of dopamine and glutamate (Chuhma et al., 2009; Stuber et al., 2010; Tecuapetla et al., 2010). Alternatively, substance P and enkephalin that are preferably expressed in, respectively, D1- and D2-like receptor-expressing MSNs in the striatum (Lu et al., 1998; Steiner and Gerfen, 1998) co-transmit with GABA, and have been shown in modulating GABAergic transmission (Maneuf et al., 1994; Tan and Bullock, 2008; Govindaiah et al., 2010; Tritsch et al., 2016). In contrast to these, our findings may be the first implicating the co-transmission of a

neuropeptide with the primary excitatory neurotransmitter glutamate in corticostriatal (and other excitatory) projections of the motive circuit.

PACAP receptors: the gate to astrocyte information storage.

In these studies, PACAP signaling in astrocytes is considered to be an important form of astrocytic regulation of incoming information. As such, we sought to identify the precise PACAP receptor(s) involved in this phenomenon. PACAP binds to three PACAP receptors (PAC1R, VPAC1R and VPAC2R) with similarly high affinities (Harmar et al., 1998; Harmar, 2001; Vaudry et al., 2009). In an initial attempt to identify the relevant receptor(s), we first examined which receptors are expressed by cortical and striatal astrocytes. Having detected all three PACAP receptors in cortical and striatal astrocytes (Chapters II and III), a finding that is consistent with others (Ashur-Fabian et al., 1997; Magistretti et al., 1998; Grimaldi and Cavallaro, 1999; Joo et al., 2004; Masmoudi-Kouki et al., 2007; Nishimoto et al., 2007; Nishimoto et al., 2011; Zhang et al., 2014), we then examined expression patterns in adult NAc astrocytes. We found that both PAC1R (Chapter IV) and VPAC2R are present in NAc astrocytes (Figure 5.3), indicating that the

GAPDH   PAC1R   VPAC1R   VPAC2R

Figure 5.3. PAC1R and VPAC2R are expressed in adult NAc astrocytes. Picture illustrates PCR products on an agarose gel (1.8%) after electrophoresis. cDNA was synthesized through reverse transcription with mRNA extracted from adult NAc astrocytes obtained via FACS. PCR was conducted with cDNA templates and primers specific to rat PAC1R, VPAC1R and VPAC2R. Presence of bands at expected sizes indicates the expression of the target genes.

expression of PAC1R and VPAC2R persists beyond any potential developmental changes. While VPAC1R appears to be undetectable in NAc astrocytes (Figure 5.3), it may be a false negative result caused by its low abundance, especially in astrocytes, and the limitation of the detecting method (i.e. PCR). In support, it has been shown that PAC1R transcripts are much more abundant than either VPAC1R or VPAC2R, especially in astrocytes, with the respective FPKM (fragments per kilobase of transcript per million mapped reads) values to be > 150, < 0.2 and ≈ 2 (Zhang et al., 2014). Moreover, both PAC1R and VPAC2R appear to be more enriched in astrocytes than in neurons, with ratios at 10:1 (PAC1R) and 5:1 (VPAC2R), while VPAC1R is more enriched in neurons, with a 5:1 ratio compared to astrocytes (Zhang et al., 2014). Because of this and related observations, we hypothesized that PAC1R may be the primary mediator for PACAP-induced regulation of astrocyte Sxc. In support, brief application of the PAC1R inhibitor PACAP6-38 reversed the capacity for neurons to promote Sxc activity in astrocytes (Chapter II).

However, we are confident that activation of VPAC receptors (VPACRs) is also sufficient to upregulate astrocytic Sxc. In support, we observed that vasoactive intestinal peptide (VIP), which activates both VPAC1R and VPAC2R (Dickson and Finlayson, 2009), significantly upregulates Sxc activity in cortical astrocytes (Figure 5.4A), suggesting that VPACRs are potentially involved, consistent with others' finding (Resch et al., 2014b).

Figure 5.4. PACAP-induced regulation of Sxc activity is likely mediated by PAC1R and VPAC receptors. Data depict mean ± SEM levels of ^{14}C-cystine in purified rat cortical (A, B, C) or striatal (D) cultures after 24 hours treatment with vehicle, or ligands including VIP (10 nM), PACAP1-38 (designated as P1-38, 10 nM), VIP6-28 (designated as V6-28, 1 μM; VPAC1R and VPAC2R non-selective antagonist) and M65 (1 μM; PAC1R antagonist), or ligand mixtures including PACAP1-38 10 nM & VIP6-28 1 μM (designated as P1-38&V6-28), VIP 10 nM & VIP6-28 1 μM (designated as VIP&V6-28) and PACAP1-38 10 nM & VIP6-28 1 μM (designated as P1-38&V6-28) (N=6-12/condition). (A-D) * indicates a significant difference relative to vehicle-treated purified astrocyte cultures, Tukey HSD, $p < 0.01$. (C) # indicates a significant difference relative to VIP-treated purified astrocyte cultures, Tukey HSD, $p < 0.05$.

Surprisingly, a non-selective VPACR antagonist VIP6-28 failed to attenuate the augment of Sxc activity induced by PACAP (Figure 5.4B). One interpretation is that VIP6-28 lost its potency in blocking VPACRs. This possibility is unlikely, as we found that VIP6-28 significantly decreased VIP-induced upregulation of Sxc activity (Figure 5.4C). Alternatively, it is possible that both PAC1R and VPACRs are capable of

mediating PACAP-induced regulation of Sxc in cultured astrocytes, and their functions in this regard are redundant. Consistent with this idea, application of selective PAC1R antagonist M65 to striatal astrocytes was not able to attenuate the impact of PACAP.

Although PAC1R and VPACRs all appear to be sufficient in mediating PACAP-induced regulation of Sxc in cultured astrocytes, whether or not they are accountable for *in vivo* actions of endogenous PACAP is not clear. This is because that PACAP applied to cultured cells is likely capable of reaching to all different receptors through diffusion in the media; while *in vivo* PACAP may be only released through the presynaptic terminals, diffuse within a confined compartment and target astrocyte processes that express a defined population of PACAP receptors, e.g. PAC1R. Alternatively, PAC1R may be the only receptors expressed in the astrocyte domains facing PACAP releasing sites of corticostriatal terminals, while VPACRs are compartmentalized to be only activated by VIP from other inputs.

VIP-induced regulation of Sxc and its potential role in GABA transmission in the NAc

The above discussion supports an idea that VIP may be another critical endogenous regulator of Sxc, through which this peptide regulates synaptic transmission in the NAc. This is because, in addition to its capability of increasing Sxc activity in astrocytes (Figure 5.4A), VIP is highly expressed in the terminal field within the NAc (Sims et al., 1980). Moreover, we observed the expression of both VPAC1R and VPAC2R in cultured striatal astrocytes (Chapter III); VPAC2R has also been detected in adult NAc astrocytes (Figure 5.2).

In contrast to PACAP, which is located in glutamatergic neurons and is involved in regulating glutamate transmission (see the above discussion), VIP has been repeatedly linked to GABAergic neurons and shown to modify GABA signaling. For example, VIP is co-expressed with GABA in a major population of the suprachiasmatic nucleus (SCN) of the hypothalamus (Moore et al., 2002). Similarly, VIP in the hippocampus is expressed exclusively by GABAergic interneurons (Acsady et al., 1996), and influences GABA release. Moreover, VIP concerts pre and postsynaptic GABAergic transmission in the hippocampus, which leads to the disinhibition of pyramidal cell dendrites and causes an enhancement of synaptic transmission (Cunha-Reis et al., 2004). These observations implicate that VIP signaling in the NAc may regulate GABA transmission, possibly through a similar mechanism to PACAP, namely, by inducing astrocyte Sxc. This could be an interesting and important direction for future studies.

However, the origin of the endogenous VIP in the NAc still needs to be determined. While some studies implicate that the majority of VIP in the NAc originates from its projections that are embedded in the medial forebrain bundle (Marley et al., 1981), others show that VIP is expressed in aspiny interneurons in rat striatum (Theriault and Landis, 1987). In contrast, I have observed abundant VIP mRNA in mixed striatal cultures containing neurons and astrocytes, and a lack of VIP in striatal astrocyte cultures (Figure 5.5). Therefore, similar to PACAP, VIP also appears to be expressed exclusively by neurons, consistent with others' finding (Zhang et al., 2014). In a similar manner to our results suggesting that neuronal PACAP increases xCT expression (Chapter II), neuron-derived VIP may contribute to the higher level of xCT mRNA that was observed in the

mixed striatal cultures compared to striatal astrocytes (Figure 5.6).Yet, whether VIP in

striatal cultures originates from the interneurons or GABAergic MSNs is uncertain.

Figure 5.5. VIP is expressed in cultured striatal neurons but not astrocytes. Picture illustrates PCR products on an agarose gel (1.8%) after electrophoresis. cDNA was synthesized through reverse transcription with mRNA extracted from striatal cell cultures: STM, mixed striatal cultures; STN, striatal neurons; STA, striatal astrocytes. PCR was conducted with cDNA templates and a primer set specific to rat VIP. Presence of bands at the expected size indicates the expression of the target gene.

Figure 5.6. Striatal neurons increase xCT expression in striatal astrocytes. Data depict mean ±SEM levels of xCT mRNA in rat striatal cell cultures (N= 4/cell type). * indicates a significant difference relative to mixed cultures, Tukey HSD, $p < 0.001$; # indicates a significant difference relative to astrocyte cultures, Tukey HSD, $p < 0.01$.

Regardless of the uncertainty of the endogenous origin, the abundance of VIP signaling in the NAc appears consistent across different studies (Sims et al., 1980; Marley et al., 1981). These evidences discussed above and our observations implicate that VIP may regulate transmission in the NAc through its actions on astrocyte functions (e.g. Sxc).

The nature of PACAP-induced regulation of Sxc

In order to understand the potential contributions of phasic PACAP release to signal integration in the NAc, we became interested in the nature of PACAP-induced regulation of Sxc. Specifically, we were interested in learning whether brief PACAP application would be capable of rapidly (i.e., on a scale of minutes, see text box)

Time is often used a key variable in predicting whether changes in protein function reflect post-translational modification or changes involving gene expression. Thus, when altered protein function is observed in a manner of minutes, such as 6-min application of PACAP altering Sxc activity, we often exclude the possibility that changes in gene expression are involved. Is this a safe assumption? To examine this, we obtained published estimates of the key phenomena involved in protein expression.

Transcription - in eukaryotes, transcription has been reported to occur at a rate of 50-100 nucleotides per second (nt/s) (Dundr et al., 2002; Darzacq et al., 2007; Singh and Padgett, 2009), but this may be interspersed with pauses, which leads to a much slower rate at 6 nt/s (Darzacq et al., 2007).

Splicing of mRNA - the estimates of splicing are less detailed, but studies provide a timeframe of 5-10 minutes to excise introns from transcripts (Singh and Padgett, 2009).


Translation in eukaryotes requires an estimate of one second per 6 amino acids (Ingolia et al., 2011).

When applying the above estimates to the gene SLC7A11 that encodes xCT, it is apparent that it would take at least 75 seconds for transcription (74706 bp) (Gibbs et al., 2004), 5 minutes for splicing, and 85 sec for the translation (502 amino acids) (Alhaddad et al., 2014). This totals to 7-8 minutes, but it does not include the time needed for protein folding, trafficking, and insertion. Hence, it is unlikely that transcription is involved in PACAP-induced regulation of Sxc when applied for 30 min or less, especially since time is required to enable exogenous PACAP to diffuse to its receptor and alter intracellular physiology needed to regulate Sxc.

upregulating Sxc. We found that PACAP applied for as few as 6-30 min (Chapters III and IV) produced a significant increase in Sxc activity. This timescale likely reflects post-translational modification of xCT. However, the regulation of Sxc through post-translational modification is still poorly understood. While the xCT protein has been reported to contain consensus phosphorylation sites for various kinases (Baker et al., 2002), there has been only a single study clearly linking Sxc activity with phosphorylation (McClatchy et al., 2016). In this study, the mutagenesis of S26 on xCT, which corresponds to a phosphorylation sequence for mitogen and stress activated protein kinase (MKS), resulted in impaired Sxc activity. Our data are consistent with this observation in that MSK and its upstream activators PKA, ERK, and Epac are required for PACAP-induced regulation of Sxc (Chapter III). This is important, in part, since these signaling pathways have been implicated in cocaine addiction (Nestler, 2004; Kalivas and O'Brien, 2008; Besnard et al., 2011; Cahill et al., 2014; Liu et al., 2016), although these changes are often presumed to occur in neurons.

In addition to the rapid regulation, the magnitude of PACAP-induced increases in Sxc was significantly greater following long-term application, which also leads to increased xCT mRNA (Chapters II and III). This is of potential interest, given prior suggestions that astrocytes enrich local synaptic integration, in part by increasing the temporal dimension or persistence of incoming signals. Hence, it is possible that PACAP-induced Sxc regulation may occur along multiple timescales that reflect this important contribution of neuron-astrocyte communication. In support, we detected basal (i.e., unstimulated) PACAP levels in NAc microdialysis samples at a concentration of at least 83-267 pM. Note, these values were not corrected by our probe recovery rates,

which are likely less than 5%. Thus, basal PACAP levels may exist at a concentration as high as 5 nM. This is interesting, since it is in range of the nanomolar affinity of PACAP for PACAP receptors (Cauvin et al., 1990; Gottschall et al., 1990; Lam et al., 1990; Gottschall et al., 1991; Suda et al., 1992). Further, we observed PACAP-induced regulation of Sxc in striatal astrocytes at concentrations as low as 1 nM (Chapter III). Both PKA and Epac are also likely involved in PACAP-induced mRNA upregulation of xCT, given that they are capable of activating transcriptional factors (Mayr and Montminy, 2001; Schmidt et al., 2013). In addition, inhibition of PKA or Epac significantly attenuated 24-hr PACAP-induced increase of Sxc activity (Chapter III). However, more work is needed to understand the direct impact of PKA and Epac on xCT expression, and to what extent the increased expression of xCT versus post-translational modification contribute to increased Sxc activity observed following long-term PACAP treatment (e.g. 24 and 72 hr).

An important assumption in our interpretations up to this point is that Sxc activity *in vivo* is primarily if not exclusively astrocytic. This has been widely reported in the literature by measuring Sxc activity and/or cellular expression of xCT (Pow, 2001; Zhang et al., 2014). However, other authors suggest that neuronal cell lines and cultures may also display Sxc (Lewerenz et al., 2012a). To examine this, we determined the percentage of xCT mRNA obtained from adult rats that was contained in astrocytes versus every other type of cells. We observed that at least 90% of the total amount of xCT mRNA was present in our GFP+ samples following fluorescence-activated cell sorting (Chapter IV). Note, the remaining 10% reflects potential xCT mRNA expression in astrocytes not sorted into the GFP+ fraction (GFAP is detected in the GFP- fraction

since it is impossible to sort every astrocyte while excluding neurons in the GFP+ fraction), other glial cells, epithelial cells, and neurons. Importantly, we found that PACAP did not alter cystine uptake in neuronal cultures (Chapter II). As a result, our data strongly implicate astrocytic Sxc in our studies. Thus, we are confident that PACAP-induced regulation of Sxc in the NAc reflects neuron-astrocyte signaling. To determine whether these findings demonstrate that PACAP-induced regulation of Sxc in astrocytes is relevant to local synaptic integration, it then became necessary to demonstrate that PACAP-induced regulation of Sxc alters the output from the NAc and behavior.

Astrocyte-Neuron Regulation

In Chapter IV, we showed that PACAP depresses AMPAR-mediated EPSCs in NAc MSNs projecting to the SN. This is the first demonstration that PACAP signaling regulates synaptic transmission in the NAc, while similar effects have been shown in other brain regions, such as hippocampus and the suprachiasmatic nucleus (SCN) (Kondo et al., 1997; Roberto and Brunelli, 2000; Kopp et al., 2001; Roberto et al., 2001; Ciranna and Cavallaro, 2003; Costa et al., 2009; Gardoni et al., 2012; Toda and Huganir, 2015). Therefore, there was a need to establish the cellular basis for PACAP-induced regulation of synaptic transmission. While PACAP-induced regulation of synaptic transmission is often presumed to involve neuronal PACAP signaling, our data provide strong support for the involvement of astrocytes. In support, PACAP-induced regulation of AMPAR-mediated synaptic transmission in the NAc is not present in Sxc loss-of-function mutants, nor is the impact of PACAP on cocaine-induced reinstatement. Interestingly, our group

has begun collecting data demonstrating that re-introducing xCT cDNA into the NAc of these mutant rats rescues PACAP-induced blockade of cocaine reinstatement. Moreover, we and others have found that the elimination of Sxc in rats and/or mice produces deficits at the molecular, cellular, and behavioral levels that are opposite to what we have observed with PACAP and have attributed to increased Sxc. This includes the attenuation of synaptic strength involving AMPARs, reduced levels of basal glutamate, heightened phosphorylation of GluA1-T840, and augmented cocaine reinstatement (Baker data not shown; Williams and Featherstone, 2014; De Bundel et al., 2011; Li et al., 2012).

Encoding astrocyte-neuron signaling: A possible role for extrasynaptic NMDARs

Having established that PACAP-induced increases in Sxc contribute to the actions of PACAP in the NAc, we next examined the glutamate receptor that may encode this unique form of neuron-astrocyte signaling. Outside the NAc, PACAP-induced regulation of AMPAR signaling appears to be NMDAR-dependent. In support, potentiation of NMDAR-mediated synaptic activity by PACAP has been repeatedly demonstrated (Liu and Madsen, 1997; Wu and Dun, 1997; Harrington et al., 1999). This effect likely involves GluN2B-containing NMDARs. For example, PACAP promotes the phosphorylation of GluN2B, and in doing so enhances NMDAR-mediated currents, (Yaka et al., 2003; Macdonald et al., 2005; Resch et al., 2014a). Moreover, PACAP-induced dephosphorylation of GluA1-T840 in the hippocampus is mediated by NMDARs (Toda and Huganir, 2015). This effect is consistent with several studies implicating that NMDARs promote the dephosphorylation of GluA1-T840 of AMPARs, possibly through induction of protein phosphatase 1- and/or 2A (Delgado et al., 2007; Lee et al., 2007;

Gray et al., 2014). Similar to work in the hippocampus (Toda and Huganir, 2015), we also found that PACAP-induced regulation of synaptic transmission in the NAc requires activation of GluN2B-containing NMDARs, as co-application of a GluN2B-selective NMDAR antagonist Ro 25-6981 blocked PACAP-induced depression of AMPAR-mediated EPSCs (Chapter IV).

Given the above findings, we are confident that PACAP-induced regulation of astrocytic Sxc regulates synaptic transmission in NAc efferents by supplying glutamate capable of activating neuronal GluN2B-containing NMDARs. Moreover, we believe that the NMDARs encoding PACAP signaling through astrocytes are located extrasynaptically (Figure 5.1B). First, extrasynaptic NMDARs are often thought or have been shown to be GluN2B containing (Papouin et al., 2012). In support, GluN2B preferably associates with scaffolding proteins SAP102 (Yoshii et al., 2003; van Zundert et al., 2004), which is primarily located outside of synaptic domains (Barria and Malinow, 2002; van Zundert et al., 2004; Petralia et al., 2010; Gladding and Raymond, 2011). Further, extrasynaptic but not synaptic NMDARs are thought to inhibit AMPAR-mediated EPSCs (Papouin and Oliet, 2014). Lastly, several studies have implicated extrasynaptic but not synaptic NMDARs in tonic regulation by either non-vesicular and/or astrocytic glutamate release (Jabaudon et al., 1999; Warr et al., 1999; Angulo et al., 2004; Fellin et al., 2004; Shigetomi et al., 2008; Bardoni et al., 2010; Nie et al., 2010). Consistent with this, extrasynaptic but not synaptic NMDARs are often found to be clustered at sites proximal to astrocytic processes (Petralia et al., 2010). Given that non-vesicular release from Sxc has been implicated as the major source of extrasynaptic glutamate in brain regions including the NAc (Baker et al., 2002; De Bundel et al., 2011;

Massie et al., 2011), it is possible that this form of neuron-astrocyte-neuron signaling

may be present in the NAc and other structures.

A possible role in astrocyte-mediated neuronal synchronization

We speculate that the PACAP-induced regulation of Sxc and extrasynaptic

NMDARs may not be limited to the synapse where PACAP is released, but underlie the

expanded spatial and temporal influence of an astrocyte on multiple local neurons, for

example, in inducing neuronal synchronization. This is because that glutamate released

from astrocytes has been shown to activate extrasynaptic NMDARs on the postsynaptic

terminals and induce characteristic slow inward currents (SICs) that are synchronized in

local neurons (Parri et al., 2001; Angulo et al., 2004; Fellin et al., 2004; Fellin et al.,

2006b; D'Ascenzo et al., 2007). Notably, in these studies, glutamate release results from

spontaneous or evoked calcium oscillations in astrocytes. Yet, whether or not a calcium-

independent astrocyte glutamate release mechanism, such as Sxc, is capable of inducing

SICs has not been investigated. Moreover, it is shown that SICs and neuronal

synchronization could be induced by stimulating the afferents (Pirttimaki et al., 2011),

suggesting that the astrocyte glutamate release mechanism that is involved in SIC

generation and synchronization is regulated by neuronal activity. Along with the above

discussion, these evidences implicate that neuronal PACAP-induced glutamate release

through astrocyte Sxc and subsequent extrasynaptic NMDAR activation may also be

capable of influencing local neuronal network (e.g. synchronizing a number of local

neurons). This could be achieved by different mechanisms, for example, PACAP-induced

signaling cascades from one astrocyte process spread within the astrocyte and regulate

Sxc on other processes that encapsulate neighboring synapses and neurons. Alternatively,

the increased spatial domains of neuropeptide transmission may allow PACAP to target

Sxc on multiple astrocyte terminals and thus to influence multiple tripartite synapses

simultaneously.

Interestingly, synchronization of SICs induced by stimulating afferents could

sustain an extended time, for example, from minutes to one hour after the initial stimulus

(D'Ascenzo et al., 2007; Pirttimaki et al., 2011). Given the expanded temporal domain of

neuropeptide mediated regulation, it is possible that phasic PACAP release in response to

neuronal activity is capable of inducing sustained Sxc upregulation, which contributes to

the prolonged impact of astrocytes on neuronal SICs. Yet, these ideas are highly

speculative and further investigation is needed to determine whether rapid effect of

PACAP on Sxc activity is long-lasting.

Impaired Neuron-Astrocyte-Neuron Communication: Implications for CNS Pathology

Drug addiction is a complex, multi-faceted disorder characterized by compulsive

drug seeking even when such behavior results in profound negative consequences to the

individual. The chronic aspect of the disease involves episodes of heightened relapse

vulnerability even following long periods of abstinence, which stem from persistent

cocaine-induced neuroadaptations that disrupt glutamate transmission (Jaffe et al., 1989;

Withers et al., 1995; Baker et al., 2003; Kalivas and Volkow, 2005; Nestler, 2005;

Hyman et al., 2006; Koob and Volkow, 2010). Of particular importance, hypofrontality

(e.g., reduced basal activity) in the PFC and other NAc-related maladaptation have been

linked to behavior in virtually every preclinical model of drug seeking and has been

found to correlate with the severity of drug craving in human substance abusers (Pierce et

al., 1996; Breiter et al., 1997; Jentsch and Taylor, 1999; Volkow et al., 1999; Park et al., 2002; Baker et al., 2003; McFarland et al., 2003; McFarland et al., 2004; Schmidt et al., 2005; Madayag et al., 2007; Kau et al., 2008; Naqvi and Bechara, 2010; Goldstein and Volkow, 2011; Ary et al., 2013).

To the extent that corticostriatal inputs are an important source of NAc PACAP, then cocaine-induced hypofrontality may indicate the existence of cocaine-induced disruptions in PACAP signaling. Interestingly, hypofrontality is also observed in rats using the cocaine reinstatement model (Chen et al., 2013). Altered firing rates may particularly impact neuropeptide release, which often requires higher level of neuronal activity (Nusbaum et al., 2001; van den Pol, 2012). Interestingly, enhancing or stimulating the rodent PFC suppresses cocaine-seeking behavior (Chen et al., 2013), and this effect may be due to normalizing astrocytic-maintained glutamate homeostasis (e.g., release and clearance) in the NAc (Berglind et al., 2009). In this latter study, intra-PFC microinjection of BDNF reversed cocaine-induced decreases in NAc extracellular glutamate levels, which have been largely attributed to Sxc activity. Hence, while it is known that cocaine-induced plasticity altering excitatory signaling involves changes in astrocytes and neurons in these regions, these collective findings support the possibility that cell-specific plasticity in the NAc may be causally related (e.g., due to a loss of PACAP). The potential for altered PACAP to contribute to cocaine-induced pathology is evident by our and others' studies showing that PACAP can regulate Sxc activity (Resch et al., 2014b; Kong et al., 2016), NMDAR and AMPAR signaling (Costa et al., 2009; Toda and Huganir, 2015), dendritic spine morphology (Gardoni et al., 2012), and LTP & LTD (Roberto and Brunelli, 2000) – all of which are altered in the NAc by cocaine.

Conclusion

Models indicate that incorporating neuronal-astrocyte communication increases the computational capacity of a neural network. Thus, the study of these forms of inter-cellular communication will be essential to our understanding of the local signal processing underlying normal and diseased brain functioning. Towards this, our work supports the idea that in the NAc, the presynaptic neuronal factor PACAP enables direct encoding of afferent information to astrocytes. This in turn promotes the activity of Sxc, a glutamate release mechanism that we found regulates AMPAR-mediated EPSCs in NAc efferents. Moreover, this integrated network is likely critical to the integration of the many inputs that are normally used to regulate adaptive behavioral responses. An interesting question is the degree to which this complex network resembles similar forms of integrated inter-cellular signaling in other systems or other regions of the brain. For example, it is shown that endocannabinoid neuromodulators activate CB1 receptors on hippocampal astrocytes (Navarrete and Araque, 2008). This leads to an increase in astrocytic glutamate release (presumed but not demonstrated to be a non-Sxc mechanism), which results in the activation of NMDARs on adjacent neurons (Navarrete and Araque, 2008). While there are interesting parallels to our own findings, this study highlights the potential for molecular integration through the release of postsynaptic factors (e.g. endocannabinoid). Hence, it is interesting to speculate that local processing may be dependent on incorporating the computational capacity of each cell in a given region, and this can be achieved by inter-cellular signaling originating from any of the participating cells. To the extent that this is the case, the key to developing a meaningful understanding

of CNS function in normal and disease states will require identifying the molecular basis

for signal integration.

BIBLIOGRAPHY

Aal-Aaboda M, Alhaddad H, Osowik F, Nauli SM, Sari Y (2015) Effects of (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline on glutamate transporter 1 and cysteine/glutamate exchanger as well as ethanol drinking behavior in male, alcohol-preferring rats. Journal of neuroscience research 93:930-937.

Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nature reviews Neuroscience 7:41-53.

Acker CD, Hoyos E, Loew LM (2016) EPSPs Measured in Proximal Dendritic Spines of Cortical Pyramidal Neurons. eNeuro 3.

Acsady L, Arabadzisz D, Freund TF (1996) Correlated morphological and neurochemical features identify different subsets of vasoactive intestinal polypeptide-immunoreactive interneurons in rat hippocampus. Neuroscience 73:299-315.

Adinoff B (2004) Neurobiologic processes in drug reward and addiction. Harvard review of psychiatry 12:305-320.

Agulhon C, Petravicz J, McMullen AB, Sweger EJ, Minton SK, Taves SR, Casper KB, Fiacco TA, McCarthy KD (2008) What is the role of astrocyte calcium in neurophysiology? Neuron 59:932-946.

Alajaji M, Bowers MS, Knackstedt L, Damaj MI (2013) Effects of the beta-lactam antibiotic ceftriaxone on nicotine withdrawal and nicotine-induced reinstatement of preference in mice. Psychopharmacology 228:419-426.

Albano R, Liu X, Lobner D (2013) Regulation of system x(c)- in the SOD1-G93A mouse model of ALS. Experimental neurology 250:69-73.

Albano R, Raddatz NJ, Hjelmhaug J, Baker DA, Lobner D (2015) Regulation of System xc(-) by Pharmacological Manipulation of Cellular Thiols. Oxidative medicine and cellular longevity 2015:269371.

Alcaro A, Huber R, Panksepp J (2007) Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain research reviews 56:283-321.

Alho H, Kolmer M, Harjuntausta T, Helen P (1995) Increased expression of diazepam binding inhibitor in human brain tumors. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 6:309-314.

Alleweireldt AT, Weber SM, Kirschner KF, Bullock BL, Neisewander JL (2002) Blockade or stimulation of D1 dopamine receptors attenuates cue reinstatement of extinguished cocaine-seeking behavior in rats. Psychopharmacology 159:284-293.

Alvarez-Buylla A, Garcia-Verdugo JM, Tramontin AD (2001) A unified hypothesis on the lineage of neural stem cells. Nature reviews Neuroscience 2:287-293.

Amen SL, Piacentine LB, Ahmad ME, Li SJ, Mantsch JR, Risinger RC, Baker DA (2011) Repeated N-acetyl cysteine reduces cocaine seeking in rodents and craving in cocaine-dependent humans. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 36:871-878.

Amiri M, Montaseri G, Bahrami F (2013) A phase plane analysis of neuron-astrocyte interactions. Neural networks : the official journal of the International Neural Network Society 44:157-165.

Anderson CM, Swanson RA (2000) Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 32:1-14.

Anderson CM, Nedergaard M (2003) Astrocyte-mediated control of cerebral microcirculation. Trends in neurosciences 26:340-344; author reply 344-345.

Anderson SM, Famous KR, Sadri-Vakili G, Kumaresan V, Schmidt HD, Bass CE, Terwilliger EF, Cha JH, Pierce RC (2008) CaMKII: a biochemical bridge linking accumbens dopamine and glutamate systems in cocaine seeking. Nature neuroscience 11:344-353.

Anggono V, Huganir RL (2012) Regulation of AMPA receptor trafficking and synaptic plasticity. Current opinion in neurobiology 22:461-469.

Angulo MC, Kozlov AS, Charpak S, Audinat E (2004) Glutamate released from glial cells synchronizes neuronal activity in the hippocampus. The Journal of neuroscience : the official journal of the Society for Neuroscience 24:6920-6927.

Anker JJ, Carroll ME (2010) Reinstatement of cocaine seeking induced by drugs, cues, and stress in adolescent and adult rats. Psychopharmacology 208:211-222.

Aoki C (1992) Beta-adrenergic receptors: astrocytic localization in the adult visual cortex and their relation to catecholamine axon terminals as revealed by electron microscopic immunocytochemistry. The Journal of neuroscience : the official journal of the Society for Neuroscience 12:781-792.

Araque A, Parpura V, Sanzgiri RP, Haydon PG (1999) Tripartite synapses: glia, the unacknowledged partner. Trends in neurosciences 22:208-215.

Araque A, Li N, Doyle RT, Haydon PG (2000) SNARE protein-dependent glutamate release from astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 20:666-673.

Araque A, Carmignoto G, Haydon PG, Oliet SH, Robitaille R, Volterra A (2014) Gliotransmitters travel in time and space. Neuron 81:728-739.

Arimura A (1998) Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems. The Japanese journal of physiology 48:301-331.

Arimura A (2007) PACAP: the road to discovery. Peptides 28:1617-1619.

Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129:2787-2789.

Ary AW, Lominac KD, Wroten MG, Williams AR, Campbell RR, Ben-Shahar O, von Jonquieres G, Klugmann M, Szumlinski KK (2013) Imbalances in prefrontal cortex CC-Homer1 versus CC-Homer2 expression promote cocaine preference. The Journal of neuroscience : the official journal of the Society for Neuroscience 33:8101-8113.

Ashur-Fabian O, Giladi E, Brenneman DE, Gozes I (1997) Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides. Journal of molecular neuroscience : MN 9:211-222.

Augur IF, Wyckoff AR, Aston-Jones G, Kalivas PW, Peters J (2016) Chemogenetic Activation of an Extinction Neural Circuit Reduces Cue-Induced Reinstatement of Cocaine Seeking. The Journal of neuroscience : the official journal of the Society for Neuroscience 36:10174-10180.

Augustin H, Grosjean Y, Chen K, Sheng Q, Featherstone DE (2007) Nonvesicular release of glutamate by glial xCT transporters suppresses glutamate receptor clustering in vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience 27:111-123.

Baker DA, Xi ZX, Shen H, Swanson CJ, Kalivas PW (2002) The origin and neuronal function of in vivo nonsynaptic glutamate. The Journal of neuroscience : the official journal of the Society for Neuroscience 22:9134-9141.

Baker DA, Madayag A, Kristiansen LV, Meador-Woodruff JH, Haroutunian V, Raju I (2008) Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 33:1760-1772.

Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, Kalivas PW (2003) Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nature neuroscience 6:743-749.

Balcar VJ, Johnston GA (1972) The structural specificity of the high affinity uptake of L-glutamate and L-aspartate by rat brain slices. Journal of neurochemistry 19:2657-2666.

Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF (2000) Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. The Journal of neuroscience : the official journal of the Society for Neuroscience 20:89-102.

Bannai S, Kitamura E (1980) Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. The Journal of biological chemistry 255:2372-2376.

Bannai S, Kitamura E (1981) Role of proton dissociation in the transport of cystine and glutamate in human diploid fibroblasts in culture. The Journal of biological chemistry 256:5770-5772.

Bardo MT, Bevins RA (2000) Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153:31-43.

Bardoni R, Ghirri A, Zonta M, Betelli C, Vitale G, Ruggieri V, Sandrini M, Carmignoto G (2010) Glutamate-mediated astrocyte-to-neuron signalling in the rat dorsal horn. The Journal of physiology 588:831-846.

Barnabe-Heider F, Wasylnka JA, Fernandes KJ, Porsche C, Sendtner M, Kaplan DR, Miller FD (2005) Evidence that embryonic neurons regulate the onset of cortical gliogenesis via cardiotrophin-1. Neuron 48:253-265.

Barnes TD, Kubota Y, Hu D, Jin DZ, Graybiel AM (2005) Activity of striatal neurons reflects dynamic encoding and recoding of procedural memories. Nature 437:1158-1161.

Barres BA (2008) The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60:430-440.

Barria A, Malinow R (2002) Subunit-specific NMDA receptor trafficking to synapses. Neuron 35:345-353.

Bechara A, Damasio H, Damasio AR (2000) Emotion, decision making and the orbitofrontal cortex. Cereb Cortex 10:295-307.

Belin D, Belin-Rauscent A, Murray JE, Everitt BJ (2013) Addiction: failure of control over maladaptive incentive habits. Current opinion in neurobiology 23:564-572.

Belova MA, Paton JJ, Morrison SE, Salzman CD (2007) Expectation modulates neural responses to pleasant and aversive stimuli in primate amygdala. Neuron 55:970-984.

Benediktsson AM, Schachtele SJ, Green SH, Dailey ME (2005) Ballistic labeling and dynamic imaging of astrocytes in organotypic hippocampal slice cultures. Journal of neuroscience methods 141:41-53.

Benquet P, Gee CE, Gerber U (2002) Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. The Journal of neuroscience : the official journal of the Society for Neuroscience 22:9679-9686.

Bergersen LH, Gundersen V (2009) Morphological evidence for vesicular glutamate release from astrocytes. Neuroscience 158:260-265.

Bergersen LH, Morland C, Ormel L, Rinholm JE, Larsson M, Wold JF, Roe AT, Stranna A, Santello M, Bouvier D, Ottersen OP, Volterra A, Gundersen V (2012) Immunogold detection of L-glutamate and D-serine in small synaptic-like microvesicles in adult hippocampal astrocytes. Cereb Cortex 22:1690-1697.

Berglind WJ, Whitfield TW, Jr., LaLumiere RT, Kalivas PW, McGinty JF (2009) A single intra-PFC infusion of BDNF prevents cocaine-induced alterations in extracellular glutamate within the nucleus accumbens. The Journal of neuroscience : the official journal of the Society for Neuroscience 29:3715-3719.

Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biological psychiatry 64:468-475.

Bernard V, Somogyi P, Bolam JP (1997) Cellular, subcellular, and subsynaptic distribution of AMPA-type glutamate receptor subunits in the neostriatum of the rat. The Journal of neuroscience : the official journal of the Society for Neuroscience 17:819-833.

Besnard A, Bouveyron N, Kappes V, Pascoli V, Pages C, Heck N, Vanhoutte P, Caboche J (2011) Alterations of molecular and behavioral responses to cocaine by selective inhibition of Elk-1 phosphorylation. The Journal of neuroscience : the official journal of the Society for Neuroscience 31:14296-14307.

Bezzi P, Gundersen V, Galbete JL, Seifert G, Steinhauser C, Pilati E, Volterra A (2004) Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nature neuroscience 7:613-620.

Blacktop JM, Seubert C, Baker DA, Ferda N, Lee G, Graf EN, Mantsch JR (2011) Augmented cocaine seeking in response to stress or CRF delivered into the ventral tegmental area following long-access self-administration is mediated by CRF receptor type 1 but not CRF receptor type 2. The Journal of neuroscience : the official journal of the Society for Neuroscience 31:11396-11403.

Blechman J, Levkowitz G (2013) Alternative Splicing of the Pituitary Adenylate Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of Brain Activity. Frontiers in endocrinology 4:55.

Bormann J (1991) Electrophysiological characterization of diazepam binding inhibitor (DBI) on GABAA receptors. Neuropharmacology 30:1387-1389.

Bossert JM, Marchant NJ, Calu DJ, Shaham Y (2013) The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology 229:453-476.

Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, Goodman JM, Kantor HL, Gastfriend DR, Riorden JP, Mathew RT, Rosen BR, Hyman SE (1997) Acute effects of cocaine on human brain activity and emotion. Neuron 19:591-611.

Bridges CC, Kekuda R, Wang H, Prasad PD, Mehta P, Huang W, Smith SB, Ganapathy V (2001) Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells. Investigative ophthalmology & visual science 42:47-54.

Bridges R, Lutgen V, Lobner D, Baker DA (2012a) Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling. Pharmacological reviews 64:780-802.

Bridges RJ, Natale NR, Patel SA (2012b) System xc(-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. British journal of pharmacology 165:20-34.

Broer S, Wagner CA (2002) Structure-function relationships of heterodimeric amino acid transporters. Cell biochemistry and biophysics 36:155-168.

Broussard JI (2012) Co-transmission of dopamine and glutamate. The Journal of general physiology 139:93-96.

Brown AM, Ransom BR (2007) Astrocyte glycogen and brain energy metabolism. Glia 55:1263-1271.

Brown AM, Baltan Tekkok S, Ransom BR (2004) Energy transfer from astrocytes to axons: the role of CNS glycogen. Neurochemistry international 45:529-536.

Brown GC, Bal-Price A (2003) Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Molecular neurobiology 27:325-355.

Burgi B, Lichtensteiger W, Lauber ME, Schlumpf M (1999) Ontogeny of diazepam binding inhibitor/acyl-CoA binding protein mRNA and peripheral benzodiazepine receptor mRNA expression in the rat. Journal of neuroendocrinology 11:85-100.

Bushong EA, Martone ME, Jones YZ, Ellisman MH (2002) Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. The Journal of neuroscience : the official journal of the Society for Neuroscience 22:183-192.

Cahill E, Salery M, Vanhoutte P, Caboche J (2014) Convergence of dopamine and glutamate signaling onto striatal ERK activation in response to drugs of abuse. Frontiers in pharmacology 4:172.

Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, Krieg PA, Krupenko SA, Thompson WJ, Barres BA (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. The Journal of neuroscience : the official journal of the Society for Neuroscience 28:264-278.

Canavan SV, Forselius EL, Bessette AJ, Morgan PT (2014) Preliminary evidence for normalization of risk taking by modafinil in chronic cocaine users. Addictive behaviors 39:1057-1061.

Capriles N, Rodaros D, Sorge RE, Stewart J (2003) A role for the prefrontal cortex in stress- and cocaine-induced reinstatement of cocaine seeking in rats. Psychopharmacology 168:66-74.

Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends in neurosciences 13:272-276.

Caudle RM (2006) Memory in astrocytes: a hypothesis. Theoretical biology & medical modelling 3:2.

Cauvin A, Buscail L, Gourlet P, De Neef P, Gossen D, Arimura A, Miyata A, Coy DH, Robberecht P, Christophe J (1990) The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK. Peptides 11:773-777.

Chao SZ, Lu W, Lee HK, Huganir RL, Wolf ME (2002) D(1) dopamine receptor stimulation increases GluR1 phosphorylation in postnatal nucleus accumbens cultures. Journal of neurochemistry 81:984-992.

Chen BT, Yau HJ, Hatch C, Kusumoto-Yoshida I, Cho SL, Hopf FW, Bonci A (2013) Rescuing cocaine-induced prefrontal cortex hypoactivity prevents compulsive cocaine seeking. Nature 496:359-362.

Chen L, Huang LY (1992) Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 356:521-523.

Chen PE, Geballe MT, Stansfeld PJ, Johnston AR, Yuan H, Jacob AL, Snyder JP, Traynelis SF, Wyllie DJ (2005) Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-

directed mutagenesis and molecular modeling. Molecular pharmacology 67:1470-1484.

Chen Q, Veenman CL, Reiner A (1996) Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience 73:715-731.

Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP (1999) Limbic activation during cue-induced cocaine craving. The American journal of psychiatry 156:11-18.

Ching J, Amiridis S, Stylli SS, Bjorksten AR, Kountouri N, Zheng T, Paradiso L, Luwor RB, Morokoff AP, O'Brien TJ, Kaye AH (2015) The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells. Oncotarget.

Cho JH, Zushida K, Shumyatsky GP, Carlezon WA, Jr., Meloni EG, Bolshakov VY (2012) Pituitary adenylate cyclase-activating polypeptide induces postsynaptically expressed potentiation in the intra-amygdala circuit. The Journal of neuroscience : the official journal of the Society for Neuroscience 32:14165-14177.

Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.

Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher DF, Bornstein P, Barres BA (2005) Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120:421-433.

Chuhma N, Choi WY, Mingote S, Rayport S (2009) Dopamine neuron glutamate cotransmission: frequency-dependent modulation in the mesoventromedial projection. Neuroscience 164:1068-1083.

Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. The Journal of neuroscience : the official journal of the Society for Neuroscience 25:7101-7110.

Chung WS, Allen NJ, Eroglu C (2015) Astrocytes Control Synapse Formation, Function, and Elimination. Cold Spring Harbor perspectives in biology 7:a020370.

Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, Thompson A, Chen C, Smith SJ, Barres BA (2013) Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 504:394-400.

Ciranna L, Cavallaro S (2003) Opposing effects by pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide on hippocampal synaptic transmission. Experimental neurology 184:778-784.

Citri A, Malenka RC (2008) Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 33:18-41.

Clarke LE, Barres BA (2013) Emerging roles of astrocytes in neural circuit development. Nature reviews Neuroscience 14:311-321.

Compere V, Li S, Leprince J, Tonon MC, Vaudry H, Pelletier G (2004) In vivo action of a new octadecaneuropeptide (ODN) antagonist on gonadotropin-releasing hormone gene expression in the male rat brain. Neuroscience 125:411-415.

Compere V, Li S, Leprince J, Tonon MC, Vaudry H, Pelletier G (2005) In vivo action of a new octadecaneuropeptide antagonist on neuropeptide Y and corticotropin-releasing hormone mRNA levels in rat. Brain research Molecular brain research 141:156-160.

Conrad KL, Tseng KY, Uejima JL, Reimers JM, Heng LJ, Shaham Y, Marinelli M, Wolf ME (2008) Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 454:118-121.

Cornish JL, Kalivas PW (2000) Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. The Journal of neuroscience : the official journal of the Society for Neuroscience 20:RC89.

Costa L, Santangelo F, Li Volsi G, Ciranna L (2009) Modulation of AMPA receptor-mediated ion current by pituitary adenylate cyclase-activating polypeptide (PACAP) in CA1 pyramidal neurons from rat hippocampus. Hippocampus 19:99-109.

Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695.

Crippa D, Schenk U, Francolini M, Rosa P, Verderio C, Zonta M, Pozzan T, Matteoli M, Carmignoto G (2006) Synaptobrevin2-expressing vesicles in rat astrocytes: insights into molecular characterization, dynamics and exocytosis. The Journal of physiology 570:567-582.

Crombag HS, Grimm JW, Shaham Y (2002) Effect of dopamine receptor antagonists on renewal of cocaine seeking by reexposure to drug-associated contextual cues. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 27:1006-1015.

Crombag HS, Bossert JM, Koya E, Shaham Y (2008) Review. Context-induced relapse to drug seeking: a review. Philosophical transactions of the Royal Society of London Series B, Biological sciences 363:3233-3243.

Cull-Candy S, Brickley S, Farrant M (2001) NMDA receptor subunits: diversity, development and disease. Current opinion in neurobiology 11:327-335.

Cunha-Reis D, Sebastiao AM, Wirkner K, Illes P, Ribeiro JA (2004) VIP enhances both pre- and postsynaptic GABAergic transmission to hippocampal interneurones leading to increased excitatory synaptic transmission to CA1 pyramidal cells. British journal of pharmacology 143:733-744.

Curtis DR, Johnston GA (1974) Amino acid transmitters in the mammalian central nervous system. Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie 69:97-188.

D'Ascenzo M, Fellin T, Terunuma M, Revilla-Sanchez R, Meaney DF, Auberson YP, Moss SJ, Haydon PG (2007) mGluR5 stimulates gliotransmission in the nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America 104:1995-2000.

Dallerac G, Rouach N (2016) Astrocytes as new targets to improve cognitive functions. Progress in neurobiology 144:48-67.

Danbolt NC (2001) Glutamate uptake. Progress in neurobiology 65:1-105.

Darzacq X, Shav-Tal Y, de Turris V, Brody Y, Shenoy SM, Phair RD, Singer RH (2007) In vivo dynamics of RNA polymerase II transcription. Nature structural & molecular biology 14:796-806.

Daw NW, Stein PS, Fox K (1993) The role of NMDA receptors in information processing. Annual review of neuroscience 16:207-222.

De Bundel D, Schallier A, Loyens E, Fernando R, Miyashita H, Van Liefferinge J, Vermoesen K, Bannai S, Sato H, Michotte Y, Smolders I, Massie A (2011) Loss of system x(c)- does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. The Journal of neuroscience : the official journal of the Society for Neuroscience 31:5792-5803.

de Sampaio e Spohr TC, Martinez R, da Silva EF, Neto VM, Gomes FC (2002) Neuro-glia interaction effects on GFAP gene: a novel role for transforming growth factor-beta1. The European journal of neuroscience 16:2059-2069.

de Wit H, Stewart J (1981) Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology 75:134-143.

Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R (2015) Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neuroscience and biobehavioral reviews 55:294-321.

Dejda A, Bourgault S, Doan ND, Letourneau M, Couvineau A, Vaudry H, Vaudry D, Fournier A (2011) Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP. Biochimie 93:669-677.

Delgado JY, Coba M, Anderson CN, Thompson KR, Gray EE, Heusner CL, Martin KC, Grant SG, O'Dell TJ (2007) NMDA receptor activation dephosphorylates AMPA receptor glutamate receptor 1 subunits at threonine 840. The Journal of neuroscience : the official journal of the Society for Neuroscience 27:13210-13221.

Delghandi MP, Johannessen M, Moens U (2005) The cAMP signalling pathway activates CREB through PKA, p38 and MSK1 in NIH 3T3 cells. Cellular signalling 17:1343-1351.

Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. The American journal of physiology 257:L163-173.

Derkach V, Barria A, Soderling TR (1999) Ca2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America 96:3269-3274.

Di Ciano P, Everitt BJ (2001) Dissociable effects of antagonism of NMDA and AMPA/KA receptors in the nucleus accumbens core and shell on cocaine-seeking behavior. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 25:341-360.

Dicke U, Roth G (2016) Neuronal factors determining high intelligence. Philosophical transactions of the Royal Society of London Series B, Biological sciences 371:20150180.

Dickson L, Finlayson K (2009) VPAC and PAC receptors: From ligands to function. Pharmacology & therapeutics 121:294-316.

Ding DC, Gabbott PL, Totterdell S (2001) Differences in the laminar origin of projections from the medial prefrontal cortex to the nucleus accumbens shell and core regions in the rat. Brain research 917:81-89.

Dingledine R, Borges K, Bowie D, Traynelis SF (1999) The glutamate receptor ion channels. Pharmacological reviews 51:7-61.

Douyard J, Shen L, Huganir RL, Rubio ME (2007) Differential neuronal and glial expression of GluR1 AMPA receptor subunit and the scaffolding proteins SAP97

and 4.1N during rat cerebellar development. The Journal of comparative neurology 502:141-156.

Doya K (2008) Modulators of decision making. Nature neuroscience 11:410-416.

Dringen R, Gebhardt R, Hamprecht B (1993) Glycogen in astrocytes: possible function as lactate supply for neighboring cells. Brain research 623:208-214.

Duan S, Anderson CM, Stein BA, Swanson RA (1999) Glutamate induces rapid upregulation of astrocyte glutamate transport and cell-surface expression of GLAST. The Journal of neuroscience : the official journal of the Society for Neuroscience 19:10193-10200.

Dugan LL, Bruno VM, Amagasu SM, Giffard RG (1995) Glia modulate the response of murine cortical neurons to excitotoxicity: glia exacerbate AMPA neurotoxicity. The Journal of neuroscience : the official journal of the Society for Neuroscience 15:4545-4555.

Dun Y, Mysona B, Van Ells T, Amarnath L, Ola MS, Ganapathy V, Smith SB (2006) Expression of the cystine-glutamate exchanger (xc-) in retinal ganglion cells and regulation by nitric oxide and oxidative stress. Cell and tissue research 324:189-202.

Dunah AW, Standaert DG (2003) Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. Journal of neurochemistry 85:935-943.

Dundr M, Hoffmann-Rohrer U, Hu Q, Grummt I, Rothblum LI, Phair RD, Misteli T (2002) A kinetic framework for a mammalian RNA polymerase in vivo. Science 298:1623-1626.

Edmonds B, Gibb AJ, Colquhoun D (1995) Mechanisms of activation of glutamate receptors and the time course of excitatory synaptic currents. Annual review of physiology 57:495-519.

Edwards S, Graham DL, Bachtell RK, Self DW (2007) Region-specific tolerance to cocaine-regulated cAMP-dependent protein phosphorylation following chronic self-administration. The European journal of neuroscience 25:2201-2213.

Eichenbaum H (2000) A cortical-hippocampal system for declarative memory. Nature reviews Neuroscience 1:41-50.

Eichenbaum H (2004) Hippocampus: cognitive processes and neural representations that underlie declarative memory. Neuron 44:109-120.

Engelund A, Fahrenkrug J, Harrison A, Hannibal J (2010) Vesicular glutamate transporter 2 (VGLUT2) is co-stored with PACAP in projections from the rat

melanopsin-containing retinal ganglion cells. Cell and tissue research 340:243-255.

Esteban JA, Shi SH, Wilson C, Nuriya M, Huganir RL, Malinow R (2003) PKA phosphorylation of AMPA receptor subunits controls synaptic trafficking underlying plasticity. Nature neuroscience 6:136-143.

Euston DR, Gruber AJ, McNaughton BL (2012) The role of medial prefrontal cortex in memory and decision making. Neuron 76:1057-1070.

Famous KR, Schmidt HD, Pierce RC (2007) When administered into the nucleus accumbens core or shell, the NMDA receptor antagonist AP-5 reinstates cocaine-seeking behavior in the rat. Neuroscience letters 420:169-173.

Farmer WT, Abrahamsson T, Chierzi S, Lui C, Zaelzer C, Jones EV, Bally BP, Chen GG, Theroux JF, Peng J, Bourque CW, Charron F, Ernst C, Sjostrom PJ, Murai KK (2016) Neurons diversify astrocytes in the adult brain through sonic hedgehog signaling. Science 351:849-854.

Fellin T, Pascual O, Haydon PG (2006a) Astrocytes coordinate synaptic networks: balanced excitation and inhibition. Physiology (Bethesda) 21:208-215.

Fellin T, Pozzan T, Carmignoto G (2006b) Purinergic receptors mediate two distinct glutamate release pathways in hippocampal astrocytes. The Journal of biological chemistry 281:4274-4284.

Fellin T, Pascual O, Gobbo S, Pozzan T, Haydon PG, Carmignoto G (2004) Neuronal synchrony mediated by astrocytic glutamate through activation of extrasynaptic NMDA receptors. Neuron 43:729-743.

Ferre S, Hoenderop JG, Bindels RJ (2011) Insight into renal Mg2+ transporters. Current opinion in nephrology and hypertension 20:169-176.

Fiacco TA, Agulhon C, Taves SR, Petravicz J, Casper KB, Dong X, Chen J, McCarthy KD (2007) Selective stimulation of astrocyte calcium in situ does not affect neuronal excitatory synaptic activity. Neuron 54:611-626.

Figiel M, Engele J (2000) Pituitary adenylate cyclase-activating polypeptide (PACAP), a neuron-derived peptide regulating glial glutamate transport and metabolism. The Journal of neuroscience : the official journal of the Society for Neuroscience 20:3596-3605.

Fischer-Smith KD, Houston AC, Rebec GV (2012) Differential effects of cocaine access and withdrawal on glutamate type 1 transporter expression in rat nucleus accumbens core and shell. Neuroscience 210:333-339.

Fischer KD, Houston AC, Rebec GV (2013) Role of the major glutamate transporter GLT1 in nucleus accumbens core versus shell in cue-induced cocaine-seeking

behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience 33:9319-9327.

Foster AC, Kemp JA (2006) Glutamate- and GABA-based CNS therapeutics. Current opinion in pharmacology 6:7-17.

Franks KM, Bartol TM, Jr., Sejnowski TJ (2002) A Monte Carlo model reveals independent signaling at central glutamatergic synapses. Biophysical journal 83:2333-2348.

Franks KM, Stevens CF, Sejnowski TJ (2003) Independent sources of quantal variability at single glutamatergic synapses. The Journal of neuroscience : the official journal of the Society for Neuroscience 23:3186-3195.

Fraser DD, Mudrick-Donnon LA, MacVicar BA (1994) Astrocytic GABA receptors. Glia 11:83-93.

Fraser DD, Duffy S, Angelides KJ, Perez-Velazquez JL, Kettenmann H, MacVicar BA (1995) GABAA/benzodiazepine receptors in acutely isolated hippocampal astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 15:2720-2732.

Fukuhara C, Suzuki N, Matsumoto Y, Nakayama Y, Aoki K, Tsujimoto G, Inouye SI, Masuo Y (1997) Day-night variation of pituitary adenylate cyclase-activating polypeptide (PACAP) level in the rat suprachiasmatic nucleus. Neuroscience letters 229:49-52.

Garcia-Caceres C et al. (2016) Astrocytic Insulin Signaling Couples Brain Glucose Uptake with Nutrient Availability. Cell 166:867-880.

Gardoni F, Saraceno C, Malinverno M, Marcello E, Verpelli C, Sala C, Di Luca M (2012) The neuropeptide PACAP38 induces dendritic spine remodeling through ADAM10-N-cadherin signaling pathway. Journal of cell science 125:1401-1406.

Gegelashvili G, Schousboe A (1998) Cellular distribution and kinetic properties of high-affinity glutamate transporters. Brain research bulletin 45:233-238.

Gegelashvili G, Danbolt NC, Schousboe A (1997) Neuronal soluble factors differentially regulate the expression of the GLT1 and GLAST glutamate transporters in cultured astroglia. Journal of neurochemistry 69:2612-2615.

Gerber GJ, Stretch R (1975) Drug-induced reinstatement of extinguished self-administration behavior in monkeys. Pharmacology, biochemistry, and behavior 3:1055-1061.

Gerfen CR, Surmeier DJ (2011) Modulation of striatal projection systems by dopamine. Annual review of neuroscience 34:441-466.

Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM, Bloom SR (1993) Distribution, molecular characterization of pituitary adenylate cyclase-activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. The Journal of endocrinology 136:159-166.

Ghosh A, Cheung YY, Mansfield BC, Chou JY (2005) Brain contains a functional glucose-6-phosphatase complex capable of endogenous glucose production. The Journal of biological chemistry 280:11114-11119.

Gibbs RA et al. (2004) Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 428:493-521.

Gladding CM, Raymond LA (2011) Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Molecular and cellular neurosciences 48:308-320.

Gochenauer GE, Robinson MB (2001) Dibutyryl-cAMP (dbcAMP) up-regulates astrocytic chloride-dependent L-[3H]glutamate transport and expression of both system xc(-) subunits. Journal of neurochemistry 78:276-286.

Goldstein RZ, Volkow ND (2011) Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nature reviews Neuroscience 12:652-669.

Golombek DA, Rosenstein RE (2010) Physiology of circadian entrainment. Physiological reviews 90:1063-1102.

Gomes FC, Garcia-Abreu J, Galou M, Paulin D, Moura Neto V (1999) Neurons induce GFAP gene promoter of cultured astrocytes from transgenic mice. Glia 26:97-108.

Gomez-Gonzalo M, Navarrete M, Perea G, Covelo A, Martin-Fernandez M, Shigemoto R, Lujan R, Araque A (2015) Endocannabinoids Induce Lateral Long-Term Potentiation of Transmitter Release by Stimulation of Gliotransmission. Cereb Cortex 25:3699-3712.

Gottschall PE, Tatsuno I, Arimura A (1991) Hypothalamic binding sites for pituitary adenylate cyclase activating polypeptide: characterization and molecular identification. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 5:194-199.

Gottschall PE, Tatsuno I, Miyata A, Arimura A (1990) Characterization and distribution of binding sites for the hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide. Endocrinology 127:272-277.

Gourlet P, Vandermeers A, Vandermeers-Piret MC, Rathe J, De Neef P, Robberecht P (1995) Fragments of pituitary adenylate cyclase activating polypeptide discriminate between type I and II recombinant receptors. European journal of pharmacology 287:7-11.

Goursaud S, Maloteaux JM, Hermans E (2008) Activation of VIP/PACAP type 2 receptor by the peptide histidine isoleucine in astrocytes influences GLAST-mediated glutamate uptake. Journal of neurochemistry 105:1165-1175.

Govindaiah G, Wang Y, Cox CL (2010) Substance P selectively modulates GABA(A) receptor-mediated synaptic transmission in striatal cholinergic interneurons. Neuropharmacology 58:413-422.

Graf EN, Wheeler RA, Baker DA, Ebben AL, Hill JE, McReynolds JR, Robble MA, Vranjkovic O, Wheeler DS, Mantsch JR, Gasser PJ (2013) Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking. The Journal of neuroscience : the official journal of the Society for Neuroscience 33:11800-11810.

Grant S, London ED, Newlin DB, Villemagne VL, Liu X, Contoreggi C, Phillips RL, Kimes AS, Margolin A (1996) Activation of memory circuits during cue-elicited cocaine craving. Proceedings of the National Academy of Sciences of the United States of America 93:12040-12045.

Gray EE, Guglietta R, Khakh BS, O'Dell TJ (2014) Inhibitory interactions between phosphorylation sites in the C terminus of alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-type glutamate receptor GluA1 subunits. The Journal of biological chemistry 289:14600-14611.

Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB (1988) Glutamate transmission and toxicity in Alzheimer's disease. Progress in neuro-psychopharmacology & biological psychiatry 12:421-430.

Grimaldi M, Cavallaro S (1999) Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes. The European journal of neuroscience 11:2767-2772.

Groc L, Choquet D (2006) AMPA and NMDA glutamate receptor trafficking: multiple roads for reaching and leaving the synapse. Cell and tissue research 326:423-438.

Groenewegen HJ, Wright CI, Beijer AV (1996) The nucleus accumbens: gateway for limbic structures to reach the motor system? Progress in brain research 107:485-511.

Grosche J, Matyash V, Moller T, Verkhratsky A, Reichenbach A, Kettenmann H (1999) Microdomains for neuron-glia interaction: parallel fiber signaling to Bergmann glial cells. Nature neuroscience 2:139-143.

Grueter BA, Winder DG (2005) Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 30:1302-1311.

Guidotti A, Corda MG, Costa E (1983) Strategies for the isolation and characterization of an endogenous effector of the benzodiazepine recognition sites. Advances in biochemical psychopharmacology 38:95-103.

Haak LL, Heller HC, van den Pol AN (1997) Metabotropic glutamate receptor activation modulates kainate and serotonin calcium response in astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 17:1825-1837.

Hahn J, Wang X, Margeta M (2015) Astrocytes increase the activity of synaptic GluN2B NMDA receptors. Frontiers in cellular neuroscience 9:117.

Halassa MM, Fellin T, Takano H, Dong JH, Haydon PG (2007) Synaptic islands defined by the territory of a single astrocyte. The Journal of neuroscience : the official journal of the Society for Neuroscience 27:6473-6477.

Hamilton NB, Attwell D (2010) Do astrocytes really exocytose neurotransmitters? Nature reviews Neuroscience 11:227-238.

Hannibal J (2002a) Neurotransmitters of the retino-hypothalamic tract. Cell and tissue research 309:73-88.

Hannibal J (2002b) Pituitary adenylate cyclase-activating peptide in the rat central nervous system: an immunohistochemical and in situ hybridization study. The Journal of comparative neurology 453:389-417.

Hannibal J, Moller M, Ottersen OP, Fahrenkrug J (2000) PACAP and glutamate are co-stored in the retinohypothalamic tract. The Journal of comparative neurology 418:147-155.

Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nature neuroscience 5:405-414.

Harmar AJ (2001) Family-B G-protein-coupled receptors. Genome biology 2:REVIEWS3013.

Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacological reviews 50:265-270.

Harrington ME, Hoque S, Hall A, Golombek D, Biello S (1999) Pituitary adenylate cyclase activating peptide phase shifts circadian rhythms in a manner similar to light. The Journal of neuroscience : the official journal of the Society for Neuroscience 19:6637-6642.

Harris KM, Kater SB (1994) Dendritic spines: cellular specializations imparting both stability and flexibility to synaptic function. Annual review of neuroscience 17:341-371.

Hashimoto H, Kunugi A, Arakawa N, Shintani N, Fujita T, Kasai A, Kawaguchi C, Morita Y, Hirose M, Sakai Y, Baba A (2003) Possible involvement of a cyclic AMP-dependent mechanism in PACAP-induced proliferation and ERK activation in astrocytes. Biochemical and biophysical research communications 311:337-343.

Haugeto O, Ullensvang K, Levy LM, Chaudhry FA, Honore T, Nielsen M, Lehre KP, Danbolt NC (1996) Brain glutamate transporter proteins form homomultimers. The Journal of biological chemistry 271:27715-27722.

Hawke Z, Ivanov TR, Bechtold DA, Dhillon H, Lowell BB, Luckman SM (2009) PACAP neurons in the hypothalamic ventromedial nucleus are targets of central leptin signaling. The Journal of neuroscience : the official journal of the Society for Neuroscience 29:14828-14835.

Haydon PG (2001) GLIA: listening and talking to the synapse. Nature reviews Neuroscience 2:185-193.

Haydon PG, Carmignoto G (2006) Astrocyte control of synaptic transmission and neurovascular coupling. Physiological reviews 86:1009-1031.

He Y, Jackman NA, Thorn TL, Vought VE, Hewett SJ (2015) Interleukin-1beta protects astrocytes against oxidant-induced injury via an NF-kappaB-Dependent upregulation of glutathione synthesis. Glia 63:1568-1580.

Herculano-Houzel S (2009) The human brain in numbers: a linearly scaled-up primate brain. Frontiers in human neuroscience 3:31.

Herman MA, Jahr CE (2007) Extracellular glutamate concentration in hippocampal slice. The Journal of neuroscience : the official journal of the Society for Neuroscience 27:9736-9741.

Herrera-Marschitz M, You ZB, Goiny M, Meana JJ, Silveira R, Godukhin OV, Chen Y, Espinoza S, Pettersson E, Loidl CF, Lubec G, Andersson K, Nylander I, Terenius L, Ungerstedt U (1996) On the origin of extracellular glutamate levels monitored in the basal ganglia of the rat by in vivo microdialysis. Journal of neurochemistry 66:1726-1735.

Herron CE, Lester RA, Coan EJ, Collingridge GL (1986) Frequency-dependent involvement of NMDA receptors in the hippocampus: a novel synaptic mechanism. Nature 322:265-268.

Hires SA, Zhu Y, Tsien RY (2008) Optical measurement of synaptic glutamate spillover and reuptake by linker optimized glutamate-sensitive fluorescent

reporters. Proceedings of the National Academy of Sciences of the United States of America 105:4411-4416.

Hnasko TS, Edwards RH (2012) Neurotransmitter corelease: mechanism and physiological role. Annual review of physiology 74:225-243.

Holmseth S, Dehnes Y, Huang YH, Follin-Arbelet VV, Grutle NJ, Mylonakou MN, Plachez C, Zhou Y, Furness DN, Bergles DE, Lehre KP, Danbolt NC (2012) The density of EAAC1 (EAAT3) glutamate transporters expressed by neurons in the mammalian CNS. The Journal of neuroscience : the official journal of the Society for Neuroscience 32:6000-6013.

Hu E, Demmou L, Cauli B, Gallopin T, Geoffroy H, Harris-Warrick RM, Paupardin-Tritsch D, Lambolez B, Vincent P, Hepp R (2011) VIP, CRF, and PACAP act at distinct receptors to elicit different cAMP/PKA dynamics in the neocortex. Cereb Cortex 21:708-718.

Hu WH, Walters WM, Xia XM, Karmally SA, Bethea JR (2003) Neuronal glutamate transporter EAAT4 is expressed in astrocytes. Glia 44:13-25.

Huang Z, Gibb AJ (2014) Mg2+ block properties of triheteromeric GluN1-GluN2B-GluN2D NMDA receptors on neonatal rat substantia nigra pars compacta dopaminergic neurones. The Journal of physiology 592:2059-2078.

Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward-related learning and memory. Annual review of neuroscience 29:565-598.

Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochemistry international 45:583-595.

Ikeda T, Iijima N, Munekawa K, Ishihara A, Ibata Y, Tanaka M (2003) Functional retinal input stimulates expression of astroglial elements in the suprachiasmatic nucleus of postnatal developing rat. Neuroscience research 47:39-45.

Ito R, Dalley JW, Robbins TW, Everitt BJ (2002) Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. The Journal of neuroscience : the official journal of the Society for Neuroscience 22:6247-6253.

Ito R, Dalley JW, Howes SR, Robbins TW, Everitt BJ (2000) Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. The Journal of neuroscience : the official journal of the Society for Neuroscience 20:7489-7495.

Itoh K, Tong KI, Yamamoto M (2004) Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free radical biology & medicine 36:1208-1213.

Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochemical and biophysical research communications 236:313-322.

Ivanov A, Pellegrino C, Rama S, Dumalska I, Salyha Y, Ben-Ari Y, Medina I (2006) Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. The Journal of physiology 572:789-798.

Ivics Z, Mates L, Yau TY, Landa V, Zidek V, Bashir S, Hoffmann OI, Hiripi L, Garrels W, Kues WA, Bosze Z, Geurts A, Pravenec M, Rulicke T, Izsvak Z (2014) Germline transgenesis in rodents by pronuclear microinjection of Sleeping Beauty transposons. Nature protocols 9:773-793.

Izumi Y, Tokuda K, Zorumski CF (2008) Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus 18:258-265.

Jabaudon D, Shimamoto K, Yasuda-Kamatani Y, Scanziani M, Gahwiler BH, Gerber U (1999) Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proceedings of the National Academy of Sciences of the United States of America 96:8733-8738.

Jaffe JH, Cascella NG, Kumor KM, Sherer MA (1989) Cocaine-induced cocaine craving. Psychopharmacology 97:59-64.

Jarjour S, Bai L, Gianoulakis C (2009) Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. Alcoholism, clinical and experimental research 33:1033-1043.

Javitt DC, Schoepp D, Kalivas PW, Volkow ND, Zarate C, Merchant K, Bear MF, Umbricht D, Hajos M, Potter WZ, Lee CM (2011) Translating glutamate: from pathophysiology to treatment. Science translational medicine 3:102mr102.

Jaworski DM (2000) Expression of pituitary adenylate cyclase-activating polypeptide (PACAP) and the PACAP-selective receptor in cultured rat astrocytes, human brain tumors, and in response to acute intracranial injury. Cell and tissue research 300:219-230.

Jenkins MA, Wells G, Bachman J, Snyder JP, Jenkins A, Huganir RL, Oswald RE, Traynelis SF (2014) Regulation of GluA1 alpha-amino-3-hydroxy-5-methyl-4-

isoxazolepropionic acid receptor function by protein kinase C at serine-818 and threonine-840. Molecular pharmacology 85:618-629.

Jensen AA, Fahlke C, Bjorn-Yoshimoto WE, Bunch L (2015) Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities. Current opinion in pharmacology 20:116-123.

Jentsch JD, Taylor JR (1999) Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology 146:373-390.

Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH, Cha CI (2004) Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. The Journal of comparative neurology 476:388-413.

Kalivas PW (2009) The glutamate homeostasis hypothesis of addiction. Nature reviews Neuroscience 10:561-572.

Kalivas PW, McFarland K (2003) Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology 168:44-56.

Kalivas PW, Volkow ND (2005) The neural basis of addiction: a pathology of motivation and choice. The American journal of psychiatry 162:1403-1413.

Kalivas PW, O'Brien C (2008) Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 33:166-180.

Kammermeier PJ (2008) Endogenous homer proteins regulate metabotropic glutamate receptor signaling in neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 28:8560-8567.

Kapitein LC, Schlager MA, Kuijpers M, Wulf PS, van Spronsen M, MacKintosh FC, Hoogenraad CC (2010) Mixed microtubules steer dynein-driven cargo transport into dendrites. Current biology : CB 20:290-299.

Katagiri H, Tanaka K, Manabe T (2001) Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction. The European journal of neuroscience 14:547-553.

Kato S, Negishi K, Mawatari K, Kuo CH (1992) A mechanism for glutamate toxicity in the C6 glioma cells involving inhibition of cystine uptake leading to glutathione depletion. Neuroscience 48:903-914.

Katter K et al. (2013) Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbits. FASEB journal : official

publication of the Federation of American Societies for Experimental Biology 27:930-941.

Kau KS, Madayag A, Mantsch JR, Grier MD, Abdulhameed O, Baker DA (2008) Blunted cystine-glutamate antiporter function in the nucleus accumbens promotes cocaine-induced drug seeking. Neuroscience 155:530-537.

Kauer JA, Malenka RC (2007) Synaptic plasticity and addiction. Nature reviews Neuroscience 8:844-858.

Kelley AE (2004) Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 44:161-179.

Kennedy MJ, Ehlers MD (2006) Organelles and trafficking machinery for postsynaptic plasticity. Annual review of neuroscience 29:325-362.

Kim JY, Kanai Y, Chairoungdua A, Cha SH, Matsuo H, Kim DK, Inatomi J, Sawa H, Ida Y, Endou H (2001) Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochimica et biophysica acta 1512:335-344.

Kivipelto L, Absood A, Arimura A, Sundler F, Hakanson R, Panula P (1992) The distribution of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity is distinct from helodermin- and helospectin-like immunoreactivities in the rat brain. Journal of chemical neuroanatomy 5:85-94.

Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241:835-837.

Knackstedt LA, Melendez RI, Kalivas PW (2010) Ceftriaxone restores glutamate homeostasis and prevents relapse to cocaine seeking. Biological psychiatry 67:81-84.

Knackstedt LA, LaRowe S, Mardikian P, Malcolm R, Upadhyaya H, Hedden S, Markou A, Kalivas PW (2009) The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biological psychiatry 65:841-845.

Kondo T, Tominaga T, Ichikawa M, Iijima T (1997) Differential alteration of hippocampal synaptic strength induced by pituitary adenylate cyclase activating polypeptide-38 (PACAP-38). Neuroscience letters 221:189-192.

Kong L, Albano R, Madayag A, Raddatz N, Mantsch JR, Choi S, Lobner D, Baker DA (2016) Pituitary Adenylate cyclase-activating polypeptide orchestrates neuronal regulation of the astrocytic glutamate-releasing mechanism system xc (.). Journal of neurochemistry 137:384-393.

Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 35:217-238.

Kopp MD, Meissl H, Dehghani F, Korf HW (2001) The pituitary adenylate cyclase-activating polypeptide modulates glutamatergic calcium signalling: investigations on rat suprachiasmatic nucleus neurons. Journal of neurochemistry 79:161-171.

Koves K, Arimura A, Gorcs TG, Somogyvari-Vigh A (1991) Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. Neuroendocrinology 54:159-169.

Koves K, Gorcs TJ, Kausz M, Arimura A (1994) Present status of knowledge about the distribution and colocalization of PACAP in the forebrain. Acta biologica Hungarica 45:297-321.

Kravitz AV, Kreitzer AC (2012) Striatal mechanisms underlying movement, reinforcement, and punishment. Physiology (Bethesda) 27:167-177.

Kravitz AV, Tye LD, Kreitzer AC (2012) Distinct roles for direct and indirect pathway striatal neurons in reinforcement. Nature neuroscience 15:816-818.

Kucukdereli H, Allen NJ, Lee AT, Feng A, Ozlu MI, Conatser LM, Chakraborty C, Workman G, Weaver M, Sage EH, Barres BA, Eroglu C (2011) Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARC. Proceedings of the National Academy of Sciences of the United States of America 108:E440-449.

Kupchik YM, Moussawi K, Tang XC, Wang X, Kalivas BC, Kolokithas R, Ogburn KB, Kalivas PW (2012) The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine. Biological psychiatry 71:978-986.

Laburthe M, Couvineau A, Tan V (2007) Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28:1631-1639.

Lalo U, Pankratov Y, Kirchhoff F, North RA, Verkhratsky A (2006) NMDA receptors mediate neuron-to-glia signaling in mouse cortical astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 26:2673-2683.

Lam HC, Takahashi K, Ghatei MA, Kanse SM, Polak JM, Bloom SR (1990) Binding sites of a novel neuropeptide pituitary-adenylate-cyclase-activating polypeptide in the rat brain and lung. European journal of biochemistry / FEBS 193:725-729.

Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB, Jr., Young AB (1995) NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. The Journal of neuroscience : the official journal of the Society for Neuroscience 15:5297-5307.

Larkum ME, Nevian T (2008) Synaptic clustering by dendritic signalling mechanisms. Current opinion in neurobiology 18:321-331.

LaRowe SD, Myrick H, Hedden S, Mardikian P, Saladin M, McRae A, Brady K, Kalivas PW, Malcolm R (2007) Is cocaine desire reduced by N-acetylcysteine? The American journal of psychiatry 164:1115-1117.

Lazarovici P, Jiang H, Fink D, Jr. (1998) The 38-amino-acid form of pituitary adenylate cyclase-activating polypeptide induces neurite outgrowth in PC12 cells that is dependent on protein kinase C and extracellular signal-regulated kinase but not on protein kinase A, nerve growth factor receptor tyrosine kinase, p21(ras) G protein, and pp60(c-src) cytoplasmic tyrosine kinase. Molecular pharmacology 54:547-558.

Le Meur K, Galante M, Angulo MC, Audinat E (2007) Tonic activation of NMDA receptors by ambient glutamate of non-synaptic origin in the rat hippocampus. The Journal of physiology 580:373-383.

Lee HK, Takamiya K, Kameyama K, He K, Yu S, Rossetti L, Wilen D, Huganir RL (2007) Identification and characterization of a novel phosphorylation site on the GluR1 subunit of AMPA receptors. Molecular and cellular neurosciences 36:86-94.

Lee HS, Ghetti A, Pinto-Duarte A, Wang X, Dziewczapolski G, Galimi F, Huitron-Resendiz S, Pina-Crespo JC, Roberts AJ, Verma IM, Sejnowski TJ, Heinemann SF (2014) Astrocytes contribute to gamma oscillations and recognition memory. Proceedings of the National Academy of Sciences of the United States of America 111:E3343-3352.

Lee JL, Milton AL, Everitt BJ (2006) Cue-induced cocaine seeking and relapse are reduced by disruption of drug memory reconsolidation. The Journal of neuroscience : the official journal of the Society for Neuroscience 26:5881-5887.

Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC (1995) Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. The Journal of neuroscience : the official journal of the Society for Neuroscience 15:1835-1853.

Leveille F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A (2008) Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 22:4258-4271.

Lewerenz J, Maher P (2009) Basal levels of eIF2alpha phosphorylation determine cellular antioxidant status by regulating ATF4 and xCT expression. The Journal of biological chemistry 284:1106-1115.

Lewerenz J, Maher P, Methner A (2012a) Regulation of xCT expression and system x (c) (-) function in neuronal cells. Amino acids 42:171-179.

Lewerenz J, Sato H, Albrecht P, Henke N, Noack R, Methner A, Maher P (2012b) Mutation of ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression. Cell death and differentiation 19:847-858.

Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V, Maher P (2013) The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxidants & redox signaling 18:522-555.

Lewerenz J, Baxter P, Kassubek R, Albrecht P, Van Liefferinge J, Westhoff MA, Halatsch ME, Karpel-Massler G, Meakin PJ, Hayes JD, Aronica E, Smolders I, Ludolph AC, Methner A, Conrad M, Massie A, Hardingham GE, Maher P (2014) Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2alpha and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy. Antioxidants & redox signaling 20:2907-2922.

Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. The Journal of neuroscience : the official journal of the Society for Neuroscience 31:6627-6638.

Li Y, Tan Z, Li Z, Sun Z, Duan S, Li W (2012) Impaired long-term potentiation and long-term memory deficits in xCT-deficient sut mice. Bioscience reports 32:315-321.

Lin Y, Hall RA, Kuhar MJ (2011) CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist. Neuropeptides 45:351-358.

Liu DD, Yang Q, Li ST (2013) Activation of extrasynaptic NMDA receptors induces LTD in rat hippocampal CA1 neurons. Brain research bulletin 93:10-16.

Liu GJ, Madsen BW (1997) PACAP38 modulates activity of NMDA receptors in cultured chick cortical neurons. Journal of neurophysiology 78:2231-2234.

Liu X, Albano R, Lobner D (2014a) FGF-2 induces neuronal death through upregulation of system xc. Brain research 1547:25-33.

Liu X, Rush T, Zapata J, Lobner D (2009) beta-N-methylamino-l-alanine induces oxidative stress and glutamate release through action on system Xc(-). Experimental neurology 217:429-433.

Liu X, Resch J, Rush T, Lobner D (2012) Functional upregulation of system xc- by fibroblast growth factor-2. Neuropharmacology 62:901-906.

Liu X, Liu Y, Zhong P, Wilkinson B, Qi J, Olsen CM, Bayer KU, Liu QS (2014b) CaMKII activity in the ventral tegmental area gates cocaine-induced synaptic plasticity in the nucleus accumbens. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 39:989-999.

Liu X, Chen Y, Tong J, Reynolds AM, Proudfoot SC, Qi J, Penzes P, Lu Y, Liu QS (2016) Epac Signaling Is Required for Cocaine-Induced Change in AMPA Receptor Subunit Composition in the Ventral Tegmental Area. The Journal of neuroscience : the official journal of the Society for Neuroscience 36:4802-4815.

Liu Y, Zhang J (2000) Recent development in NMDA receptors. Chinese medical journal 113:948-956.

Lobner D (2000) Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis? Journal of neuroscience methods 96:147-152.

Lochner A, Moolman JA (2006) The many faces of H89: a review. Cardiovascular drug reviews 24:261-274.

Logan WJ, Snyder SH (1971) Unique high affinity uptake systems for glycine, glutamic and aspartic acids in central nervous tissue of the rat. Nature 234:297-299.

Losonczy A, Somogyi P, Nusser Z (2003) Reduction of excitatory postsynaptic responses by persistently active metabotropic glutamate receptors in the hippocampus. Journal of neurophysiology 89:1910-1919.

Lu XY, Ghasemzadeh MB, Kalivas PW (1998) Expression of D1 receptor, D2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the nucleus accumbens. Neuroscience 82:767-780.

Luscher C, Malenka RC (2012) NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD). Cold Spring Harbor perspectives in biology 4.

Lutgen V, Qualmann K, Resch J, Kong L, Choi S, Baker DA (2013) Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc(-) activity in the medial prefrontal cortex. Psychopharmacology 226:531-540.

Lynch MA (2004) Long-term potentiation and memory. Physiological reviews 84:87-136.

Lynch WJ, Nicholson KL, Dance ME, Morgan RW, Foley PL (2010) Animal models of substance abuse and addiction: implications for science, animal welfare, and society. Comparative medicine 60:177-188.

Macdonald DS, Weerapura M, Beazely MA, Martin L, Czerwinski W, Roder JC, Orser BA, MacDonald JF (2005) Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. The Journal of neuroscience : the official journal of the Society for Neuroscience 25:11374-11384.

Macpherson T, Morita M, Hikida T (2014) Striatal direct and indirect pathways control decision-making behavior. Frontiers in psychology 5:1301.

Madayag A, Kau KS, Lobner D, Mantsch JR, Wisniewski S, Baker DA (2010) Drug-induced plasticity contributing to heightened relapse susceptibility: neurochemical changes and augmented reinstatement in high-intake rats. The Journal of neuroscience : the official journal of the Society for Neuroscience 30:210-217.

Madayag A, Lobner D, Kau KS, Mantsch JR, Abdulhameed O, Hearing M, Grier MD, Baker DA (2007) Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine. The Journal of neuroscience : the official journal of the Society for Neuroscience 27:13968-13976.

Magistretti PJ, Cardinaux JR, Martin JL (1998) VIP and PACAP in the CNS: regulators of glial energy metabolism and modulators of glutamatergic signaling. Annals of the New York Academy of Sciences 865:213-225.

Malarkey EB, Parpura V (2008) Mechanisms of glutamate release from astrocytes. Neurochemistry international 52:142-154.

Malenka RC, Nicoll RA (1993) NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms. Trends in neurosciences 16:521-527.

Malinow R, Malenka RC (2002) AMPA receptor trafficking and synaptic plasticity. Annual review of neuroscience 25:103-126.

Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM (1994) On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Experimental neurology 125:65-71.

Mangiavacchi S, Wolf ME (2004) D1 dopamine receptor stimulation increases the rate of AMPA receptor insertion onto the surface of cultured nucleus accumbens neurons through a pathway dependent on protein kinase A. Journal of neurochemistry 88:1261-1271.

Mantsch JR, Baker DA, Funk D, Le AD, Shaham Y (2016) Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 41:335-356.

Manzoni O, Michel JM, Bockaert J (1997) Metabotropic glutamate receptors in the rat nucleus accumbens. The European journal of neuroscience 9:1514-1523.

Mao LM, Guo ML, Jin DZ, Fibuch EE, Choe ES, Wang JQ (2011) Post-translational modification biology of glutamate receptors and drug addiction. Frontiers in neuroanatomy 5:19.

Maragakis NJ, Rothstein JD (2004) Glutamate transporters: animal models to neurologic disease. Neurobiology of disease 15:461-473.

Marino MJ, Wittmann M, Bradley SR, Hubert GW, Smith Y, Conn PJ (2001) Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata. The Journal of neuroscience : the official journal of the Society for Neuroscience 21:7001-7012.

Marley PD, Emson PC, Hunt SP, Fahrenkrug J (1981) A long ascending projection in the rat brain containing vasoactive intestinal polypeptide. Neuroscience letters 27:261-266.

Martin LJ, Blackstone CD, Huganir RL, Price DL (1993) The striatal mosaic in primates: striosomes and matrix are differentially enriched in ionotropic glutamate receptor subunits. The Journal of neuroscience : the official journal of the Society for Neuroscience 13:782-792.

Martin R, Bajo-Graneras R, Moratalla R, Perea G, Araque A (2015) Circuit-specific signaling in astrocyte-neuron networks in basal ganglia pathways. Science 349:730-734.

Masmoudi-Kouki O, Gandolfo P, Leprince J, Vaudry D, Pelletier G, Fournier A, Vaudry H, Tonon MC (2006) PACAP stimulates biosynthesis and release of endozepines from rat astrocytes. Annals of the New York Academy of Sciences 1070:411-416.

Masmoudi-Kouki O, Gandolfo P, Castel H, Leprince J, Fournier A, Dejda A, Vaudry H, Tonon MC (2007) Role of PACAP and VIP in astroglial functions. Peptides 28:1753-1760.

Masmoudi O, Gandolfo P, Leprince J, Vaudry D, Fournier A, Patte-Mensah C, Vaudry H, Tonon MC (2003) Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates endozepine release from cultured rat astrocytes via a PKA-dependent mechanism. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 17:17-27.

Massie A, Schallier A, Kim SW, Fernando R, Kobayashi S, Beck H, De Bundel D, Vermoesen K, Bannai S, Smolders I, Conrad M, Plesnila N, Sato H, Michotte Y (2011) Dopaminergic neurons of system x(c)(-)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 25:1359-1369.

Masuo Y, Ohtaki T, Masuda Y, Tsuda M, Fujino M (1992) Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections. Brain research 575:113-123.

Masuo Y, Suzuki N, Matsumoto H, Tokito F, Matsumoto Y, Tsuda M, Fujino M (1993) Regional distribution of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat central nervous system as determined by sandwich-enzyme immunoassay. Brain research 602:57-63.

Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylation-dependent factor CREB. Nature reviews Molecular cell biology 2:599-609.

McBain CJ, Mayer ML (1994) N-methyl-D-aspartic acid receptor structure and function. Physiological reviews 74:723-760.

McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. The Journal of cell biology 85:890-902.

McClatchy DB, Savas JN, Martinez-Bartolome S, Park SK, Maher P, Powell SB, Yates JR, 3rd (2016) Global quantitative analysis of phosphorylation underlying phencyclidine signaling and sensorimotor gating in the prefrontal cortex. Molecular psychiatry 21:205-215.

McCulloch WS, Pitts W (1990) A logical calculus of the ideas immanent in nervous activity. 1943. Bulletin of mathematical biology 52:99-115; discussion 173-197.

McFarland K, Kalivas PW (2001) The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience 21:8655-8663.

McFarland K, Lapish CC, Kalivas PW (2003) Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience 23:3531-3537.

McFarland K, Davidge SB, Lapish CC, Kalivas PW (2004) Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. The Journal of neuroscience : the official journal of the Society for Neuroscience 24:1551-1560.

McLaughlin J, See RE (2003) Selective inactivation of the dorsomedial prefrontal cortex and the basolateral amygdala attenuates conditioned-cued reinstatement of extinguished cocaine-seeking behavior in rats. Psychopharmacology 168:57-65.

Meldrum BS (2000) Glutamate as a neurotransmitter in the brain: review of physiology and pathology. The Journal of nutrition 130:1007S-1015S.

Melendez RI, Vuthiganon J, Kalivas PW (2005) Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. The Journal of pharmacology and experimental therapeutics 314:139-147.

Miguens M, Del Olmo N, Higuera-Matas A, Torres I, Garcia-Lecumberri C, Ambrosio E (2008) Glutamate and aspartate levels in the nucleus accumbens during cocaine self-administration and extinction: a time course microdialysis study. Psychopharmacology 196:303-313.

Miller EK, Cohen JD (2001) An integrative theory of prefrontal cortex function. Annual review of neuroscience 24:167-202.

Minelli A, Barbaresi P, Reimer RJ, Edwards RH, Conti F (2001) The glial glutamate transporter GLT-1 is localized both in the vicinity of and at distance from axon terminals in the rat cerebral cortex. Neuroscience 108:51-59.

Mitchell SJ, Silver RA (2000) Glutamate spillover suppresses inhibition by activating presynaptic mGluRs. Nature 404:498-502.

Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochemical and biophysical research communications 164:567-574.

Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochemical and biophysical research communications 170:643-648.

Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352.

Moller K, Zhang YZ, Hakanson R, Luts A, Sjolund B, Uddman R, Sundler F (1993) Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 57:725-732.

Molofsky AV, Krencik R, Ullian EM, Tsai HH, Deneen B, Richardson WD, Barres BA, Rowitch DH (2012) Astrocytes and disease: a neurodevelopmental perspective. Genes & development 26:891-907.

Montana V, Ni Y, Sunjara V, Hua X, Parpura V (2004) Vesicular glutamate transporter-dependent glutamate release from astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 24:2633-2642.

Moore RY, Speh JC, Leak RK (2002) Suprachiasmatic nucleus organization. Cell and tissue research 309:89-98.

Moran MM, Melendez R, Baker D, Kalivas PW, Seamans JK (2003) Cystine/glutamate antiporter regulation of vesicular glutamate release. Annals of the New York Academy of Sciences 1003:445-447.

Moran MM, McFarland K, Melendez RI, Kalivas PW, Seamans JK (2005) Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. The Journal of neuroscience : the official journal of the Society for Neuroscience 25:6389-6393.

Morgane PJ, Galler JR, Mokler DJ (2005) A review of systems and networks of the limbic forebrain/limbic midbrain. Progress in neurobiology 75:143-160.

Moriguchi S, Shioda N, Maejima H, Zhao X, Marszalec W, Yeh JZ, Fukunaga K, Narahashi T (2007) Nefiracetam potentiates N-methyl-D-aspartate (NMDA) receptor function via protein kinase C activation and reduces magnesium block of NMDA receptor. Molecular pharmacology 71:580-587.

Moroo I, Tatsuno I, Uchida D, Tanaka T, Saito J, Saito Y, Hirai A (1998) Pituitary adenylate cyclase activating polypeptide (PACAP) stimulates mitogen-activated protein kinase (MAPK) in cultured rat astrocytes. Brain research 795:191-196.

Mounien L, Do Rego JC, Bizet P, Boutelet I, Gourcerol G, Fournier A, Brabet P, Costentin J, Vaudry H, Jegou S (2009) Pituitary adenylate cyclase-activating polypeptide inhibits food intake in mice through activation of the hypothalamic melanocortin system. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 34:424-435.

Moussawi K, Kalivas PW (2010) Group II metabotropic glutamate receptors (mGlu2/3) in drug addiction. European journal of pharmacology 639:115-122.

Moussawi K, Pacchioni A, Moran M, Olive MF, Gass JT, Lavin A, Kalivas PW (2009) N-Acetylcysteine reverses cocaine-induced metaplasticity. Nature neuroscience 12:182-189.

Moussawi K, Zhou W, Shen H, Reichel CM, See RE, Carr DB, Kalivas PW (2011) Reversing cocaine-induced synaptic potentiation provides enduring protection from relapse. Proceedings of the National Academy of Sciences of the United States of America 108:385-390.

Muguruza C, Meana JJ, Callado LF (2016) Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs. Frontiers in pharmacology 7:130.

Murphy TH, Schnaar RL, Coyle JT (1990) Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 4:1624-1633.

Mysona B, Dun Y, Duplantier J, Ganapathy V, Smith SB (2009) Effects of hyperglycemia and oxidative stress on the glutamate transporters GLAST and system xc- in mouse retinal Muller glial cells. Cell and tissue research 335:477-488.

Nakagawa T, Cheng Y, Ramm E, Sheng M, Walz T (2005) Structure and different conformational states of native AMPA receptor complexes. Nature 433:545-549.

Nakazawa K, McHugh TJ, Wilson MA, Tonegawa S (2004) NMDA receptors, place cells and hippocampal spatial memory. Nature reviews Neuroscience 5:361-372.

Naqvi NH, Bechara A (2010) The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making. Brain structure & function 214:435-450.

Navarrete M, Araque A (2008) Endocannabinoids mediate neuron-astrocyte communication. Neuron 57:883-893.

Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nature reviews Neuroscience 2:119-128.

Nestler EJ (2004) Historical review: Molecular and cellular mechanisms of opiate and cocaine addiction. Trends in pharmacological sciences 25:210-218.

Nestler EJ (2005) The neurobiology of cocaine addiction. Science & practice perspectives 3:4-10.

Newpher TM, Ehlers MD (2008) Glutamate receptor dynamics in dendritic microdomains. Neuron 58:472-497.

Niciu MJ, Kelmendi B, Sanacora G (2012) Overview of glutamatergic neurotransmission in the nervous system. Pharmacology, biochemistry, and behavior 100:656-664.

Nie H, Zhang H, Weng HR (2010) Bidirectional neuron-glia interactions triggered by deficiency of glutamate uptake at spinal sensory synapses. Journal of neurophysiology 104:713-725.

Nishimoto M, Miyakawa H, Wada K, Furuta A (2011) Activation of the VIP/VPAC2 system induces reactive astrocytosis associated with increased expression of glutamate transporters. Brain research 1383:43-53.

Nishimoto M, Furuta A, Aoki S, Kudo Y, Miyakawa H, Wada K (2007) PACAP/PAC1 autocrine system promotes proliferation and astrogenesis in neural progenitor cells. Glia 55:317-327.

Niswender CM, Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annual review of pharmacology and toxicology 50:295-322.

Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A (1984) Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307:462-465.

Nusbaum MP, Blitz DM, Swensen AM, Wood D, Marder E (2001) The roles of co-transmission in neural network modulation. Trends in neurosciences 24:146-154.

O'Connor E, Devesa A, Garcia C, Puertes IR, Pellin A, Vina JR (1995) Biosynthesis and maintenance of GSH in primary astrocyte cultures: role of L-cystine and ascorbate. Brain research 680:157-163.

O'Shea RD (2002) Roles and regulation of glutamate transporters in the central nervous system. Clinical and experimental pharmacology & physiology 29:1018-1023.

Oliveira JF, Sardinha VM, Guerra-Gomes S, Araque A, Sousa N (2015) Do stars govern our actions? Astrocyte involvement in rodent behavior. Trends in neurosciences 38:535-549.

Olney JW (1990) Excitotoxic amino acids and neuropsychiatric disorders. Annual review of pharmacology and toxicology 30:47-71.

Palacin M, Nunes V, Font-Llitjos M, Jimenez-Vidal M, Fort J, Gasol E, Pineda M, Feliubadalo L, Chillaron J, Zorzano A (2005) The genetics of heteromeric amino acid transporters. Physiology (Bethesda) 20:112-124.

Palmer CL, Cotton L, Henley JM (2005) The molecular pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Pharmacological reviews 57:253-277.

Palmer LM, Stuart GJ (2009) Membrane potential changes in dendritic spines during action potentials and synaptic input. The Journal of neuroscience : the official journal of the Society for Neuroscience 29:6897-6903.

Panatier A, Vallee J, Haber M, Murai KK, Lacaille JC, Robitaille R (2011) Astrocytes are endogenous regulators of basal transmission at central synapses. Cell 146:785-798.

Paoletti P (2011) Molecular basis of NMDA receptor functional diversity. The European journal of neuroscience 33:1351-1365.

Paoletti P, Neyton J (2007) NMDA receptor subunits: function and pharmacology. Current opinion in pharmacology 7:39-47.

Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nature reviews Neuroscience 14:383-400.

Papadopoulos V, Lecanu L, Brown RC, Han Z, Yao ZX (2006) Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 138:749-756.

Papouin T, Oliet SH (2014) Organization, control and function of extrasynaptic NMDA receptors. Philosophical transactions of the Royal Society of London Series B, Biological sciences 369:20130601.

Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M, Groc L, Pollegioni L, Mothet JP, Oliet SH (2012) Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150:633-646.

Park WK, Bari AA, Jey AR, Anderson SM, Spealman RD, Rowlett JK, Pierce RC (2002) Cocaine administered into the medial prefrontal cortex reinstates cocaine-seeking behavior by increasing AMPA receptor-mediated glutamate transmission in the nucleus accumbens. The Journal of neuroscience : the official journal of the Society for Neuroscience 22:2916-2925.

Parpura V, Zorec R (2010) Gliotransmission: Exocytotic release from astrocytes. Brain research reviews 63:83-92.

Parri HR, Gould TM, Crunelli V (2001) Spontaneous astrocytic Ca2+ oscillations in situ drive NMDAR-mediated neuronal excitation. Nature neuroscience 4:803-812.

Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY, Takano H, Moss SJ, McCarthy K, Haydon PG (2005) Astrocytic purinergic signaling coordinates synaptic networks. Science 310:113-116.

Pasti L, Volterra A, Pozzan T, Carmignoto G (1997) Intracellular calcium oscillations in astrocytes: a highly plastic, bidirectional form of communication between neurons and astrocytes in situ. The Journal of neuroscience : the official journal of the Society for Neuroscience 17:7817-7830.

Pelloux Y, Everitt BJ, Dickinson A (2007) Compulsive drug seeking by rats under punishment: effects of drug taking history. Psychopharmacology 194:127-137.

Perea G, Araque A (2005) Properties of synaptically evoked astrocyte calcium signal reveal synaptic information processing by astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 25:2192-2203.

Perego C, Vanoni C, Bossi M, Massari S, Basudev H, Longhi R, Pietrini G (2000) The GLT-1 and GLAST glutamate transporters are expressed on morphologically distinct astrocytes and regulated by neuronal activity in primary hippocampal cocultures. Journal of neurochemistry 75:1076-1084.

Pereira A, Jr., Furlan FA (2010) Astrocytes and human cognition: modeling information integration and modulation of neuronal activity. Progress in neurobiology 92:405-420.

Perez-Alvarez A, Navarrete M, Covelo A, Martin ED, Araque A (2014) Structural and functional plasticity of astrocyte processes and dendritic spine interactions. The Journal of neuroscience : the official journal of the Society for Neuroscience 34:12738-12744.

Perez V, Bouschet T, Fernandez C, Bockaert J, Journot L (2005) Dynamic reorganization of the astrocyte actin cytoskeleton elicited by cAMP and PACAP: a role for phosphatidylInositol 3-kinase inhibition. The European journal of neuroscience 21:26-32.

Petralia RS, Wang YX, Hua F, Yi Z, Zhou A, Ge L, Stephenson FA, Wenthold RJ (2010) Organization of NMDA receptors at extrasynaptic locations. Neuroscience 167:68-87.

Petrelli F, Pucci L, Bezzi P (2016) Astrocytes and Microglia and Their Potential Link with Autism Spectrum Disorders. Frontiers in cellular neuroscience 10:21.

Pierce RC, Bell K, Duffy P, Kalivas PW (1996) Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. The Journal of neuroscience : the official journal of the Society for Neuroscience 16:1550-1560.

Pin JP, Galvez T, Prezeau L (2003) Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacology & therapeutics 98:325-354.

Pinheiro PS, Mulle C (2008) Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nature reviews Neuroscience 9:423-436.

Pirttimaki TM, Hall SD, Parri HR (2011) Sustained neuronal activity generated by glial plasticity. The Journal of neuroscience : the official journal of the Society for Neuroscience 31:7637-7647.

Platt SR (2007) The role of glutamate in central nervous system health and disease--a review. Veterinary journal 173:278-286.

Polsky A, Mel B, Schiller J (2009) Encoding and decoding bursts by NMDA spikes in basal dendrites of layer 5 pyramidal neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 29:11891-11903.

Porrino LJ, Lyons D, Smith HR, Daunais JB, Nader MA (2004) Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. The Journal of neuroscience : the official journal of the Society for Neuroscience 24:3554-3562.

Porter JT, McCarthy KD (1996) Hippocampal astrocytes in situ respond to glutamate released from synaptic terminals. The Journal of neuroscience : the official journal of the Society for Neuroscience 16:5073-5081.

Povysheva NV, Johnson JW (2012) Tonic NMDA receptor-mediated current in prefrontal cortical pyramidal cells and fast-spiking interneurons. Journal of neurophysiology 107:2232-2243.

Pow DV (2001) Visualising the activity of the cystine-glutamate antiporter in glial cells using antibodies to aminoadipic acid, a selectively transported substrate. Glia 34:27-38.

Pow DV, Barnett NL (2000) Developmental expression of excitatory amino acid transporter 5: a photoreceptor and bipolar cell glutamate transporter in rat retina. Neuroscience letters 280:21-24.

Price CJ, Kim P, Raymond LA (1999) D1 dopamine receptor-induced cyclic AMP-dependent protein kinase phosphorylation and potentiation of striatal glutamate receptors. Journal of neurochemistry 73:2441-2446.

Purrier N, Engeland WC, Kofuji P (2014) Mice deficient of glutamatergic signaling from intrinsically photosensitive retinal ganglion cells exhibit abnormal circadian photoentrainment. PloS one 9:e111449.

Quian Quiroga R, Panzeri S (2009) Extracting information from neuronal populations: information theory and decoding approaches. Nature reviews Neuroscience 10:173-185.

Raps SP, Lai JC, Hertz L, Cooper AJ (1989) Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain research 493:398-401.

Reichel CM, Moussawi K, Do PH, Kalivas PW, See RE (2011) Chronic N-acetylcysteine during abstinence or extinction after cocaine self-administration produces enduring reductions in drug seeking. The Journal of pharmacology and experimental therapeutics 337:487-493.

Reid MS, Berger SP (1996) Evidence for sensitization of cocaine-induced nucleus accumbens glutamate release. Neuroreport 7:1325-1329.

Reissner KJ, Brown RM, Spencer S, Tran PK, Thomas CA, Kalivas PW (2014) Chronic administration of the methylxanthine propentofylline impairs reinstatement to cocaine by a GLT-1-dependent mechanism. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 39:499-506.

Reissner KJ, Gipson CD, Tran PK, Knackstedt LA, Scofield MD, Kalivas PW (2015) Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. Addiction biology 20:316-323.

Resch JM, Maunze B, Phillips KA, Choi S (2014a) Inhibition of food intake by PACAP in the hypothalamic ventromedial nuclei is mediated by NMDA receptors. Physiology & behavior 133:230-235.

Resch JM, Albano R, Liu X, Hjelmhaug J, Lobner D, Baker DA, Choi S (2014b) Augmented cystine-glutamate exchange by pituitary adenylate cyclase-activating polypeptide signaling via the VPAC1 receptor. Synapse.

Robberecht P, Gourlet P, De Neef P, Woussen-Colle MC, Vandermeers-Piret MC, Vandermeers A, Christophe J (1992) Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. European journal of biochemistry / FEBS 207:239-246.

Robbins TW, Ersche KD, Everitt BJ (2008) Drug addiction and the memory systems of the brain. Annals of the New York Academy of Sciences 1141:1-21.

Roberto M, Brunelli M (2000) PACAP-38 enhances excitatory synaptic transmission in the rat hippocampal CA1 region. Learn Mem 7:303-311.

Roberto M, Scuri R, Brunelli M (2001) Differential effects of PACAP-38 on synaptic responses in rat hippocampal CA1 region. Learn Mem 8:265-271.

Roberts-Wolfe DJ, Kalivas PW (2015) Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders. CNS & neurological disorders drug targets 14:745-756.

Robertson JM (2013) Astrocyte domains and the three-dimensional and seamless expression of consciousness and explicit memories. Medical hypotheses 81:1017-1024.

Robertson JM (2014) Astrocytes and the evolution of the human brain. Medical hypotheses 82:236-239.

Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL (1996) Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16:1179-1188.

Rogan MT, Staubli UV, LeDoux JE (1997) Fear conditioning induces associative long-term potentiation in the amygdala. Nature 390:604-607.

Rogers JL, Ghee S, See RE (2008) The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse. Neuroscience 151:579-588.

Rondard P, Pin JP (2015) Dynamics and modulation of metabotropic glutamate receptors. Current opinion in pharmacology 20:95-101.

Rose EM, Koo JC, Antflick JE, Ahmed SM, Angers S, Hampson DR (2009) Glutamate transporter coupling to Na,K-ATPase. The Journal of neuroscience : the official journal of the Society for Neuroscience 29:8143-8155.

Roth G, Dicke U (2005) Evolution of the brain and intelligence. Trends in cognitive sciences 9:250-257.

Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW (1994) Localization of neuronal and glial glutamate transporters. Neuron 13:713-725.

Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke JP, Welty DF (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675-686.

Rushworth MF, Noonan MP, Boorman ED, Walton ME, Behrens TE (2011) Frontal cortex and reward-guided learning and decision-making. Neuron 70:1054-1069.

Salgado S, Kaplitt MG (2015) The Nucleus Accumbens: A Comprehensive Review. Stereotactic and functional neurosurgery 93:75-93.

Santello M, Cali C, Bezzi P (2012) Gliotransmission and the tripartite synapse. Advances in experimental medicine and biology 970:307-331.

Sasaki H, Sato H, Kuriyama-Matsumura K, Sato K, Maebara K, Wang H, Tamba M, Itoh K, Yamamoto M, Bannai S (2002) Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. The Journal of biological chemistry 277:44765-44771.

Sato H, Tamba M, Ishii T, Bannai S (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. The Journal of biological chemistry 274:11455-11458.

Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S (2000) Molecular cloning and expression of human xCT, the light chain of amino acid transport system xc. Antioxidants & redox signaling 2:665-671.

Sato H, Nomura S, Maebara K, Sato K, Tamba M, Bannai S (2004) Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation. Biochemical and biophysical research communications 325:109-116.

Schildge S, Bohrer C, Beck K, Schachtrup C (2013) Isolation and culture of mouse cortical astrocytes. Journal of visualized experiments : JoVE.

Schlag BD, Vondrasek JR, Munir M, Kalandadze A, Zelenaia OA, Rothstein JD, Robinson MB (1998) Regulation of the glial Na+-dependent glutamate

transporters by cyclic AMP analogs and neurons. Molecular pharmacology 53:355-369.

Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE (2012) N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 37:2143-2152.

Schmidt HD, Anderson SM, Famous KR, Kumaresan V, Pierce RC (2005) Anatomy and pharmacology of cocaine priming-induced reinstatement of drug seeking. European journal of pharmacology 526:65-76.

Schmidt M, Dekker FJ, Maarsingh H (2013) Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacological reviews 65:670-709.

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nature protocols 3:1101-1108.

Schoepp DD (2001) Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. The Journal of pharmacology and experimental therapeutics 299:12-20.

Schrader LA, Tasker JG (1997) Presynaptic modulation by metabotropic glutamate receptors of excitatory and inhibitory synaptic inputs to hypothalamic magnocellular neurons. Journal of neurophysiology 77:527-536.

Scofield MD, Boger HA, Smith RJ, Li H, Haydon PG, Kalivas PW (2015) Gq-DREADD Selectively Initiates Glial Glutamate Release and Inhibits Cue-induced Cocaine Seeking. Biological psychiatry 78:441-451.

Seal RP, Edwards RH (2006) Functional implications of neurotransmitter co-release: glutamate and GABA share the load. Current opinion in pharmacology 6:114-119.

See RE, Kruzich PJ, Grimm JW (2001) Dopamine, but not glutamate, receptor blockade in the basolateral amygdala attenuates conditioned reward in a rat model of relapse to cocaine-seeking behavior. Psychopharmacology 154:301-310.

Seifert G, Zhou M, Steinhauser C (1997a) Analysis of AMPA receptor properties during postnatal development of mouse hippocampal astrocytes. Journal of neurophysiology 78:2916-2923.

Seifert G, Rehn L, Weber M, Steinhauser C (1997b) AMPA receptor subunits expressed by single astrocytes in the juvenile mouse hippocampus. Brain research Molecular brain research 47:286-294.

Self DW, Barnhart WJ, Lehman DA, Nestler EJ (1996) Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271:1586-1589.

Seo H, Lee K (2016) Epac2 contributes to PACAP-induced astrocytic differentiation through calcium ion influx in neural precursor cells. BMB reports 49:128-133.

Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology 168:3-20.

Shelton MK, McCarthy KD (1999) Mature hippocampal astrocytes exhibit functional metabotropic and ionotropic glutamate receptors in situ. Glia 26:1-11.

Shepherd JD, Huganir RL (2007) The cell biology of synaptic plasticity: AMPA receptor trafficking. Annual review of cell and developmental biology 23:613-643.

Shi GX, Cai W, Andres DA (2012) Rit-mediated stress resistance involves a p38-mitogen- and stress-activated protein kinase 1 (MSK1)-dependent cAMP response element-binding protein (CREB) activation cascade. The Journal of biological chemistry 287:39859-39868.

Shigetomi E, Bowser DN, Sofroniew MV, Khakh BS (2008) Two forms of astrocyte calcium excitability have distinct effects on NMDA receptor-mediated slow inward currents in pyramidal neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience 28:6659-6663.

Shih AY, Erb H, Sun X, Toda S, Kalivas PW, Murphy TH (2006) Cystine/glutamate exchange modulates glutathione supply for neuroprotection from oxidative stress and cell proliferation. The Journal of neuroscience : the official journal of the Society for Neuroscience 26:10514-10523.

Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. The Journal of neuroscience : the official journal of the Society for Neuroscience 23:3394-3406.

Shouval HZ, Bear MF, Cooper LN (2002) A unified model of NMDA receptor-dependent bidirectional synaptic plasticity. Proceedings of the National Academy of Sciences of the United States of America 99:10831-10836.

Sims KB, Hoffman DL, Said SI, Zimmerman EA (1980) Vasoactive intestinal polypeptide (VIP) in mouse and rat brain: an immunocytochemical study. Brain research 186:165-183.

Singh J, Padgett RA (2009) Rates of in situ transcription and splicing in large human genes. Nature structural & molecular biology 16:1128-1133.

Slezak M, Pfrieger FW (2003) New roles for astrocytes: regulation of CNS synaptogenesis. Trends in neurosciences 26:531-535.

Sloan SA, Barres BA (2014) Mechanisms of astrocyte development and their contributions to neurodevelopmental disorders. Current opinion in neurobiology 27:75-81.

Snyder GL, Allen PB, Fienberg AA, Valle CG, Huganir RL, Nairn AC, Greengard P (2000) Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience 20:4480-4488.

Soni N, Reddy BV, Kumar P (2014) GLT-1 transporter: an effective pharmacological target for various neurological disorders. Pharmacology, biochemistry, and behavior 127:70-81.

Stefanik MT, Kalivas PW (2013) Optogenetic dissection of basolateral amygdala projections during cue-induced reinstatement of cocaine seeking. Frontiers in behavioral neuroscience 7:213.

Stefanik MT, Moussawi K, Kupchik YM, Smith KC, Miller RL, Huff ML, Deisseroth K, Kalivas PW, LaLumiere RT (2013) Optogenetic inhibition of cocaine seeking in rats. Addiction biology 18:50-53.

Steiner H, Gerfen CR (1998) Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Experimental brain research 123:60-76.

Stipursky J, Romao L, Tortelli V, Neto VM, Gomes FC (2011) Neuron-glia signaling: Implications for astrocyte differentiation and synapse formation. Life sciences 89:524-531.

Stuber GD, Hnasko TS, Britt JP, Edwards RH, Bonci A (2010) Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate. The Journal of neuroscience : the official journal of the Society for Neuroscience 30:8229-8233.

Stumm R, Kolodziej A, Prinz V, Endres M, Wu DF, Hollt V (2007) Pituitary adenylate cyclase-activating polypeptide is up-regulated in cortical pyramidal cells after focal ischemia and protects neurons from mild hypoxic/ischemic damage. Journal of neurochemistry 103:1666-1681.

Su ZZ, Leszczyniecka M, Kang DC, Sarkar D, Chao W, Volsky DJ, Fisher PB (2003) Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proceedings of the National Academy of Sciences of the United States of America 100:1955-1960.

Suda K, Smith DM, Ghatei MA, Bloom SR (1992) Investigation of the interaction of VIP binding sites with VIP and PACAP in human brain. Neuroscience letters 137:19-23.

Sun W, McConnell E, Pare JF, Xu Q, Chen M, Peng W, Lovatt D, Han X, Smith Y, Nedergaard M (2013) Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. Science 339:197-200.

Swanson RA, Liu J, Miller JW, Rothstein JD, Farrell K, Stein BA, Longuemare MC (1997) Neuronal regulation of glutamate transporter subtype expression in astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 17:932-940.

Swayze RD, Lise MF, Levinson JN, Phillips A, El-Husseini A (2004) Modulation of dopamine mediated phosphorylation of AMPA receptors by PSD-95 and AKAP79/150. Neuropharmacology 47:764-778.

Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, Nedergaard M (2006) Astrocyte-mediated control of cerebral blood flow. Nature neuroscience 9:260-267.

Tan CO, Bullock D (2008) Neuropeptide co-release with GABA may explain functional non-monotonic uncertainty responses in dopamine neurons. Neuroscience letters 430:218-223.

Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K (1997) Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276:1699-1702.

Tang XC, Kalivas PW (2003) Bidirectional modulation of cystine/glutamate exchanger activity in cultured cortical astrocytes. Annals of the New York Academy of Sciences 1003:472-475.

Tao-Cheng JH, Gallant PE, Brightman MW, Dosemeci A, Reese TS (2007) Structural changes at synapses after delayed perfusion fixation in different regions of the mouse brain. The Journal of comparative neurology 501:731-740.

Tapia R, Medina-Ceja L, Pena F (1999) On the relationship between extracellular glutamate, hyperexcitation and neurodegeneration, in vivo. Neurochemistry international 34:23-31.

Tecuapetla F, Patel JC, Xenias H, English D, Tadros I, Shah F, Berlin J, Deisseroth K, Rice ME, Tepper JM, Koos T (2010) Glutamatergic signaling by mesolimbic dopamine neurons in the nucleus accumbens. The Journal of neuroscience : the official journal of the Society for Neuroscience 30:7105-7110.

Theriault E, Landis DM (1987) Morphology of striatal neurons containing VIP-like immunoreactivity. The Journal of comparative neurology 256:1-13.

Timmerman W, Westerink BH (1997) Brain microdialysis of GABA and glutamate: what does it signify? Synapse 27:242-261.

Toda AM, Huganir RL (2015) Regulation of AMPA receptor phosphorylation by the neuropeptide PACAP38. Proceedings of the National Academy of Sciences of the United States of America 112:6712-6717.

Tong Y, Toranzo D, Pelletier G (1991) Localization of diazepam-binding inhibitor (DBI) mRNA in the rat brain by high resolution in situ hybridization. Neuropeptides 20:33-40.

Torp R, Hoover F, Danbolt NC, Storm-Mathisen J, Ottersen OP (1997) Differential distribution of the glutamate transporters GLT1 and rEAAC1 in rat cerebral cortex and thalamus: an in situ hybridization analysis. Anatomy and embryology 195:317-326.

Trantham-Davidson H, LaLumiere RT, Reissner KJ, Kalivas PW, Knackstedt LA (2012) Ceftriaxone normalizes nucleus accumbens synaptic transmission, glutamate transport, and export following cocaine self-administration and extinction training. The Journal of neuroscience : the official journal of the Society for Neuroscience 32:12406-12410.

Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacological reviews 62:405-496.

Trenga CA, Kunkel DD, Eaton DL, Costa LG (1991) Effect of styrene oxide on rat brain glutathione. Neurotoxicology 12:165-178.

Tritsch NX, Ding JB, Sabatini BL (2012) Dopaminergic neurons inhibit striatal output through non-canonical release of GABA. Nature 490:262-266.

Tritsch NX, Granger AJ, Sabatini BL (2016) Mechanisms and functions of GABA co-release. Nature reviews Neuroscience 17:139-145.

Tsien JZ, Huerta PT, Tonegawa S (1996) The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell 87:1327-1338.

Tyszkiewicz JP, Gu Z, Wang X, Cai X, Yan Z (2004) Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex. The Journal of physiology 554:765-777.

Tzschentke TM (2007) Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addiction biology 12:227-462.

Vallejo I, Vallejo M (2002) Pituitary adenylate cyclase-activating polypeptide induces astrocyte differentiation of precursor cells from developing cerebral cortex. Molecular and cellular neurosciences 21:671-683.

van den Pol AN (2012) Neuropeptide transmission in brain circuits. Neuron 76:98-115.

Van der Kloot W (1991) The regulation of quantal size. Progress in neurobiology 36:93-130.

van Zundert B, Yoshii A, Constantine-Paton M (2004) Receptor compartmentalization and trafficking at glutamate synapses: a developmental proposal. Trends in neurosciences 27:428-437.

Vanderschuren LJ, Everitt BJ (2004) Drug seeking becomes compulsive after prolonged cocaine self-administration. Science 305:1017-1019.

Vanderschuren LJ, Di Ciano P, Everitt BJ (2005) Involvement of the dorsal striatum in cue-controlled cocaine seeking. The Journal of neuroscience : the official journal of the Society for Neuroscience 25:8665-8670.

Vargas-Caballero M, Robinson HP (2004) Fast and slow voltage-dependent dynamics of magnesium block in the NMDA receptor: the asymmetric trapping block model. The Journal of neuroscience : the official journal of the Society for Neuroscience 24:6171-6180.

Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacological reviews 52:269-324.

Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacological reviews 61:283-357.

Ventura R, Harris KM (1999) Three-dimensional relationships between hippocampal synapses and astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience 19:6897-6906.

Verkhratsky A (2009) Neurotransmitter Receptors in Astrocytes. In: Astrocytes in (Patho)Physiology of the Nervous System (Haydon PG, Parpura V, eds), pp 49-67. Boston, MA: Springer US.

Verkhratsky A, Kirchhoff F (2007) NMDA Receptors in glia. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry 13:28-37.

Verrey F, Closs EI, Wagner CA, Palacin M, Endou H, Kanai Y (2004) CATs and HATs: the SLC7 family of amino acid transporters. Pflugers Archiv : European journal of physiology 447:532-542.

Verrico CD, Haile CN, Mahoney JJ, 3rd, Thompson-Lake DG, Newton TF, De La Garza R, 2nd (2014) Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study. Drug and alcohol dependence 141:72-78.

Vijayaraghavan S (2009) Glial-neuronal interactions--implications for plasticity and drug addiction. The AAPS journal 11:123-132.

Vilchez D, Ros S, Cifuentes D, Pujadas L, Valles J, Garcia-Fojeda B, Criado-Garcia O, Fernandez-Sanchez E, Medrano-Fernandez I, Dominguez J, Garcia-Rocha M, Soriano E, Rodriguez de Cordoba S, Guinovart JJ (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nature neuroscience 10:1407-1413.

Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, Pappas N (1999) Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. The American journal of psychiatry 156:19-26.

Volkow ND, Wang GJ, Ma Y, Fowler JS, Wong C, Ding YS, Hitzemann R, Swanson JM, Kalivas P (2005) Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction. The Journal of neuroscience : the official journal of the Society for Neuroscience 25:3932-3939.

Volman V, Ben-Jacob E, Levine H (2007) The astrocyte as a gatekeeper of synaptic information transfer. Neural computation 19:303-326.

Volterra A, Meldolesi J (2005) Astrocytes, from brain glue to communication elements: the revolution continues. Nature reviews Neuroscience 6:626-640.

Wang JQ, Liu X, Zhang G, Parelkar NK, Arora A, Haines M, Fibuch EE, Mao L (2006) Phosphorylation of glutamate receptors: a potential mechanism for the regulation of receptor function and psychostimulant action. Journal of neuroscience research 84:1621-1629.

Warr O, Takahashi M, Attwell D (1999) Modulation of extracellular glutamate concentration in rat brain slices by cystine-glutamate exchange. The Journal of physiology 514 (Pt 3):783-793.

Waschek JA, Casillas RA, Nguyen TB, DiCicco-Bloom EM, Carpenter EM, Rodriguez WI (1998) Neural tube expression of pituitary adenylate cyclase-activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis.

Proceedings of the National Academy of Sciences of the United States of America 95:9602-9607.

Weerth SH, Holtzclaw LA, Russell JT (2007) Signaling proteins in raft-like microdomains are essential for Ca2+ wave propagation in glial cells. Cell calcium 41:155-167.

Williams LE, Featherstone DE (2014) Regulation of hippocampal synaptic strength by glial xCT. The Journal of neuroscience : the official journal of the Society for Neuroscience 34:16093-16102.

Williams SR, Wozny C (2011) Errors in the measurement of voltage-activated ion channels in cell-attached patch-clamp recordings. Nature communications 2:242.

Withers NW, Pulvirenti L, Koob GF, Gillin JC (1995) Cocaine abuse and dependence. Journal of clinical psychopharmacology 15:63-78.

Wolosker H (2006) D-serine regulation of NMDA receptor activity. Science's STKE : signal transduction knowledge environment 2006:pe41.

Wu SY, Dun NJ (1997) Potentiation of NMDA currents by pituitary adenylate cyclase activating polypeptide in neonatal rat sympathetic preganglionic neurons. Journal of neurophysiology 78:1175-1179.

Wyllie DJ, Behe P, Colquhoun D (1998) Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors. The Journal of physiology 510 (Pt 1):1-18.

Xi ZX, Baker DA, Shen H, Carson DS, Kalivas PW (2002) Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. The Journal of pharmacology and experimental therapeutics 300:162-171.

Yagodin SV, Holtzclaw L, Sheppard CA, Russell JT (1994) Nonlinear propagation of agonist-induced cytoplasmic calcium waves in single astrocytes. Journal of neurobiology 25:265-280.

Yaka R, He DY, Phamluong K, Ron D (2003) Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1. The Journal of biological chemistry 278:9630-9638.

Yang Y, Yee D (2014) IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC. Cancer research 74:2295-2305.

Yang Y, Gozen O, Watkins A, Lorenzini I, Lepore A, Gao Y, Vidensky S, Brennan J, Poulsen D, Won Park J, Li Jeon N, Robinson MB, Rothstein JD (2009) Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 61:880-894.

Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR (2003) Functional hemichannels in astrocytes: a novel mechanism of glutamate release. The Journal of neuroscience : the official journal of the Society for Neuroscience 23:3588-3596.

Yin HH, Knowlton BJ (2006) The role of the basal ganglia in habit formation. Nature reviews Neuroscience 7:464-476.

Yoshii A, Sheng MH, Constantine-Paton M (2003) Eye opening induces a rapid dendritic localization of PSD-95 in central visual neurons. Proceedings of the National Academy of Sciences of the United States of America 100:1334-1339.

Zelenaia O, Schlag BD, Gochenauer GE, Ganel R, Song W, Beesley JS, Grinspan JB, Rothstein JD, Robinson MB (2000) Epidermal growth factor receptor agonists increase expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-kinase and transcription factor NF-kappaB. Molecular pharmacology 57:667-678.

Zhang Q, Fukuda M, Van Bockstaele E, Pascual O, Haydon PG (2004) Synaptotagmin IV regulates glial glutamate release. Proceedings of the National Academy of Sciences of the United States of America 101:9441-9446.

Zhang Q, Shi TJ, Ji RR, Zhang YZ, Sundler F, Hannibal J, Fahrenkrug J, Hokfelt T (1995) Expression of pituitary adenylate cyclase-activating polypeptide in dorsal root ganglia following axotomy: time course and coexistence. Brain research 705:149-158.

Zhang S, Trussell LO (1994) A characterization of excitatory postsynaptic potentials in the avian nucleus magnocellularis. Journal of neurophysiology 72:705-718.

Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA, Wu JQ (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. The Journal of neuroscience : the official journal of the Society for Neuroscience 34:11929-11947.

Zhou CJ, Yada T, Kohno D, Kikuyama S, Suzuki R, Mizushima H, Shioda S (2001) PACAP activates PKA, PKC and Ca(2+) signaling cascades in rat neuroepithelial cells. Peptides 22:1111-1117.

Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA, Pozzan T, Carmignoto G (2003) Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nature neuroscience 6:43-50.

Zupan V, Hill JM, Brenneman DE, Gozes I, Fridkin M, Robberecht P, Evrard P, Gressens P (1998) Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. Journal of neurochemistry 70:2165-2173.